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Chapter 1 
General Introduction 
A modified version of this Chapter is in press in: 
Biological Chemistry Hoppe-Seyler. 

Introduction 
1.1 Tumour angiogenesis 
The process of angiogenesis 
One of the major roles of the vasculature is its transport function: the supply of oxygen 
and nutrients to cells and the transport of waste products from cells. In higher organisms 
blood vessels are essential for the survival of nearly every living tissue. The initial 
formation of the vasculature in embryonic development is called vasculogenesis, and 
involves the differentiation of blood vessels from mesoderm tissue and from blood islands 
in the yolk sac. The growth of new vessels from existing blood vessels is called 
angiogenesis or neovascularization. In adult organisms most blood vessels do not grow: 
angiogenesis only takes place in regenerating tissues like the female reproductive organs 
or during wound healing. Angiogenesis is a highly regulated process involving many 
stimulatory and inhibitory factors (for a review see 1,2, and below). 
Tumour angiogenesis 
Tumour cells of course are as dependent on the vasculature as cells in normal tissues. 
Avascular tumours do not grow beyond the size of 1-2 mm3, whereas after vascularization 
tumours quickly expand to much larger sizes (3). Mitotic rates of tumour cells decrease 
with increasing distance from capillaries (3) and tumours with a high blood supply have a 
higher fraction of dividing cells and lower necrosis rates than tumours with a low blood 
supply (4). Thus, tumours are truly dependent on angiogenesis for their own growth. 
Furthermore, angiogenesis is essential for metastasis, the most life-threatening aspect of 
cancer, as blood vessels provide an escape road for disseminating tumour cells (1,3,5). 
Many studies have recently been published which report a correlation between tumour 
vascularization and metastatic risk in patients (6-10). 
Apart from the fact that angiogenesis is essential for the growth of tumours themselves, 
tumour vasculature is also important in clinical practice. The response to anti-tumour 
therapies, like conventional chemotherapy, as well as e.g. the use of photodynamic 
sensitizers, or of anti-tumour antibodies coupled to toxins or radionuclides, is largely 
dependent on the presence, distribution and permeability of tumour blood vessels (11-15). 
Of course, also in tumour imaging the delivery of tracers depends on the degree of 
tumour vascularization. 
Properties of the tumour vascular bed 
Much effort has been put into studying the vasculature of tumours. To distinguish blood 
vessels in cross-sections of tissues or tumour specimens, markers are used which stain 
one of the components of the vascular system. There is a number of polyclonal antibodies 
reacting with endothelial cell-associated antigens, such as von Willebrand factor (vWF) or 
angiotensin-converting enzyme (16), as well as monoclonal antibodies directed against 
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endothelial cells (17,18). Also some lectins, e.g. from Ulex europaeus or Grifonia 
simplicifolia (19), are used to stain endothelial cells. These markers are generally not 
completely specific for endothelial cells, and do not recognize all types of endothelium 
(reviewed in 20). Antibodies reacting with pericytes (21,22) or with components of the 
basal lamina (e.g. laminin or collagen type IV (16)) can be used as vascular markers as 
well. Again, these markers also cross-react with other cell types, or with extracellular 
matrix from other cell types (20). For this reason, in studying the vasculature of tumours, 
or of any tissue, several vascular markers should be used in parallel to obtain highest 
reliability. 
Tumour angiogenesis has properties somewhat different from normal angiogenesis: the 
fast growth of tumour cells requires that angiogenesis takes place at a high rate in order 
to supply all parts of an expanding tumour. Although different types of tumour 
vasculature exist (23), a series of structural abnormalities is often found in tumour 
vessels, when compared with blood vessels in normal tissues. In general, tumour 
vasculature is considered to be of an "immature" nature. Some of the characteristics often 
reported to be found in tumour vasculature are: a high turnover rate of endothelial cells, 
gaps in the endothelial lining and basement membrane, low amounts of pericytes, a 
heterogeneous (or chaotic) organization and distribution of the tumour vasculature (the 
existence of e.g. non-functional capillary sprouts, or arteriovenous anastomoses), an 
increased vascular permeability, and the occurrence of intravascular coagulation (reviewed 
in 1,11,24, and 23,25). Tumour blood flow, oxygen pressure, and tissue pH values are 
generally very variable, but on average mostly lower than in many normal tissues (11). 
Because of the absence of lymphatic vessels, interstitial pressure is often high in tumours, 
leading to further transport problems (15). It is not surprising therefore that necrosis is a 
general phenomenon, especially in larger tumours (4,11). 
Intravascular coagulation in tumour vessels 
An experimental approach for anti-tumour therapy with the vasculature as its target, is 
the induction of intravascular clotting in the tumour vascular bed, thereby obstructing 
tumour blood flow. Within normal blood vessels there is a non-thrombogenic 
environment, due to heparin-like molecules and other anti-coagulant molecules on the 
endothelial lining (26). However, tumour vasculature is often prone to intravascular 
coagulation, which leads to spontaneous deposition of fibrin and the occurrence of 
intravascular clots or thrombi (25). 
Malignant cells themselves can produce procoagulant molecules like tissue factor and 
"cancer procoagulant" (27,28) and provide a cell surface on which thrombin formation 
can be completed (29), but this only leads to fibrin formation outside of the tumour 
vessels. Intravascular clotting in tumour blood vessels is likely to be caused by soluble 
factors secreted by tumour cells that induce the expression of coagulation factors on 
neighbouring endothelial cells. Cytokines like interleukin-1 (30), vascular permeability 
factor (31), endothelial-monocyte activating polypeptide II (EMAP II, 32,33) and some 
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less well-characterized proteins (34,35) induce the procoagulant molecule tissue factor on 
endothelial cells, and have been shown to be expressed by tumour cells. 
Tumour necrosis factor (TNF) also is an inducer of tissue factor on endothelial cells, 
and, when administered to mice carrying Meth A fibrosarcomas, TNF caused an elevated 
deposition of fibrin, appearance of thrombi and a reduced blood flow, specifically in the 
tumour vascular bed, ultimately leading to tumour necrosis (36). Apparently, the tumour 
vasculature was more sensitive to TNF treatment than the vasculature in normal tissues. 
This may be caused by tumour-produced factors which act synergistically with TNF in 
tissue factor induction. Such factors, "Meth A factor" (or EMAP I), vascular permeability 
factor, and EMAP II have indeed been identified in conditioned media from these 
sarcoma cells (31,35,33). Treatment of human cancers with TNF, either by direct 
administration, or indirectly, as achieved in the past after exposure to "Coley's toxins", 
which induce the endogenous expression of TNF, has had varying success. Recently, 
however, some trials have been reported in which human sarcomas, melanomas, and 
squamous cell carcinomas were treated successfully with TNF in combination with other 
agents (e.g. interferon-7 and melphalan) in isolated limb perfusions (37-40). The 
remissions resulting from such treatments were accompanied by signs of activation of 
tumour endothelial cells, platelet aggregation, and coagulative and haemorrhagic necrosis. 
To understand the mechanisms that lead to intravascular coagulation in the tumour 
vasculature, either spontaneously or after TNF treatment, it is important to identify the 
factors produced by human tumour cells that induce this effect. In purification protocols 
of such factors (31,35), an in vitro assay which measures induction of tissue factor on 
endothelial cells is generally used. Induction of tissue factor activity was preceded by an 
elevation of tissue factor mRNA levels in the endothelial cells (31). Tissue factor 
induction can therefore also be assayed at the RNA level. A quantitative RT-PCR assay 
might facilitate the measurement of tissue factor mRNA levels, and therefore might aid 
the search for procoagulant-inducing factors, as it would require only small amounts of 
endothelial cell RNA to be tested. The development of such an assay will be described in 
Chapter 2 of this thesis. 
1.2 Angiogenic factors 
Positive regulation of angiogenesis is mediated by molecules referred to as "angiogenic 
factors", and in order to induce the growth of blood vessels, tumour cells have to produce 
such angiogenic factors. In general, angiogenic factors belong to the classes of growth 
factors or cytokines, but it should be noted that the action of angiogenic growth factors is 
distinct from the action of growth factors involved in oncogenic transformation, the 
process of cells becoming independent of external stimuli for cell division. Growth factors 
like platelet-derived growth factor (PDGF), epidermal growth factor (EGF), transforming 
growth factor alpha (TGFa), fibroblast growth factors (FGF), and many more, are often 
expressed by tumour cells along with their cognate receptors, which can lead to autocrine 
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stimulation of tumour cell growth. It is not surprising therefore that the genes of some 
growth factors and receptors have initially been identified as (proto-)oncogenes (for 
instance the PDGF-B gene: c-sis, the FGF-3 gene: int-2, the EGF-R gene: c-erbB; 
reviewed in 41,42). The mode of action of angiogenic factors, on the other hand, is 
paracrine, i.e. the target of the growth factor is another cell type than the producing cell. 
The angiogenesis-inducing effect of growth factors is usually tested in a chicken 
chorioallantoic membrane (CAM) assay or in a corneal micropocket assay (1), but in 
some cases growth factors are being considered angiogenic only because of their ability to 
promote endothelial cell division. The angiogenic factors mentioned in this Chapter are 
summarized in Table 1. 
Angiogenic factors that stimulate endothelial cell division 
Many angiogenic factors directly stimulate the growth of endothelial cells. Among the 
first factors characterized as angiogenic factors are: acidic and basic fibroblast growth 
factor (aFGF and bFGF, the first one was also known as endothelial cell growth factor: 
ECGF, 43-45), transforming growth factor alpha (TGFa), and a factor related to TGFa, 
epidermal growth factor (EGF, 46). These factors are often produced by tumour cells and 
they have a direct stimulating effect on endothelial cell mitosis. These factors also have 
an effect on a variety of other cell types, however, and can play a role in transformation 
of tumour cells as well (reviewed in 41,42). Platelet-derived growth factor (PDGF) is 
another pleiotropic mitogen which is also considered an angiogenic factor, since it induces 
cellular proliferation of human microvascular endothelial cells (47). 
Some other angiogenic factors have a more restricted target cell specificity, like platelet-
derived endothelial cell growth factor (PD-ECGF), vascular permeability factor/vascular 
endothelial growth factor (VPF/VEGF), placenta growth factor (P1GF, a factor closely 
related to VPF/VEGF), and interleukin 8 (IL-8). PD-ECGF is an inducer of in vivo 
angiogenesis, and has been found to be produced by tumour cells (48,49). Its growth 
stimulatory effect on endothelial cells has been doubted, however: a stimulatory effect of 
PD-ECGF on DNA synthesis in endothelial cells has been demonstrated, but no effect on 
cellular proliferation has been reported (2). Interesting in this respect is the finding that 
PD-ECGF is related to, if not identical with thymidine Phosphorylase, an essential 
enzyme in nucleic acid metabolism (50). VPF/VEGF does stimulate endothelial cell 
division in vitro as well as angiogenesis in vivo, and is gaining more and more interest, as 
it is clear that it plays an essential role in tumour angiogenesis (51-53). P1GF also 
stimulates proliferation of endothelial cells, and is therefore considered an angiogenic 
factor. P1GF has been found to be produced by some tumours (54,55). IL-8 is a cytokine 
mainly secreted by macrophages, and is an inducer of endothelial cell proliferation and of 
angiogenesis in vivo (56). Recently, it was shown that IL-8 is produced by melanoma 
cells and that the level of IL-8 expression correlated with the metastatic potential of the 
melanoma lines in nude mice (57). 
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Angiogenic factors 
Factor 
aFGF 
bFGF 
TGFa 
EGF 
VPF/VEGF 
PIGF 
PD-ECGF 
IL-8 
PDGF 
TGFß 
TNFa 
Angiogenin 
Effect on EC 
proliferation 
+ 
+ 
+ 
+ 
+ 
+ 
+/0 
+ 
+/0 
-
_ 
0 
EC 
migration 
+ 
+ 
+ 
+ 
+ 
— 
+ 
0 
EC proteolytic 
activity 
+ 
+ 
+ 
— 
Table 1. Growth factors and cytokines that stimulate angiogenesis. Their effects on endothelial cells in 
vitro are shown. Symbols: + , stimulatory effect; -, inhibitory effect; 0, no effect; if the effect is not 
known, no notification is given. Angiogenic factors that do not stimulate endothelial cell division, 
migration, or proteolytic activity are believed to induce angiogenesis indirectly. For abbreviations and 
references see the text. 
Indirectly acting angiogenic factors 
Some factors which are angiogenic in vivo have no influence on endothelial cell 
proliferation in vitro, or even inhibit endothelial cell proliferation. These factors may 
induce angiogenesis indirectly by attracting and activating other cell types, like 
monocytes, and thus stimulate the production of directly acting angiogenic factors by 
these cells. Tumour necrosis factor alpha (TNFa) and transforming growth factor beta 
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(TGFß) belong to this class of molecules: they are angiogenic in vivo (58,59) but inhibit 
endothelial cell mitosis in vitro (60-65). Angiogenin is also angiogenic in vivo (66), but 
the mechanism by which it induces angiogenesis is somewhat enigmatic: it stimulates 
endothelial cells to increase 1,2-diacyIglycerol and inositol triphosphate levels and to 
secrete prostacyclin (67,68), but it appears to have no effect on endothelial cell 
proliferation (1,2). Its major in vitro activity seems to be its ribonucleolytic activity 
towards ribosomal RNA, and thus inhibition of protein synthesis (69,70), which at first 
glance is difficult to reconcile with induction of angiogenesis. PDGF-BB is also thought 
to have an indirect effect on tumour angiogenesis, by promoting connective tissue stroma 
formation, which in its turn is a support for ingrowing blood vessels (71). 
The importance of proteolysis and cooperation between angiogenic factors 
It should be stressed that angiogenesis is a process involving more steps than endothelial 
cell proliferation alone. In order to form new vessels, endothelial cells have to migrate in 
a certain direction and form tubules. VPF/VEGF, aFGF, bFGF, IL-8, PD-ECGF, and 
TNFa are chemotactic for endothelial cells (72,73,44,45,48,56,58), and in that way 
contribute to migration. Breakdown of the basal lamina surrounding the endothelial cell 
layer is another important (and initial) step in migration. In endothelial cells bFGF and 
VPF/VEGF induce the expression of specific proteases involved in extracellular matrix 
degradation, like collagenases (44,45,74) and constituents of the plasminogen activator 
pathway. bFGF induces both urokinase plasminogen activator (uPA) and its inhibitor PAI-
1, thereby increasing the uPA/PAI-1 ratio (75,76), while VPF/VEGF is most potent in 
the induction of tissue-type plasminogen activator (tPA, 76). In connection with these 
activities, bFGF and VPF/VEGF are capable of inducing invasion and capillary-like tube 
formation of endothelial cells in collagen gels (also called in vitro angiogenesis); at least 
bFGF does so for fibrin gels as well (77). VPF/VEGF and bFGF act synergistically in 
inducing in vitro angiogenesis in collagen gels (77), which may be explained by the fact 
that bFGF upregulates the expression of the receptors for VPF (78). 
VPF activity might be suppressed by TNFa, since TNFa down-regulates the expression 
of VPF receptors (78). TGFß, which enhances the formation of extracellular matrix (79), 
modulates the effect of bFGF on the proteolytic activity of endothelial cells, by 
decreasing the uPA/PAI-1 ratio that is increased by bFGF (75). In in vitro angiogenesis in 
fibrin gels, however, TGFß either potentiates or inhibits the effect of bFGF, depending 
on the concentration of TGFß added (80). 
It is of importance to note that some of the angiogenic factors (like TGFa and TGFß) 
are expressed as latent precursor molecules which are activated by specific proteolytic 
cleavage (81,82,79). Other angiogenic factors (the members of the FGF family, and some 
variants of VPF/VEGF) are immobilized by binding to heparin-like molecules in 
extracellular matrix, but are released by proteolytic processes (83,84). Thus, by inducing 
extracellular proteolysis angiogenic factors may activate or mobilize themselves or each 
other. 
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These examples indicate that the mode of cooperation of the many angiogenic factors in 
vivo is very complex. Some angiogenic factors may not be able to initiate all steps 
required for angiogenesis, but in concert with other factors can contribute to the 
completion of the whole process. Furthermore, the action of angiogenic factors is 
counteracted by several anti-angiogenic factors (85, see below), in normal situations 
leading to a balance between angiogenesis and anti-angiogenesis. This balance can shift 
towards angiogenesis if this is required by the situation, like for instance after wounding, 
during the menstrual cycle, or during tumour growth. 
Anti-angiogenesis 
A new and promising approach in anti-tumour therapy is the use of anti-angiogenic 
agents. The rationale behind this is that by blocking angiogenesis a tumour will become 
deprived of its nutrients and oxygen, and will eventually decrease in size or disappear. 
The mode of action of anti-angiogenic agents differs: they usually inhibit endothelial cell 
division, either directly, or indirectly by influencing the action of angiogenic factors. 
Anti-angiogenic factors often also influence the proteolytic properties of the endothelial 
cell surface (86). 
Some endogenous, mutually unrelated molecules are inhibitors of angiogenesis, such as 
thrombospondin, platelet factor 4, a tissue inhibitor of metalloproteinase: TIMP (85), 
interferon-α (87) and an oestrogen metabolite (88). These factors probably play a role in 
maintaining the natural balance between stimulation and inhibition of angiogenesis. Also 
analogues or derivatives of endogenous molecules, products derived from bacteria or 
fungi, and synthetic molecules have been shown to be potent inhibitors of angiogenesis in 
experimental situations, e.g. retinole acid, suramin (86), heparin (89), heparin-steroid 
conjugates (90), heparinase (91), fumagillin derivatives (92), and thalidomide (93). A 
growing list of angiogenesis inhibitors have also been shown to be effective suppressors 
of tumour angiogenesis and tumour growth (88,90,92,94-96), and at least one analogue of 
fumagillin, TNP-470, was successful in inhibiting metastasis of melanoma in mice (96). 
An exciting discovery was recently made that primary tumours of a Lewis lung 
carcinoma subline produce an anti-angiogenic factor, called angiostatin, which is identical 
to an internal part of plasminogen. This tumour-derived factor suppresses angiogenesis in 
and growth of its own metastases (97). This factor, and other angiogenesis suppressors, 
might become of great therapeutic value. Perhaps even more inhibitors of angiogenesis 
will be discovered or developed in the future. A quest for inhibitors or receptor 
antagonists of angiogenic growth factors, for instance, might open interesting new 
possibilities. 
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1.3 Introducing VPF 
Biological activities of VPF 
In recent years, increasing attention has been paid to the angiogenic factor VPF/VEGF. 
Vascular permeability factor (VPF) was initially isolated as a protein factor secreted by 
guinea pig tumours growing in the peritoneal cavity, which induced accumulation of 
serum protein-containing ascites fluid. The isolated protein also induced rapid and 
transient leakage of serum proteins from the dermal vasculature in guinea pig skin without 
inducing endothelial cell damage, as measured in a so-called Miles assay (98). Later this 
factor was found to be identical to vascular endothelial growth factor (VEGF) or 
vasculotropin, which had been isolated and cloned by several independent groups as an 
endothelial cell-specific mitogen and an inducer of angiogenesis in vivo, as measured in a 
chorioallantoic membrane (CAM) assay (51,99-102). In the remainder of this Chapter, 
this factor will be referred to as vascular permeability factor (VPF), since its effect on 
vascular permeability (in guinea pig skin) is more pronounced than its effect on 
endothelial cell proliferation (84,98,101,103,104). 
VPF has later been shown to induce rapid von Willebrand factor release from 
endothelial cells (105), to be chemotactic for endothelial cells (72), and to increase the 
expression of GLUT-1 glucose transporter (106), tissue factor (31), interstitial collagenase 
(74), plasminogen activators, and plasminogen activator inhibitor-1 (76) by endothelial 
cells (see Table 2). VPF thus induces multiple processes directly involved in 
angiogenesis, like endothelial cell proliferation, migration, and specific protease 
expression, but VPF also stimulates the activation of coagulation pathways by the 
endothelium and enhances vascular permeability. The latter phenomena are considered to 
be properties of tumour vasculature (11,24), but angiogenesis during wound healing is 
associated with hyperpermeable microvessels and formation of fibrin as well (107). 
VPF is also capable of inducing endothelial cells to invade three-dimensional collagen 
gels and to form capillary-like tubes in it (77). VPF therefore has the capacity to promote 
angiogenesis in an in vitro model system on its own, although in cooperation with bFGF 
the induction of in vitro angiogenesis is strikingly more prominent (77). 
VPF is often referred to as an endothelial cell-specific factor, but this is not completely 
true, as VPF also induces tissue factor expression on monocytes, and is chemotactic for 
monocytes (31). In all other cell types tested, VPF did not elicit a response, so it is 
probably correct to say that VPF has a very restricted target cell specificity, with 
endothelial cells being the main target. 
Bioavailability of VPF 
The VPF translation product is provided with a secretory signal peptide that is cleaved 
off during secretion from the producer cells (51,101). This feature is not common to all 
growth factors: for instance aFGF, bFGF and PD-ECGF lack a signal peptide, so in order 
18 
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Biological effects of VPF 
On cultured endothelial cells: In vivo: 
Immediate effects: Immediate effect: 
Tyrosine phosphorylation Vascular permeability 
Increase of intracellular Ca2+ and IP3 
Release of vWF 
Increased expression of: 
GLUT-1 glucose transporter 
Tissue Factor 
tPA, uPA, PAI-1 
Interstitial collagenase 
Other effects: Long-term effect: 
DNA synthesis and proliferation Angiogenesis 
Chemotaxis 
Invasion and tube formation in 
collagen gels 
Table 2. Biological activities of VPF on endothelial cells in vitro and in vivo. For references and 
abbreviations see the text. 
to reach their target cells alternative mechanisms of secretion must exist for these factors 
(108,48). But even with this secretory pathway, it is not self-evident that VPF can reach 
its target cells, since some variants of VPF are retained by the producer cells at 
extracellular sites. 
Several molecular variants of the VPF protein exist due to alternative splicing of its 
mRNA. The pre-mRNA for VPF contains 8 exons, of which exons 6 and 7 can either be 
present or absent in the mature mRNA (109). The VPF variants generally found in human 
cells have a length of 189 amino acids (encoded by all 8 exons), 165 amino acids (lacking 
the amino acids from exon 6) and 121 amino acids (lacking the amino acids from exons 6 
and 7, see Fig. 1). The analogous mouse, rat, and bovine proteins are 188, 164 and 120 
amino acids long (99,110,111). Two other, rare forms of human VPF mRNA have been 
described in literature: a variant encoding a 206 amino acid protein (containing all exons 
and part of the 7th intron) was found in liver (112), and a variant encoding a 145 amino 
acid protein (lacking exon 7 only) was found in uterine tissue (113). 
19 
Chapter 1 
Exon 6 of the VPF messenger codes for a basic stretch of amino acids, due to which the 
VPF splice variants containing these residues (VPF189, VPF^, and probably also VPF145) 
have a high affinity for heparin (VPF,89 elutes from heparin sepharose columns between 
0.9-2.0 M NaCl). Because of this these variants are retained by the producer cells on 
extracellular heparin-like molecules, probably proteoglycans (84). VPF,,,, was only 
released from the cells after addition of suramin or heparin to the medium, or by 
heparinase treatment of the producer cells. Moreover, plasmin cleavage resulted in the 
release of the N-terminal half of VPF18„ which was still biologically active (84). 
VPF165 has a lower affinity for heparin (it is completely eluted from heparin sepharose 
by 0.9 M NaCl), and is only partly retained by the producer cells, whereas VPF,2, has no 
significant affinity for heparin and is completely released from the producer cells (84). 
These two soluble VPF variants are almost the only species found in conditioned media 
from mammalian cells, generally migrating as bands of 15-24 kD on SDS-PAGE under 
reducing conditions (114). Under non-reducing conditions, however, VPF migrates as a 
broad band of between 34 and 43 kD (98), indicating that in its native form VPF is a 
dimeric protein. 
VPF mRNA 
exons 1-8 
-exon 6 
VL - exons 6 + 7 
I VPF proteins 
с 
с 
cecee 
cecee 
cc 
« 
cc 
Ш 
cc ecce с 
cc ecce с с 
с 
189 аа 
165 аа 
С С ССС С СС 
121 аа 
signal peptide mature protein 
Figure 1. Schematic illustration of the three most abundant splice variants of VPF mRNA, and of the 
primary structures of the encoded proteins. Solid boxes: secretory signal peptides; Hatched box: highly 
basic amino acid stretch encoded by exon 6. Also depicted are the N-linked glycosylation site (*), and 
the cysteine residues (C). The eight cysteine residues in the N-terminal half of VPF are conserved with 
PDGF, the other cysteines are unique for VPF. 
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The amino acids encoded by exons 6 and 7 do not appear to be essential for biological 
activity (84), but as demonstrated above, they are important for the availability of VPF. 
The smaller VPF variants are diffusible molecules probably able to reach their target cells 
easily, while the variants containing the exon 6-encoded amino acids are stored 
extracellularly, but can be recruited, for instance by plasmin cleavage, if their action is 
needed. Specific expression and storage of cell-bound VPF variants in theory might be 
valuable for tissues which do not require instant angiogenesis. However, in most human 
tissues, tumours, and cultured cells - transformed or non-transformed -, the mRNAs 
coding for the soluble VPF variants of 121 and 165 amino acids were the predominant 
species (112,113,115-117). Also in embryonic and adult mouse tissue, and in rat 
endothelial cells the mRNAs for the soluble variants were the major species found 
(110,111). Exceptions were human kidney and haemangioblastoma, in which the VPF189 
mRNA was expressed in abundancy along with the VPF121 mRNA (118), and rat heart, in 
which the VPF1M messenger was the predominant species (119). 
Cellular receptors for VPF 
In initial searches for VPF receptors endothelial cells of various sources were used, and 
two classes of VPF binding sites were always found. There were large differences in the 
affinities reported for these receptors, however. High affinity binding sites had 
dissociation constants of between 1-13 pM (with 500-25000 binding sites per cell), 
whereas for lower affinity binding sites dissociation constants of between 10-1500 pM 
were reported (with 3000-180000 sites per cell) (120-123,103). After cross-linking of 
VPF and receptor, complexes were detected of a molecular mass of 270 kD or 225 kD, 
often together with several smaller complexes. Binding of VPF to its receptors was 
inhibited by protamin and suramin (121,123), but was enhanced by heparin at 
concentrations between 0.1-10 /ig/ml (124). Pretreatment of endothelial cells with 
heparinase abolished binding of VPF, but binding was restored by the addition of soluble 
heparin, indicating that the binding of VPF to its receptors is dependent on the presence 
of heparin, or on heparin-like molecules on the cell surface (124). 
The binding of aFGF and bFGF on high-affinity FGF receptors is also dependent on 
heparin, and heparin is thought to potentiate this binding either by influencing the 
conformation of the FGF molecules, or by influencing the conformation of FGF receptors 
(125). The necessity of heparin-like molecules for the binding of VPF to its receptors was 
described for VPF16J (124), having significant affinity for heparin. It was, however, not 
tested if the binding of VPF,2I, lacking the affinity for heparin, to VPF receptors is also 
dependent on heparin. Testing the heparin dependence for receptor binding of both VPF 
variants might provide interesting information about the mechanism by which heparin 
exerts its potentiating effect. 
More recently, two receptors for VPF have been cloned. The product of the fins-like 
tyrosine kinase gene {fit), isolated from a human placenta cDNA library (126), was 
characterized as a receptor for VPF (127), forming a 205 kD complex with VPF, and 
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having a high affinity for it (50% inhibition of binding caused by 20 pM of unlabelled 
VPF; ICso=20 pM). The fit receptor might be the high affinity binding site on endothelial 
cells reported in earlier studies. Very recently it was demonstrated that also P1GF, a 
growth factor related to VPF, binds with high affinity to the fit receptor (128). Another 
putative tyrosine kinase gene: fetal liver kinase 1 {flk-1) isolated from a mouse cDNA 
library (129) was also found to code for a VPF receptor (130). The human homologue of 
the flk-1 gene was isolated independently from an endothelial cell cDNA library, and 
designated kinase insert domain-containing receptor (KDR) (131,132). Complexes of VPF 
with the flk-1/KDR receptor had a molecular mass of 220 kD (133) or 235 and 195 kD 
(132), while dissociation constants varied between 75-600 pM in different studies 
(130,132,133), which is in the range of the lower affinity VPF binding sites on 
endothelial cells found in other studies. 
The sequences of the cDNAs encoding the VPF receptors fit and flk-1/KDR predict two 
homologous transmembrane proteins, which both have 7 extracellular immunoglobulin-
like (IgG-like) domains and a tyrosine kinase domain interrupted by a so-called kinase 
insert. The tyrosine kinase domain is shared between very many growth factor receptors, 
and IgG-like domains and a kinase insert sequence are also found in e.g. the PDGF-
receptor family and the FGF-receptor family (134). The VPF receptors thus have many 
features in common with other growth factor receptors. 
Following binding of VPF to the flk-1/KDR receptor, autophosphorylation of a single 
protein was indeed demonstrated (130,133). An increase in intracellular Ca2+ was evident 
after binding of VPF to both the fit and the flk-1/KDR receptor (127,130), which is 
consistent with the finding that VPF induces rapid inositol triphosphate (IP3) formation 
and an increase of intracellular Ca2+ levels in human endothelial cells (105). Therefore, 
signalling of activated VPF receptors probably proceeds through activation of 
phosphoinositide-specific phospholipase C-7 (PLC-7), but probably also by other 
pathways. It has been shown for many receptor tyrosine kinases that after 
autophosphorylation, intracellular messenger molecules like PLC-7, GTPase-activating 
protein (GAP), and phosphatidyl inositol 3-kinase (РІЗ-kinase) are activated, presumably 
through binding to phosphorylated tyrosine residues in the intracellular domain of the 
receptor (134). The first data on the signalling by VPF-receptors suggest that this family 
of receptors is not exceptional in this context. 
Expression of VPF receptors is often said to be restricted to endothelial cells. This 
conclusion is based on in situ hybridizations with an fit probe on embryonic and adult 
mouse tissues (135), on hybridizations with an flk-1 probe on developing mouse organs 
(133), and on the finding that transcripts of the fit and the KDR gene were present in 
cultured endothelial cells but absent in some non-endothelial cells (103). However, flk-1 
transcripts have been identified in murine umbilical vein stroma, which is non-endothelial 
tissue (130), the flk-1 cDNA was cloned from a mouse cell population enriched in 
haemopoietic stem cells (129), and VPF binding sites (with a dissociation constant of 300-
500 pM) have been identified on monocytes, which were also responsive to VPF 
(136,31). High-affinity binding sites for VPF have even been found on human melanoma 
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cells, HeLa cells, mouse NIH-3T3 fibroblasts, and bovine granulosa cells (137,124), but 
no activation of these putative receptors by VPF, nor a response of these cells to VPF, 
has been demonstrated. 
Another resemblance with some other growth factor receptors (FGF-receptors fig and 
bek, 125), is that a soluble VPF receptor can be generated by alternative splicing of the 
fit pre-mRNA (138). A sequence encoding a truncated receptor was isolated from an 
endothelial cell cDNA library. The encoded protein lacked the membrane-spanning 
domain and the intracellular tyrosine kinase domains, and it was secreted from the 
producing cells. This soluble receptor molecule bound VPF in solution and prevented 
VPF to bind to cellular receptors, thus neutralizing VPF activity. Expression of this 
receptor variant by endothelial cells might provide a means of modulating VPF activity in 
vivo, and perhaps might be part of a feedback mechanism. 
1.4 Expression of VPF in normal tissues and in pathological states 
VPF was originally isolated from guinea pig line 10 tumour cells, and its activity was 
immediately linked to the accumulation of ascites associated with this malignancy (98). 
Also VEGF activity was isolated from a variety of transformed cells such as mouse 
tumour cell line AtT20, rat glioma cells, the human leukemia cell line HL60, and the 
human histiocytic lymphoma cell line U937 (51,100,101,139). VEGF was also isolated, 
however, from an untransformed cell type: bovine pituitary folliculo-stellate cells (140), 
indicating that expression of VPF/VEGF is not confined to tumour cells alone. Cloning of 
the cDNA sequence for VPF has made it easier to study its expression in several tissues, 
tumours and cell lines. Nevertheless, few quantitative studies have been published as yet 
comparing VPF expression levels between normal tissues and tumours. This Chapter will 
summarize some reports on the expression of VPF under physiological conditions, in 
tumours, and in other diseases (for an overview, see Table 3). 
VPF expression in normal tissues 
Several adult organs and tissues in guinea pig and man have been found to contain VPF 
mRNA, particularly lung, kidney, adrenal gland, liver, stomach, heart (especially the 
cardiac myocytes), as well as peritoneal macrophages (141,119). In healthy organs, with 
generally quiescent blood vessels, VPF may play a role in maintaining the existing density 
of the vasculature, or in maintaining a basal level of vascular permeability necessary for 
transport of, for instance, nutrients. 
Expression of VPF mRNA during mouse brain development was highest during the 
periods of active vascularization (prenatal and postnatal) and was reduced in adult brain in 
which angiogenesis had ceased (110). These data suggest that VPF is involved in 
embryonic and fetal angiogenesis. VPF gene expression was further shown to be 
regulated by differentiation processes: during differentiation of mouse preadipocyte cells 
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A 
Roles of VPF expression 
In normal physiology In pathological conditions 
Embryonic and fetal angiogenesis Wound healing 
Maintenance of adult vasculature Rheumatoid arthritis 
Angiogenesis during menstrual cycle Ovarian hyperstimulation 
syndrome 
Retinopathies 
Tumours 
В 
Features of VPF expression in tumours 
Expression of VPF is often higher in tumours than in normal tissues 
VPF expression can be upregulated by hypoxia 
VPF accumulates in tumour blood vessels 
С 
Roles of VPF in tumours 
VPF is essential for tumour angiogenesis 
VPF causes vascular hyperpermeability and fibrin matrix generation 
Does VPF influence metastasis? 
Table 3. A: Summary of the normal processes and the diseases in which VPF is thought to play a 
role; B: Some generally accepted phenomena concerning VPF expression in tumours; C: Summary of 
the processes in tumour biology in which VPF is thought to play a role. For details and references see 
the text. 
to adipocyte cells and during differentiation of mouse myogenic C2C12 cells to myocytes 
VPF messenger levels were increased (142). 
Recurring angiogenesis takes place in the female reproductive organs of mammals, 
coinciding with the oestrous cycle. In rat corpus luteum, in murine ovarian and uterine 
tissues with an expanding vasculature, and in human endometrium and myometrium 
expression of VPF mRNA was found (143,144,113). Spatial distribution of VPF 
messengers changed during the course of the oestrous cycle (113), and expression was 
seen especially in steroid-responsive cell types (144), suggesting that VPF expression is 
hormonally regulated in these tissues. Consistent with this hypothesis is the finding that 
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endometrium-derived carcinoma cell lines increased their VPF expression in response to 
oes trad iol (113). 
Expression of VPF mRNA has also been demonstrated in cultured rat and bovine brain 
capillary endothelial cells, in cultured aortic smooth muscle cells, and in human brain 
capillary pericytes (111, 145, and Chapter 3). If these cells express VPF also in vivo, 
autocrine stimulation of endothelial cells would be possible, and endothelial cells would 
be stimulated permanently by directly surrounding cells. However, data obtained with 
cells in vitro should be interpreted cautiously, as cells growing in culture may behave 
differently from cells in vivo. 
VPF expression under pathological conditions 
After wounding of skin, a healing process takes place in which also angiogenesis is 
involved. During this process, keratinocytes at the wound edge, and keratinocytes 
migrating to cover the wound surface were shown to have markedly increased levels of 
VPF mRNA compared to resting keratinocytes (107). This upregulation suggests that VPF 
is an important factor in neovascularization during wound healing. 
VPF expression is also thought to play a role in a number of diseases (see also Table 
ЗА). VPF expression was shown to be much higher in inflamed rheumatoid arthritis (RA) 
compared to other forms of arthritis, like osteoarthritis. VPF production was 
predominantly seen in the synovial lining, especially by macrophages. High levels of VPF 
were also found in RA synovial fluid, an effusion rich in plasma proteins (72,146). VPF 
therefore might play a role in the vascularization of RA synovial tissue, which is rich in 
blood vessels, and also in the enhanced vascular permeability and the accumulation of 
synovial fluid associated with RA. 
Ovarian hyperstimulation syndrome (OHSS) is an overreaction of the ovarium to 
ovulation induction therapy, and is characterized by effusion of protein-rich fluid from 
blood vessels into the peritoneal cavity. This ascites fluid was found to contain significant 
amounts of VPF, which may therefore be responsible for the observed vascular 
hyperpermeability (147). 
Expression of VPF in human retina has recently been found by several authors, and is 
thought to play a role in the pathogenesis of eye diseases involving ocular 
neovascularization, like diabetic retinopathy (148-150). 
VPF expression in tumours 
Notwithstanding the fact that VPF is expressed, and is probably important, in many 
physiological situations, much of the research on VPF has focused on its role in tumour 
biology. For a schematic overview of the present ideas about VPF expression in tumours, 
and of the presumed roles of VPF in tumour biology, see also Table 3 (B and C). 
It is generally assumed that VPF expression levels correlate with the tumourigenic 
potential of cells, and that VPF levels in tumours are higher than in surrounding normal 
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tissue. One of the earliest observations leading to this hypothesis was that guinea pig line 
10 carcinoma cells, and a series of human tumour cells (osteogenic sarcoma, bladder 
carcinoma, cervical carcinoma, and fibrosarcoma cells) produced and secreted high levels 
of VPF activity (151). Most interestingly, two of these tumourigenic cell lines were 
derived from non-tumourigenic parental cell lines which secreted much less VPF activity. 
Later it was also found that human tumourigenic fibrosarcoma and osteosarcoma lines 
produced higher levels of VPF mRNA than related but non-tumourigenic fibroblast and 
osteosarcoma lines (141). Also, expression of VPF mRNA in transformed and poorly 
differentiated phaeochromocytoma cells was down-regulated during differentiation into 
neuron-like cells (142). 
Studies with human, mostly colonic, adenocarcinomas revealed that they often contained 
higher levels of VPF messenger than less malignant adenomas, and than surrounding 
normal epithelium and mucosa (142,152). Also in most well-vascularized human renal 
cell carcinomas increased messenger levels of VPF, as well as of the related factor P1GF, 
were found compared to adjacent normal kidney tissue (117). 
Many observations have led to the idea that hypoxia may be an important VPF-inducing 
mechanism in tumours: locally reduced oxygen pressure due to insufficient vascularization 
might induce VPF expression, in an attempt to stimulate further angiogenesis and thereby 
to improve oxygen supply. Different groups have demonstrated an upregulation of VPF 
transcript levels adjacent to necrotic (presumably hypoxic) areas in human and rat 
glioblastoma (153-155). This upregulation was likely to be caused by hypoxia, as VPF 
mRNA levels were also increased in glioma cell lines cultured under low oxygen tension 
(153,155). In human adenocarcinomas increased VPF messenger levels were also found 
around necrotic sites, although this was only observed in tumour stroma but not in tumour 
cells (152). 
VPF secreted by tumour cells is believed to accumulate in nearby tumour blood vessels. 
In solid guinea pig line 10 tumours and in human lymphomas, VPF mRNA was found to 
be synthesized in tumour cells, but upon immunohistochemistry using an anti-VPF 
antibody staining was observed mainly on the endothelium of tumour blood vessels and of 
blood vessels immediately adjacent to the tumour (156). No staining for VPF was found 
in more distant blood vessels. Other studies have revealed that transcripts for the VPF 
receptors fit and flk-1/KDR are present in higher amounts in tumour endothelial cells than 
in endothelial cells outside of the tumours (152,154,155). This not only suggests that VPF 
accumulates in tumour blood vessels because many binding sites for VPF are present 
there, it also suggests that tumour blood vessels are more responsive to VPF than normal 
blood vessels. 
Does VPF expression actually play a role in the development of the tumour vascular 
bed? There is indirect evidence that VPF does indeed influence tumour 
neovascularization. In glioma, the sites of highest VPF production - near necrotic foci -
were surrounded by clusters of newly formed microvessels (153), thus showing a clear 
spatial correlation between VPF expression and angiogenesis. 
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Transfection experiments have recently provided direct evidence for the importance of 
VPF in tumour angiogenesis and tumour growth. By transfection of non-tumourigenic 
Chinese hamster ovary (CHO) cells with a VPF expression construct, these cells acquired 
the ability to proliferate in nude mice and to form vascularized lesions (157). Similarly, 
transfection of the human tumour cell line HeLa with a VPF expression construct 
conferred to these cells a growth advantage in nude mice compared to control cells, which 
was associated with a higher angiogenic activity in the xenografts (158). In Chapters 3 
and 4 of this thesis, experiments will be described in which the role of VPF expression in 
tumour angiogenesis is determined, using VPF-transfected melanoma cell lines growing as 
tumours in nude mice. 
The importance of VPF in tumour angiogenesis was also demonstrated through 
inhibition of VPF activity by use of neutralizing antibodies. The growth-stimulatory effect 
of enhanced VPF expression by a transfected HeLa cell line was suppressed by such a 
treatment (158). In xenografts of rhabdomyosarcoma and glioblastoma cells in nude mice 
treatment with a neutralizing antibody against VPF also inhibited tumour growth, and 
decreased the vascular density of the lesions. The antibody did not affect the growth rate 
of the tumour cells in vitro (52). In another elegant approach VPF activity was inhibited 
by virus-mediated gene transfer into endothelial cells in vivo of a sequence encoding a 
dominant-negative mutant of the flk-1 VPF receptor. Glioblastomas in nude mice were 
growth inhibited by this treatment, and ended up as a non-vascularized and highly 
necrotic tumour cell mass (53). 
VPF expression by tumours may also enhance the permeability of tumour blood vessels. 
This was demonstrated by the fact that the relative expression levels of VPF in a series of 
tumour cell lines correlated with the in vivo vessel permeability in tumours developing 
from these lines after injection into nude mice (159). Furthermore, the accumulation of 
VPF on the endothelium of tumour blood vessels was associated with hyperpermeability 
of these vessels for macromolecules (156). A VPF-induced enhancement of vascular 
permeability may facilitate tumour vascularization, as vessel permeability can lead to the 
deposition of a fibrin matrix around existing vessels, which in its turn is a substrate for 
developing tumour stroma and ingrowing capillaries (reviewed in 160). 
Since angiogenesis is an important step in metastasis, VPF expression might also 
influence this process. However, no reports have as yet been published which directly 
correlate VPF expression with metastasis. 
VPF in tumour diagnosis and potential clinical applications 
The many observations on VPF expression in tumours indicate that the level of VPF 
expression in suspect cancers might be an indicator for prognosis. On the other hand, 
VPF expression was also found in normal tissues (presumably in lower quantities), and 
was associated with other diseases than cancer as well, as discussed above. This can 
hamper the use of VPF as a prognostic marker for cancer. Nevertheless, methods 
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determining VPF protein or messenger levels are being developed, and may become 
important tools in tumour diagnosis in the future. 
For the measurement of VPF mRNA levels in tumours Northern blotting techniques 
might be useful, but given the small amounts of material generally available from 
biopsies, a quantitative RT-PCR method would probably be more practical. As yet, only a 
few studies have compared VPF messenger levels between malignant and less malignant 
or normal tissues (117,141,152). These studies have, however, not answered the question 
if VPF mRNA quantitations are useful in tumour diagnosis or prognosis. 
For the determination of VPF protein, in the lesions themselves or in body fluids, 
specific immuno-assays are required. A time-resolved immunofluorometric assay (IFA) 
for VPF was shown to be potentially useful as a diagnostic test for malignancy: the VPF 
levels in human ascitic tumour effusions correlated with the presence of malignant cells in 
the lesions (161,162). No VPF was detected with this method in plasma and urine from 
tumour-bearing animals or from patients with malignant cancers. 
The spatial distribution of VPF expression might also be indicative for the degree of 
tumour malignancy. In gliomas the distribution of VPF expression was such that the 
highest levels of VPF mRNA were found around necrotic foci (153,154), and there was 
also evidence that induction of VPF expression is mediated by hypoxia in these tumours 
(154,155). In other tumour types VPF expression was more homogeneous (152). It would 
be interesting to investigate if differences in spatial expression of VPF in tumours 
(induced levels around necrotic sites versus homogeneous expression) in some way relate 
to prognosis. Theoretically, therefore, the diagnosis of tumour malignancy may also 
benefit from methods that determine the spatial distribution of VPF expression, such as in 
situ hybridization and immunohistochemistry. 
VPF at present is thought to have an important role in tumour angiogenesis, which in its 
turn is important for metastasis, as discussed before. Blocking of VPF activity therefore 
may inhibit both tumour progression and metastasis, and might have clinical applications. 
Among the many agents recently tested for their anti-angiogenic and tumour-inhibiting 
activity (see above), VPF inhibitors might also find a place. 
In an experimental model, inactivation of VPF by transfecting endothelial cells with 
dominant-negative VPF receptor constructs was effective in inhibiting tumour 
angiogenesis and tumour growth (53). Also in animal models, neutralization of VPF by 
anti-VPF antibodies has been shown to suppress tumour angiogenesis and tumour growth 
efficiently (52,158). These approaches may also be applicable clinically, provided that 
virus-mediated gene transfer is accepted in clinical practice, or that sufficient amounts of 
neutralizing anti-VPF antibodies become available. 
Blocking of VPF activity may also be achieved by the use of the serum protein a2-
macroglobulin (a2M), which binds and inactivates VPF in vitro (163), or by using an 
excess of soluble VPF receptor, which is endogenously produced by endothelial cells, and 
which binds and inactivates VPF in solution (138). The ability of these endogenous 
proteins to inhibit angiogenesis in vivo has not been described yet, however. 
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A future approach in anti-angiogenesis might be the design of VPF receptor antagonists, 
which should be able to bind to, and occupy VPF receptors without activating them. Also 
dominant-negative VPF analogues might be designed, which should dimerize with, and 
thereby inactivate normal VPF polypeptide chains. Attempts to produce such analogues of 
other growth factors, for instance of the related factor PDGF, have shown that this will 
be very difficult (164). Knowledge about the structure of the protein, and about the 
receptor-binding domains of the factor is certainly a prerequisite for success. 
1.5 Regulation of VPF expression 
Expression of VPF has to be tightly regulated, as different levels of VPF activity are 
required in various tissues, developmental stages, and physiological circumstances. Little 
is known about the mechanisms regulating VPF expression, however. 
There is evidence that regulation of VPF gene expression in ovarium and uterus 
involves hormones like oestradiol (113,144), but nothing is known about the cellular 
mechanisms occurring after hormone stimulation. Similarly, the mechanisms by which 
upregulation of VPF expression takes place in keratinocytes during wound healing (107) 
are as yet unknown. 
Hypoxia induction of VPF gene expression 
Induction of VPF expression by hypoxia appears to be a direct way of improving a 
vasculature that is incapable in delivering sufficient nutrients and oxygen to all cells. In 
such a situation cellular hypoxia can elevate the expression of VPF, which can induce the 
formation of the necessary new blood vessels. Hypoxia-induced expression of VPF has 
been shown in glioma in vivo, and in a variety of cell lines in vitro, such as glioblastoma 
cells, hepatoma cells, and retinal pigment epithelial cells (148,153-155,165). The 
expression of some other genes is induced by hypoxia as well, but the mechanisms 
involved in this kind of induction are only beginning to be understood (reviewed in 166). 
Nitric oxide (NO) plays a role in hypoxia-induced expression of the PDGF-B chain gene 
and the endothelin-1 gene (167), but for regulation of the VPF gene an involvement of 
NO has not been reported yet. There is circumstantial evidence, however, that a haeme 
protein acts as an oxygen sensor, and is involved in hypoxia-induced upregulation of VPF 
and erythropoietin (EPO) gene expression (165). In glioma cells and in hepatoma cells 
hypoxia-induced expression of these genes was mimicked by addition of cobalt chloride 
(CoCl2), and was inhibited by carbon monoxide (CO): cobalt and CO are known to bind 
strongly to haeme groups. Hypoxia also induced the levels of c-jun and junB mRNA, 
while CoCl2 induced c-jun and c-fos mRNA levels, which code for proteins that can 
dimerize to form transcription factor AP-1. Putative recognition sites for AP-1 are present 
in the 5'-flanking region of the VPF gene (109). Furthermore, a number of sequences 5' 
of the VPF gene are 90% homologous to hypoxia-responsive enhancers present 3' of the 
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EPO gene (165, see also Fig. 2). These c/i-acting regulatory elements may be involved in 
hypoxia-induced expression of the VPF gene. 
Growth factor induction of VPF expression 
VPF expression has also been shown to be induced by growth factors. PDGF-BB 
induced the level of VPF mRNA in NIH-3T3 cells rapidly and transiently (maximum 
level reached after 1 h, 168). In monocytic U937 cells, mouse embryo fibroblasts, and 
human lung adenocarcinoma cells VPF mRNA levels were elevated by exposure to TGF-
fll, with a maximum reached after 4-8 h. In the fibroblasts the VPF protein level was 
shown to be increased as well (169,170). Induction of VPF expression - in tumour cells 
and in infiltrating cells - might be one of the ways by which TGF-ß exerts its angiogenic 
activity in vivo (see above). 
Growth factor induction of VPF expression is probably mediated via a protein kinase С 
(PKC)-dependent pathway, since the PKC-activating phorbol ester PMA increased the 
VPF messenger levels in U937, NIH-3T3, preadipocyte, and vascular smooth muscle 
cells (168,169,142,109), and PDGF-induced upregulation of VPF mRNA levels in NIH-
3T3 cells was abolished by downregulation of PKC (by preincubation with PMA, 168). 
flanking 
region 
flanking 
region 
1 kb 
Figure 2. Schematic illustration of the VPF gene structure. The upper line shows the 8 exons (solid 
bars), the introns (double lines), and the S' and 3' flanking regions of the gene (single lines). The 
transcription initiation site (-•), the putative translation initiation codon (ATG) and the stopcodon (*) 
are also depicted. The lower une is an enlargement of a 5' flanking region of the VPF gene and the 
first exon. This also shows three alternative out-of-frame initiation codons (atg and gtg) and a number 
of sequences closely matching the consensus for transcriptional regulation elements: Al, AP-1 binding 
site; A2, AP-2 binding site; N, nuclear factor 1 binding site; HS, heat shock element; HO, hypoxia-
responsive enhancer; S, Spi binding site (refs. 109,167). 
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VPF mRNA in mouse adipocytes was also induced by cyclic AMP analogues, which 
suggests that also cAMP-dependent protein kinase is involved in a pathway leading to 
enhanced VPF expression (142). 
Transcriptional regulation 
Ultimately, induction of VPF expression (by growth factors or otherwise) will probably 
be the result of binding of transcription factors to elements present in the VPF gene. In 
the 5' flanking region, and also within the VPF gene, 4 putative AP-1 binding sites, 2 
putative AP-2 binding sites, and a putative nuclear factor I binding site are present. A 
consensus heat shock element is present in the VPF gene, which may be involved in 
induction of VPF gene expression in response to stress. Furthermore, 8 GC box 
sequences, which are putative Spl-binding sites, are present in the regulatory region of 
the VPF gene, while a TATA box is absent close to the start site of transcription (109, 
see also Fig. 2). The presence of Spi binding sites and the absence of a TATA box are 
features often found in house-keeping genes, but it is clear that the VPF gene is inducible 
by external factors, as is discussed above. 
In tumour cells a constitutively high expression of VPF is often found (see above). 
Perhaps in these cells transformation has caused aberrant expression of oncogenes or 
tumour suppressor genes, which may in their turn influence VPF gene expression. 
Elevated expression of c-jun and/or c-fos, for instance, which form the AP-1 transcription 
factor, might explain increased transcription of the VPF gene, but no such relation has as 
yet been demonstrated. However, a mutation in tumour suppressor gene p53 frequently 
found in tumours does result in increased VPF mRNA levels in NIH-3T3 cells, and 
potentiates PMA-stimulated VPF mRNA expression (171). 
Post-transcriptional regulatory mechanisms 
Transcription factors obviously regulate expression at the level of transcription, but VPF 
expression may also be regulated post-transcriptionally. As discussed above, by 
alternative splicing multiple protein forms of VPF are generated which differ in their 
affinity for heparin-like molecules, and which are stored on the extracellular matrix of the 
producer cells to a different extent. Thus, there is a possibility of regulating the 
bioavailability of VPF by selective alternative splicing. In some organs, like kidney and 
heart, large amounts of the mRNA coding for a cell-bound VPF variant were found 
(118,119), whereas in most other cases the soluble variants were found to be 
predominant. 
Regulation of VPF expression might also take place at the level of messenger stability. 
VPF mRNA has a much longer half-life in the presence of the protein synthesis inhibitor 
cycloheximide (165), indicating that its breakdown is dependent on active processes. 
Regulation of VPF mRNA stability may be possible, although it is not known by what 
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mechanisms the mRNA is destroyed, and by what mechanisms this breakdown may be 
regulated. 
VPF expression may further be regulated at the translational level. In the VPF 
messenger, 5' of the proposed AUG translation initiation site there is one extra out-of-
frame AUG codon, followed three codons further by a stop codon. In addition, there are 
two potential out-of-frame GUG initiation codons (109, see also Fig. 2). Furthermore, the 
5' non-coding sequence immediately upstream of the initiation site is extremely GC-rich 
(109). These features have also been found in the messengers for other growth factors, 
like those encoding the PDGF-A and В chains (172). The sequences upstream of the 
initiation site of the PDGF-B chain messenger have a profound inhibitory effect on 
translation efficiency (173,174). In endothelial cells an alternative PDGF-B chain mRNA 
was expressed which lacks these 5' translation inhibitory sequences (175). Also in the 
VPF messenger the 5' non-coding region may inhibit translation, but no experiments have 
as yet been published confirming this. 
1.6 Structural properties of the VPF protein 
Properties of the VPF protein and regions essential for biological activity 
VPF is formed from a preprotein containing a leader sequence which is needed for 
secretion of VPF, and which is cleaved off during secretion. The mature, secreted VPF 
polypeptide is largely N-glycosylated, presumably on the asparagine residue on position 
75 in man (or residue 74 in most mammals) (51,101,114). Glycosylation is not essential 
for biological activity of VPF, but enhances the secretion of VPF from the producer cells 
(114). 
As stated before, VPF exists in several molecular variants due to alternative splicing of 
exons 6 and 7 from its pre-mRNA (112). The VPF variants differ especially in their 
cellular retainment (84). The smaller VPF variants appear to be the predominant products 
of most cell types, and these are also the efficiently released variants. Electrophoresis 
under reducing conditions of medium conditioned by VPF-producing cells generally yields 
VPF bands between 15 and 24 kD, typical for VPF121 and VPFI6J. For instance, guinea 
pig line 10 tumour cells mainly secreted glycosylated VPF proteins of 19.5 and 24 kD, 
along with some non-glycosylated VPF proteins of 15 and 20 kD (114). Under non-
reducing conditions these proteins migrated as a broad band of between 34 and 43 kD 
(98), indicating that native VPF occurs as an S-linked dimer. The larger VPF variants of 
189 and 206 amino acids are rarely seen, but if expressed they appear as bands of 
somewhat higher molecular mass (mainly 27 and 29 kD after reduction, 112). The 
different splice variants, either glycosylated or non-glycosylated, make many 
combinations of homodimers and heterodimers possible. 
The amino acids encoded by the alternatively spliced exons 6 and 7 do not appear to be 
essential for biological activity, as VPF121, which lacks these residues, is biologically 
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active in several assays (112). The 6 most C-terminal residues, encoded by exon 8, and 
present in all molecular variants of VPF, probably are not essential for biological activity 
either, since by plasmin cleavage of VPF189 the N-terminal part of this protein (migrating 
as a 17 kD band upon reduction) is released which is biologically active (112). Exon 1 
only encodes residues of the signal peptide, which is responsible for secretion, and 
perhaps also for correct protein folding, but is no longer present in the mature protein 
itself. The region relevant for biological activity of VPF can thus be limited to the 
residues encoded by exons 2-5. 
Antibodies produced against peptides corresponding with amino acids 1-26 and 171-189 
of VPF189 (i.e. reacting with the extreme N-terminus and C-terminus) showed much better 
binding to native VPF, and achieved much higher inhibition of VPF activity than 
antibodies raised against peptides corresponding with the internal part of the VPF 
sequence (176). These results suggest that the N-terminus and the C-terminus are the 
exposed regions of the VPF protein in solution, and that these regions are essential for 
biological activity. These conclusions are somewhat premature, however. The extreme C-
terminus was shown in other experiments to be non-essential for activity (see above). 
Inhibition of activity by the anti C-terminal antibody might also be caused by an indirect 
effect, for instance by steric hindrance of the receptor-binding site. Furthermore, some of 
the antibodies against the middle part of VPF reacted weakly with denatured and reduced 
VPF as well, indicating that their poor binding to native VPF may simply reflect 
properties of the antibodies, and therefore they may not give valuable information about 
the VPF structure. 
Resemblance between VPF, PDGF, and PIGF 
The preproteins of the PDGF-A and В chains, PIGF, and VPF all contain a secretory 
signal peptide (172,54). The mature proteins of PDGF and PIGF also resemble VPF in 
that they exist as S-linked dimers. The sequence identity with VPF is 15%, 18%, and 
53% for the PDGF-A chain, the PDGF-B chain, and PIGF, respectively (101,54). 
In the genes of all four proteins, exon 6 codes for a highly basic stretch of amino acids, 
that becomes part of the C-terminal half of the mature protein. Exons 6 of the genes for 
VPF, PDGF-A chain and PIGF are subject to alternative splicing (109,177,55). The 
residues encoded by exons 6 cause the proteins to remain cell-associated. In mutants of 
the PDGF-A and В chains lacking a signal peptide these residues have even been shown 
to act as a nuclear targeting signal (178,179). 
The conservation of 8 cysteine residues between VPF, the PDGF-A and В chains, and 
PIGF (51,101,54) may be important, in that they presumably determine much of the 
protein structure. The role of these cysteines in maintaining the structure of PDGF is well 
known. The cysteines 1, 3, 5, 6, 7 and 8 form intrachain disulfide bonds which are 
arranged in a so-called "cystine knot", also seen in nerve growth factor (NGF) and TGF-
ß2 (180,181). Cysteines 2 and 4 form disulfide bridges between two PDGF subunits in a 
cross-wise manner, i.e. Cys 2 is linked to Cys 4 of the other subunit, and vice versa 
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(182,180). Substitutions of cysteines 2 and/or 4 of PDGF by serines prevented S-linked 
dimerization, but such mutants of the PDGF-B chain existed as biologically active non-
covalent dimers (182,183). Similar PDGF-A chain mutants were incapable of binding to 
PDGF receptors and did not have biological activity, however (182). There is strong 
evidence, therefore, that PDGF must exist as a dimer in order to bind and activate its 
receptor. 
In Chapter 5 of this thesis, experiments will be described which test if also in VPF 
cysteine residues 2 and 4 are involved in intermolecular disulfide bonds, and if so, if 
covalent dimerization of VPF by these disulfide bridges is essential for biological activity. 
Apart from the 8 cysteine residues conserved with PDGF, other cysteine residues are 
present in VPF and P1GF (51,101,54, see also Fig. 1), the function of which is as yet 
unknown. Binding of a2-macroglobulin to VPF involves the formation of a DTT-labile 
disulfide bond (163), suggesting that at least one of the cysteine residues in VPF is in a 
reduced form. 
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1.7 Aims of the studies described in this thesis 
The work that was carried out in the project leading to this thesis was focused on 
tumour-secreted factors which influence vascular endothelium, and thus tumour 
vasculature. Initially, attention was given to the purification, characterization, and cloning 
of one or more of such protein factors secreted by a human melanoma cell line. 
Especially factors which upregulate tissue factor expression (i.e. procoagulant activity) by 
endothelial cells were under survey, since such factors may induce the coagulative 
properties often found in tumour vasculature (25). Furthermore, such factors may cause 
the high sensitivity of tumour blood vessels to TNF treatment, which in some animal 
tumours has caused the occurrence of thrombi obstructing blood flow and haemorrhagic 
necrosis (35,36), and which in melanoma patients has caused significant remissions (39). 
Incubation of endothelial cells in melanoma cell-conditioned medium caused the 
induction of procoagulant activity as well as an elevation of tissue factor messenger 
levels. Therefore, in the purification protocol of this melanoma-derived factor, either an 
assay measuring procoagulant activity (PCA), or an assay measuring tissue factor mRNA 
levels could be used. To achieve maximum sensitivity with the latter approach, a 
quantitative RT-PCR assay was set up, which made it possible to measure tissue factor 
mRNA levels accurately even with small amounts of endothelial cells. The development 
of this assay, as well as an application of this assay, are described in Chapter 2. 
An article by Clauss et al. (31) showed that murine vascular permeability factor (VPF), 
which was until then only known to induce endothelial cell proliferation, angiogenesis, 
and enhanced vascular permeability, also caused increased tissue factor expression by 
endothelial cells. VPF was also known to be produced by a number of tumours and 
tumour cell lines, and therefore VPF might be (one of) the protein factor(s) that we were 
purifying. From the time when it was discovered that some human melanoma lines indeed 
expressed the mRNA for VPF, priority was given to the research on VPF. 
One of the items in further study was the role of VPF in the biological behaviour of a 
series of human melanoma lines in nude mice. First, the question was addressed whether 
there was a correlation between the level of VPF expression and the metastatic potential 
of the melanoma xenografts. The expression of VPF was studied in these melanoma lines 
in cell culture as well as in the resulting tumours. The expression patterns were found to 
be more complicated than expected, and a clear correlation with metastatic frequency 
could not be found. In order to obtain more evidence for a role of VPF in melanoma 
angiogenesis and metastasis, the effect of altered expression levels of VPF - achieved by 
stable transfections of one of the melanoma lines with VPF expression constructs - on the 
development of the tumour vascular bed and on the metastatic potential were studied. The 
results of these investigations are described in Chapters 3 and 4. 
Finally, studies on the structure/function relationship of the VPF protein were initiated, 
analogous to studies performed by others on PDGF (182). For this purpose a number of 
VPF mutants was generated with one of the cysteine residues changed to a serine residue. 
These mutants were expressed in mammalian cells which allowed the synthesis of 
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functionally active VPF wild type protein. The mutant proteins were tested for their 
ability to dimerize, and were tested for biological activity in a number of assays, 
including, again, the procoagulant assay (PCA). Conclusions could be drawn from these 
studies regarding the relation between dimerization and biological activity, and about 
disulfide bonds essential for VPF dimerization. These experiments are presented in 
Chapter 5. 
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Chapter 2 
We have developed a sensitive and quantitative RT-PCR assay for the 
determination of tissue factor (TF) mRNA levels in human cells. An in vitro 
synthesized internal standard RNA was used to correct for differences in reverse 
transcription or amplification of various RNA samples. The PCR products were 
quantitated by hybridization. The sensitivity was such that less than 0.2 μg of total 
endothelial RNA sufficed to measure its TF mRNA content. The RT-PCR assay was 
used to determine TF mRNA levels in endothelial cells treated with a factor from 
human melanoma cells and/or TNF. In this way the amount of TF mRNA could be 
induced to a level that was at least 80-fold higher than that in non-induced cells. This 
increase was in the same order of magnitude as the induction of measured TF 
activity. 
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Introduction 
Expression of procoagulant activity by the endothelium is a feature that is usually 
associated with pathological phenomena. For this reason it is important to study the 
mechanisms underlying the activated procoagulant state. Several agents such as LPS, 
PMA, IL-1 and TNF (1-4) as well as some tumour-derived factors (5-8) are known to act 
as inducers of procoagulant activity. Although some of these factors can act in a 
synergistic fashion (6,7), it appears that they have a common target as the procoagulant 
activity is generally mediated by tissue factor (TF; 2,9,10). To dissect and understand the 
intracellular processes leading to an enhanced TF expression it is necessary to have an 
assay that allows the determination of both TF activity and TF messenger RNA level. 
RNA levels are usually assayed by the Northern technique. However, in this technique 
the amount of RNA is a limiting factor. In those cases where too little RNA is available, 
or where specific mRNA levels are too low, the polymerase chain reaction preceded by 
reverse transcription (RT-PCR) is the obvious way to improve the sensitivity of detection. 
To compare levels of mRNA quantitatively by RT-PCR, some precautions must be taken 
and internal controls must be included in the assay - for examples see (11-15). In this 
paper we present a quantitative RT-PCR assay for TF mRNA. As an internal standard we 
used an in vitro produced control RNA which is amplified by use of the same primers as 
TF mRNA and which yields a PCR product of a greater length than the TF messenger 
product. In an application of this technique, we have measured the non-induced level of 
TF mRNA in cultured human endothelial cells, and we followed the changes in the levels 
of TF mRNA in these cells after stimulating procoagulant activity by TNF and/or by a 
protein factor derived from a human melanoma cell line. TF mRNA levels were elevated 
to about 80-fold the basal level, which approximately equaled the increase in procoagulant 
activity. 
Materials and methods 
Chemicals and materials 
Normal tissue cultureware was from Costar (Cambridge, MA, USA) and fibronectin 
coated tissue cultureware was from Collaborative Biomedical Products (Bedford, MA, 
USA). EMEM and L-glutamine were from Flow laboratories (Irvine, UK); FCS from 
Integro (Zaandam, The Netherlands) and NCS from Gibco BRL (Paisley, UK). 
Gentamycin was from the Schering Corporation (Amstelveen, The Netherlands); heparin 
from Organon Teknika (Boxtel, The Netherlands); trypsin from Difco (Detroit, MI, USA) 
and polymyxin В was from Pfizer (Rotterdam, The Netherlands). Ribonucleotides, 
deoxyribonucleotides and random hexamer oligonucleotides were from Pharmacia LKB 
(Woerden, The Netherlands). Calcium-Thromboplastin, Collagenase, Klenow enzyme, 
T7-RNA polymerase and the cDNA synthesis kit were from Boehringer (Mannheim, 
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Germany) and recombinant human TNFa was a kind gift of Boehringer (Ingelheim, 
Germany). RQl-DNase was from Promega (Madison, WI, USA); AMV-reverse 
transcriptase was from Stratagene (San Diego, CA, USA) and Supertaq polymerase was 
from HT Biotechnology (Cambridge, UK). [a-"P]dATP (3000 Ci/mmol) was from 
Amersham (Amersham, UK). All other chemicals were reagent grade and purchased from 
standard suppliers. Oligonucleotide primers were synthesized by a Millipore 8400 
Cyclone plus nucleic acid synthesizer (Bedford, Ma, USA) and PCR reactions were 
performed in a Bioexcellence PHC-1 DNA incubator. Autoradiographs were scanned with 
an Ultroscan XL Enhanced Laser Densitometer from LKB (Bromma, Sweden). 
Cell culture 
The human melanoma cell line BLM was cultured as described elsewhere (16). Human 
umbilical vein endothelial cells (HUVEC) were isolated by collagenase treatment 
essentially as in (17). They were cultured in Eagle's modified essential medium (EMEM) 
supplemented with 15% heat inactivated human serum, 15% FCS, 2 mM L-glutamine, 
150 μg/mI endothelial cell growth factor (isolated from calf brain as described in (18)), 
10 mM HEPES pH 7.3, 5 U/ml heparin and 40 μg/ml gentamycin in fibronectin-coated 
tissue culture flasks. Cells were detached from their flasks using 0.125% trypsin, 0.2% 
EDTA in PBS, and split 1:2 or 1:4 every 2 to 3 days. 
Procoagulant assay 
Procoagulant activity was determined in a clotting assay essentially as in (19). 
Endothelial cells were grown in 30 mm wells to confluence. Medium was replaced by 
PMB medium (EMEM supplemented with 15% newborn calf serum, 50 /zg/ml polymyxin 
B, 2 mM L-glutamine and 40 μ£/πι1 gentamycin). After the addition of procoagulant 
inducing agents, cells were incubated for 5 hours and then suspended by scraping with a 
rubber policeman. Cells were washed in 0.5 ml veronal buffer, and finally resuspended in 
100 μΐ veronal buffer (7 mM veronal, 4 mM Na-acetate, 130 mM NaCl, pH 7.4). After 
the addition of 100 μΐ 20 mM CaCl2 and 100 μΙ human plasma, the time needed for fibrin 
clot formation at 37°C was recorded. All determinations were performed in duplicate. 
Values were converted to TF units, using a standard curve prepared by diluting Calcium-
Thromboplastin in clotting buffer. One unit of TF activity was assigned arbitrarily as the 
equivalent of a 10,000-fold dilution of the stock concentration prescribed by the 
manufacturer. 
Isolation of RNA 
Cytoplasmic RNA was isolated from HUVEC by the method described in (20). RNA 
concentration was measured spectrophotometrically at 260 nm (21). 
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Analysis of RNA by Northern hybridization 
Samples of RNA were denatured in formaldehyde buffer containing 50% formamide 
(formaldehyde buffer is: 6.5% formaldehyde, 25 mM NaH2P04/Na2HP04, pH 7.0) at 
55 °C for 15 min and run on a 1% agarose gel in formaldehyde buffer. RNA was then 
transferred to nitrocellulose in 20 χ SSC (1 χ SSC is: 0.15 M NaCl, 0.015 M Na-citrate, 
pH 7.0) and baked at 80°C for 2 h under vacuum (21). Hybridizations were performed 
overnight at 45eC in 50% formamide, 6 χ SSC, 0.1% SDS, 0.1 mg/ml denatured herring 
sperm DNA and 5 χ Denhardt's (21) and filters were subsequently washed 3 χ 20 min in 
0.2 χ SSC, 0.1% SDS at 65°C and exposed to X-ray films at -70°C. The following 
probes were used: the 1.03 kb insert from HTF8, a cDNA clone comprising the complete 
human tissue factor protein coding region (22), and the insert from pHGR21, a cDNA 
clone encoding human poly-ubiquitin (23). The fragments were labelled with [a-32P]dATP 
after random hexamer priming (24). 
Control RNA for the RT-PCR 
The insert from HTF8 (22) was recloned into the Smal site of pUC19, yielding the 
plasmid pTFl. A 0.4 kb £coRl fragment containing a non-mammalian sequence -ayl, a 
repeat unit from the Drosophila hydei Y-chromosomal gene "nooses" (25)- was ligated 
into the £c0Rl-site at the end of the 5th exon (26; position 817) (Fig. 1) by standard 
techniques (21). The insert of the resulting clone pTFayl was transferred to pGEM-9Zf-, 
yielding clone pGEM-TFayl. Control RNA was synthesized in vitro using 250 ng of 
tfmdIII-digested pGEM-TFayl DNA in 40 mM Tris/HCl pH 8.0, 50 mM NaCl, 8 mM 
MgCl2, 2 mM spermidine, 10 mM DTT, 1 mM of each NTP, 100 U RNasin, and 100 U 
T7 RNA polymerase in a 50 μΐ volume (21). The reaction was performed at 37°C for 2 
h. Plasmid DNA was then digested by treatment with RQl-DNasel. RNA was extracted 
with phenol, ethanol precipitated and redissolved in distilled water. To confirm the 
integrity and correct length (1.5 kb) of the control RNA, and to determine its 
concentration, a sample of this RNA was run on a 1% agarose/formaldehyde gel (as 
described above) together with a dilution range of №«dIII-linearized and denatured pTFl 
plasmid DNA. A nitrocellulose blot of this gel was hybridized to the TF probe at 44°C. 
No residual pGEM-TFayl plasmid DNA could be detected in the RNA preparation. 
RT-PCR protocol 
Preparations of HUVEC RNA and control RNA were diluted in distilled water 
containing 100 ng/μΐ carrier (yeast ribosomal) RNA. HUVEC RNA (between 10 and 900 
ng) and control RNA (between 0.1 and 1.0 pg) (Fig. 1) were mixed and 2 μΐ of 5 χ 
cDNA first strand buffer (0.25 M Tris/HCl pH 8.3, 0.25 M KCl, 50 mM MgCl2, 50 mM 
DTT), 2.5 μΐ of dNTP solution (2 mM each), 1 μΐ (0.5 μg) of the TF specific reverse 
primer (5'-CAGTGCAATATAGCATTTGCAGTAGC-3*) (Fig. 1) and distilled water up 
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TF mRNA PCR product 
^ ^ 0.3 kb 
control RNA 0.4 kb insertion 
—• • - 0.7 kb 
TF gene intron 
^ ^
7 Г
 ^ 2 j T k b 
Figure 1. Outline of the RT-PCR assay. Specific primers corresponding to positions 723-748 
(forward) and 1005-980 (reverse) (22) amplify a 0.3 kb region of the tissue factor mRNA consisting of 
parts of the 5th and 6th exon. In vitro transcribed control RNA added to each reaction has a 0.4 kb 
insertion and gives rise to a 0.7 kb PCR product. Contaminating genomic DNA should yield a 2.0 kb 
fragment which spans the 1.7 kb 5th intron (26). 
to 9.5 μ\ were added. The mixture was incubated at 65°C for 5 min and directly placed 
on ice. Then 0.25 /tl (6 U) of RNasin and 0.25 μ\ (6.5 U) of AMV reverse transcriptase 
were added. The reverse transcriptase reaction was incubated for 1 h at 42CC. 
Subsequently the nucleic acids were ethanol precipitated and redissolved in 20 μ\ distilled 
water. PCRs were performed with one fifth or one half of the cDNA, to which 5 μ\ of 10 
χ Taq polymerase buffer (100 mM Tris/HCl pH 9.0, 500 mM KCl, 0.1% gelatin, 1% 
Triton X-100), 5 /il of dNTP solution (2 mM each), 1 μ\ (0.5 /ig) of reverse primer, 1 μ\ 
(0.5 /ig) of forward primer (5*-CTACTGTTTCAGTGTTCAAGCAGTGA-3') (Fig. 1), 
distilled water up to 50 μ\, and 0.1 μΐ (0.5 U) of Supertaq polymerase were added. Each 
cycle consisted of a denaturation step at 96°C for 1 min, an annealing step at 62°C for 
1.5 min, and an elongation step at 72°C for 4 min. 20 cycles were used when 1 pg of 
control RNA was reverse transcribed; 25 cycles were used when 0.1 pg of control RNA 
was reverse transcribed. 10 μ\ and 1 μ\ samples of the PCR reactions were run on a 1.3% 
agarose gel in 0.5 χ TBE (1 χ TBE is 100 mM Tris, 100 mM boric acid, 2.5 mM 
EDTA, pH 8.2). DNA was "Southern blotted" (21) and hybridized to the TF probe at 
42°C in 50% formamide, 6 χ SSC, 0.1% SDS, 0.1 mg/mi denatured herring sperm DNA 
and 5 χ Denhardt's, washed 3 χ 20 min in 0.2 χ SSC, 0.1% SDS at 65 °C and exposed to 
X-ray film at -70°C. Intensities of the hybridization signals were quantified by scanning 
and integration of autoradiographic bands on several exposures with a laser densitometer. 
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Results 
Concentration-dependent induction of procoagulant activity by melanoma-derived HS-1 
activity 
Culture supernatants of the human melanoma cell line BLM (16) were found to induce 
procoagulant activity on human umbilical vein endothelial cells (HUVEC). A partially 
purified component from this supernatant, denoted here as heparin-sepharose fraction 1 
(HS-1; see legend to Fig. 2), was used in the studies reported below. HS-1 caused a dose-
dependent induction of procoagulant activity that approached a maximum of about 100-
fold the initial level at 100 μ\ HS-1. To determine the mode of cooperation between the 
HS-1 activity and TNF, the experiment was repeated in the presence of 50 pM TNF. 
Addition of TNF did cause an enhanced procoagulant activity in the presence of HS-1. 
However, the increase in activity was not synergistic but probably due to an additive 
effect of HS-1 and TNF. The maximum level of procoagulant activity was not 
significantly increased by addition of TNF (Fig. 2). 
l o o qr 
20 40 60 80 
HS-1 added (μΐ) 
100 
Figure 2. Procoagulant activity on 
endothelial cells treated with HS-1 in the 
presence or absence of TNF. Serum-ftee 
BLM culture supernatant was subjected 
to heparin-sepharose affinity chroma­
tography. The major activity, which 
eluted around 0.1 M NaCl, was called 
HS-1. Different amounts of HS-1 were 
assayed alone (O) or together with 50 
pM TNF ( Δ ) . Clotting times were 
compared to a standard curve of TF 
activity prepared using serial dilutions of 
Ca-Thromboplastin. 1 unit was arbitrarily 
defined as the activity matching to a 
10,000-fold dilution of Ca-Thrombo­
plastin stock solution. Values are the 
average of duplicate measurements. 
Standard deviations were omined since 
they were small compared to the size of 
the symbols in the figure (3-7% of the 
values). 
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HS-1 also increases the TF mRNA contents in H UVE С 
To determine the effect of HS-1 and TNF on the tissue factor mRNA levels HUVEC 
were incubated with varying amounts of HS-1 in the absence or presence of TNF. Total 
RNA was isolated 2 h after the start of the incubations - the time point when maximal TF 
mRNA levels were found upon treatment with LPS and PMA (27) - and 2 μg aliquots 
were Northern blotted (Fig. 3). In non-treated HUVEC TF mRNA could hardly be 
detected, whereas in HS-1 and TNF-treated HUVEC two TF mRNA bands of 2.3 kb and 
1.9 kb became apparent after prolonged exposure. The appearance of a major band of 2.3 
kb is in accordance with the data from others, while double bands were also found earlier 
(6,27). These results showed a clear induction of the TF mRNA upon HS-1 treatment. 
However, the intensities of the signals were just above the limit of detection, which 
makes quantitation of these results highly unreliable. 
To improve the sensitivity of TF mRNA determination, we developed a quantitative RT-
PCR assay. The strategy is outlined in Fig. 1: primer sites on the TF transcript were 
chosen such that they are located in different, adjacent exons, thus allowing a distinction 
between amplification of TF mRNA and of possible genomic DNA contaminants. In 
addition, an RNA to be used as an internal control was synthesized. This RNA has the 
same primer sites but should yield a PCR product 400 nucleotides longer than the one 
derived from authentic TF mRNA. 
Figure 3. Northern analysis of tissue factor 
mRNA levels. HUVEC were incubated with: 
0 μ\ (1), 10 μΐ (2), 30 μΐ (3), 100 μΐ (4) of 
HS-1 alone, and with: 0 μ\ (5), 10 μ\ (6), 30 
μ\ (7), 100 μ\ (8) of HS-1 along with 50 pM 
TNF. Samples of total RNA (approximately 
2 μg except for Lane 5) isolated from these 
cells were loaded on a gel. The resulting 
Northern blot was first hybridized to a tissue 
factor probe (upper part) and then hybri­
dized to a ubiquitin probe (lower part). 
Autoradiographs were exposed for 14 days 
with two intensifying screens (tissue factor) 
and for 2 days with one intensifying screen 
(ubiquitin). Arrowheads indicate postitions 
of 18S and 28S ribosomal RNA. Note that 
much less RNA was loaded in lane 5. 
1 2 3 4 5 6 7 8 
Tissue factor 
2.3 kb · 
1.9 kb < 
Ubiquitin 
« 
2.2 kb <- * « · m m m m 
54 
Quantitative RT-PCR for TF mRNA 
Challenging the RT-PCR 
First, the question was addressed whether under the conditions applied the RT-PCR 
yields quantitative results. To test this RNA was isolated from HUVEC which had been 
incubated with 100 /Л of crude BLM culture supernatant for 2 hours. This amount of 
crude supernatant is equivalent in activity to approximately 30 μ\ of partially purified HS-
1 (see Fig. 2) and these cells should contain enhanced levels of TF mRNA (see Fig. 3). 
Aliquots of this RNA (from 10 to 900 ng) were mixed with known amounts of control 
RNA (0.1 or 1.0 pg) and subjected to the RT-PCR. To visualize and quantify the TF 
specific PCR bands, the PCR products were Southern blotted and hybridized with a TF 
probe. As expected, higher inputs of HUVEC RNA yielded more 0.3 kb PCR product 
relative to the 0.7 kb control product (Fig. 4). The output ratio TF mRNA product : 
control product was quantified by densitometry and plotted as a function of the amount of 
input RNA (Fig. 5). Curves were drawn from the series using 0.1 pg of control RNA (A 
and C), and 1.0 pg of control RNA (В and D). Theoretically, these are expected to be 
1 2 3 4 5 6 7 8 9 10 
« * « · · · - · « 0.7 kb 
Figure 4. RT-PCR with different amounts of induced HUVEC RNA and control RNA. RNA was 
isolated from HUVEC which were incubated with 100 μ\ of crude BLM culture supernatant. It was 
mixed with in vitro transcribed control RNA and reverse transcribed. One fifth of the cDNA was used 
for PCR. 10 μί samples of the PCR products were separated on gel, blotted and hybridized to a tissue 
factor probe. The autoradiograph was exposed for 3 days without an intensifying screen. 1: 1 pg 
control RNA - no reverse transcriptase was used in the first reaction; 2: yeast ribosomal RNA 
(carrier); 3: 0.1 pg control RNA; 4: 0.1 pg control RNA and 10 ng HUVEC RNA; 5: 0.1 pg control 
RNA and 30 ng HUVEC RNA; 6: 0.1 pg control RNA and 100 ng HUVEC RNA; 7: 0.1 pg control 
RNA and 300 ng HUVEC RNA; 8: 1 pg control RNA and 100 ng HUVEC RNA; 9: 1 pg control 
RNA and 300 ng HUVEC RNA; 10: 1 pg control RNA and 900 ng HUVEC RNA. Reactions 1-7 
were cycled 25 times, reactions 8-10 were cycled 20 times. Note that a faint band of 0.7 kb appeared 
when control RNA was subjected to the PCR without prior reverse transcription (lane 1). This may be 
caused by a contamination with pGEM-TFayl plasmid DNA. It might also be the consequence of a 
slight reverse transcriptase activity present in Taq polymerase (28). Its contribution to the 0.7 kb band 
in the normal RT-PCR reactions can be neglected. In none of the total RNA preparations were bands 
of 2.0 kb resulting from amplification of genomic DNA seen. 
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straight lines. The slopes of some curves however showed a slight decrease. This non-
linearity is probably caused by saturation of the hybridization with bands that contain 
large amounts of PCR product (this decrease apparently is more pronounced in Figs. 5 A 
and В where more PCR product was loaded). Results should preferably be quantified 
from hybridizations on small amounts of PCR product. The amount of TF mRNA in the 
RNA preparation used in this experiment was estimated from three points in Figs. 5 С 
and D each. The mean value found was 19 pg/jig total RNA, with a standard deviation of 
2 1 % (n=6). Mean values calculated independently from Figs. 5 С and D were such that 
standard deviation was 18% (n=2) . These experiments thus show that this RT-PCR can 
measure TF mRNA levels reproducibly. Within limits, the results are not affected 
significantly by the amount of endothelial cell RNA and control RNA used in the assay. 
Endothelial cell RNA (^ g) 
Figure 5. Quantitation of 
RT-PCR test results. Inten­
sities of bands on auto-
radiographs (such as shown 
in Fig. 4) were measured by 
densitometry. Ratios of 
intensities of the 0.3 kb and 
the 0.7 kb bands were 
plotted against the input 
amount of HUVEC RNA. A: 
0.1 pg control RNA; 10 μϊ 
product loaded. B: 1.0 pg 
control RNA; 10 μϊ product 
loaded. C: 0.1 pg control 
RNA; 1 μϊ product loaded. 
D: 1.0 pg control RNA; 1 μϊ 
product loaded. 
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The induction of TF mRNA by HS-1 measured by RT-PCR 
The results presented in Figs. 4 and 5 show that the RT-PCR can indeed be used for a 
quantitative measurement of TF RNA. Hence we applied this method to quantitate the 
changes in TF mRNA levels in HUVEC treated with different amounts of HS-1 with and 
without TNF. RT-PCR was performed with 0.2 pg samples of HUVEC RNA which were 
mixed with 0.2 pg or 1 pg of control RNA. The PCR signals obtained are shown in Fig. 
6 and show the expected trend towards an increase in TF mRNA upon stimulation with 
HS-1. To correct for differences in reverse transcription and amplification, the PCR 
mRNA signal (the 0.3 kb band) was divided by the control RNA signal (the 0.7 kb band). 
The ratio obtained was plotted against the added amount of HS-1 in Fig. 7. Again, the 
effects of TNF and HS-1 were additive rather than synergistic. Although the TF mRNA 
content (Fig. 7) appears to reach its plateau earlier than procoagulant activity (Fig. 2), 
both curves are quite comparable. 
To illustrate the potential of this method, we have estimated from our data a number of 
TF mRNA levels in endothelial cells upon induction with TNF and/or HS-1. In RNA 
from non-treated endothelial cells the messenger/control product ratio (m/c) was 0.048. A 
TF mRNA level of 0.54 pg/jig was calculated. In cells treated with 50 pM TNF (m/c 
ratio of 0.67) and in maximally induced cells (m/c ratio of 3.94) TF mRNA values of 7.5 
pg/pg and 44 pg/fig were found, respectively. Hence, the maximum induction of TF 
mRNA achieved in this experiment was about 80 times the basal level. Higher inductions 
might also be possible however, as from Fig. 7 it is not clear whether the maximum level 
of TF mRNA has been reached yet. Since endothelial cells isolated from human material 
are quite heterogeneous, the same experiment repeated with another batch of endothelial 
cells may yield different results. 
Discussion 
Previous studies have used Northern hybridizations to assay tissue factor mRNA 
(6,10,27). However, it is often difficult to obtain enough RNA to achieve reliable results 
with this technique. This recently led to the use of a semi-quantitative RT-PCR assay to 
determine differences in TF mRNA expression (8). We have presented in this paper a 
highly sensitive method for quantitative measurement of tissue factor mRNA levels in 
human cells, which should be applicable even with amounts of RNA much less than the 
0.2 ¿ig used by us. In our PCR assay we have used only one set of primers to amplify the 
messenger and control RNAs. As the specificity of primers is seldom absolute, this 
resulted in a smear of PCR products upon ethidium bromide staining. Hybridization with 
a TF probe was necessary to stain the TF specific fragments. The specificity of the PCR 
could have been improved by the use of a second set of primers, so-called "nested 
primers". However, such a procedure requires additional manipulations, while 
hybridization has the further advantage that band intensities can be simply quantitated. 
57 
Chapter 2 
1 2 3 4 5 6 7 8 9 10 
* * « 0.7 kb 
* 0.3 kb 
Figure 6. RT-PCR on RNA from HUVEC that were treated with various amounts of HS-1 in the 
presence or absence of TNF. Endothelial cells were incubated with: no HS-1 (2,3), 10 μΐ HS-1 (4), 30 
μΐ HS-1 (5), 100 μΐ HS-1 (6) alone, and with: no HS-1 (7), 10 μΙ HS-1 (8), 30 μΐ HS-1 (9), 100 μΐ 
HS-1 (10) along with 50 pM TNF. RNA was isolated from these cells and used in the following 
reactions: 1: 0.2 pg control RNA only; 2: 0.2 pg control RNA and 0.2 /xg non-induced HUVEC 
RNA. 3-10: 1 pg control RNA and 0.2 μg HUVEC RNA. After reverse transcription one half of the 
cDNA was used for PCR. Reactions 1 and 2 were cycled 23 times, reactions 3-10 were cycled 20 
times. 10 μΐ samples of the PCR products were separated on a gel, blotted and hybridized with a tissue 
factor probe. The autoradiograph was exposed for 24 h without an intensifying screen. 
HS-1 added (μΐ) 
Figure 7. Quantitation of RT-PCR 
results. Bands as in Fig. 6, lanes 3-10, 
but from blots with 1 μΐ of the PCR 
products, were quantified by densi­
tometry. Ratios of intensities of the 0.3 
kb and the 0.7 kb bands were plotted 
against the amount of HS-1 added to the 
endothelial cells. One series was per­
no formed without TNF (О), and another 
series was performed in the presence of 
50 pM TNF ( Δ ) . 
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The output ratio of target and control PCR fragments increased, as expected, with the 
input ratios of TF mRNA and control RNA. RT-PCR on dilution series of endothelial cell 
RNA with either 0.1 pg or 1.0 pg control RNA resulted in approximately equal estimates 
of the TF mRNA level, showing that this assay is applicable to a broad range of input 
RNA concentrations. Quantitation of the bands showed that blots are easily overloaded, 
causing non-linear relations between input and output ratios. Loading small amounts of 
PCR product should minimize this problem. 
We have applied this technique to follow changes in the TF mRNA level in endothelial 
cells upon incubation with a factor secreted by human melanoma cells. An increase in 
procoagulant activity was coincident with a rise in TF mRNA levels. Upon stimulation 
with 100 μ\ HS-1 and TNF, TF mRNA levels and procoagulant activities were elevated 
by the same order of magnitude (80/100-fold the basal level). This correlation is not 
unexpected, since TF mRNA accumulation may preceed elevated TF protein expression. 
However, the TF mRNA level is not necessarily the only factor determining the final 
procoagulant activity. Post-transcriptional processes may also play an important role. 
Furthermore, not all TF protein that is synthesized by the endothelial cells will be 
assayed. A large part of the TF protein is located extracellularly, and some of this is left 
behind after scraping of the cells, as was shown by procoagulant assays on intact cell 
layers and in wells from which the cells were removed by scraping. Procoagulant 
activities were much higher when scraped cells were used (data not shown), suggesting 
that intracellular TF is released by injury of cells, or that the assay is influenced by 
damaged membranes. Thus, the amount of TF activity measured differs with the method 
used to harvest the cells. Therefore we have only compared relative procoagulant 
activities, and expressed them in arbitrary units. 
The procoagulant inducing activity from the human melanoma cell line BLM is 
mediated by a protein factor, the nature of which is still under investigation. Some 
tumour-derived procoagulant inducing proteins isolated by others appeared to act 
synergistically with TNF (6,7). We did not observe this synergism between the 
melanoma-derived factor HS-1 and TNF, neither at the level of TF mRNA, nor at the 
level of procoagulant activity. This effect might nevertheless be demonstrable at lower 
concentrations of either TNF or HS-1. 
Acknowledgements 
We thank Boehringer Ingelheim for their generous gift of TNFa, and Dr. Evan Sadler 
for providing the cDNA probe for tissue factor. 
59 
Chapter 2 
References 
1. Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N: Cultured human 
endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983, 71:1893-1896 
2. Nawroth PP, Stem DM, Kisiel W, Bach R: Cellular requirements for tissue factor generation by 
bovine aortic endothelial cells in culture. Thromb Res 1985, 40:677-691 
3 . Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA: Interleukin 1 (IL-1) induces 
biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J 
Exp Med 1984, 160:618-623 
4. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA: Recombinant tumor 
necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization 
and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986, 83:4533-4537 
5. Noguchi M, Sakai T, Kisiel W: Identification and partial purification of a novel tumor-derived 
protein that induces tissue factor on cultured human endothelial cells. Biochem Biophys Res Comm 
1989, 160:222-227 
6. Clauss M, Murray JC, Vianna M, de Waal R, Thurston G, Nawroth P, Gerlach H, Gerlach M, 
Bach R, Familletti PC, Stern D: A polypeptide factor produced by fibrosarcoma cells that induces 
endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J 
Biol Chem 1990, 265:7078-7083 
7. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan YCE, Olander JV, 
Connolly DT, Stern D: Vascular permeability factor: a tumor-derived polypeptide that induces 
endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 
1990, 172:1535-1545 
8. Kao J, Ryan J, Brett G, Chen J, Shen H, Fan YG, Godman G, Familletti PC, Wang F, Pan YCE, 
Stem D, Clauss M: Endothelial Monocyte-Activating Polypeptide II. A novel tumor-derived 
polypeptide that activates host-response mechanisms. J Biol Chem 1992, 267:20239-20247 
9. Stem DM, Drillings M, Kisiel W, Nawroth P, Nossel HL, LaGamma KS: Activation of factor DC 
bound to cultured bovine aortic endothelial cells. Proc Natl Acad Sci USA 1984, 81:913-917 
10. Bloem LJ, Chen L, Königsberg WH, Bach R: Serum stimulation of quiescent human fibroblasts 
induces the synthesis of tissue factor mRNA followed by the appearance of tissue factor antigen and 
procoagulant activity. J Cell Physiol 1989, 139:418-423 
11. Robinson MO, Simon MI: Determining transcript number using the polymerase chain reaction: 
Pgk-2, mP2, and PGK-2 transgene mRNA levels during spermatogenesis. Nucleic Acids Res 1991, 
19:1557-1562 
12. Chelly J, Kaplan JC, Maire P, Gautron S, Kahn A: Transcription of the dystrophin gene in human 
muscle and non-muscle tissues. Nature 1988, 333:858-860 
13. Becker-André M, Hahlbrock К: Absolute mRNA quantification using the polymerase chain 
reaction (PCR). A novel approach by a PCR aided transcript titration assay (PATTY). Nucleic Acids 
Res 1989, 17:9437-9446 
14. Gilliland G, Perrin S, Blanchard К, Bunn HF: Analysis of cytokine mRNA and DNA: Detection 
and quantitation by competitive polymerase chain reaction. Proc Natl Acad Sci USA 1990, 87:2725-
2729 
15. Wang A, Doyle MV, Mark DF: Quantitation of mRNA by the polymerase chain reaction. Proc 
Natl Acad Sci USA 1989, 86:9717-9721 
16. van Muijen GNP, Cornelissen LMHA, Jansen CFJ, Figdor CG, Johnson JP, Вгбскег EB, Ruiter 
DJ: Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into 
nude mice. Clin Exp Metastasis 1991, 9:259-272 
17. Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial cells derived from 
umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973, 52:2745-
2756 
60 
Quantitative RT-PCR for TF mRNA 
18. Maciag T, Cerandolo J, Ilsley S, Kelley PR, Forand R: An endothelial cell growth factor from 
bovine hypothalamus: Identification and partial characterization. Proc Natl Acad Sci USA 1979, 
76:5674-5678 
19. Helin H, Edgington TS: Allogeneic induction of the human Τ cell-instructed monocyte 
procoagulant response is rapid and is elicited by HLA-DR. J Exp Med 1983, 158:962-975 
20. Gough NM: Rapid and quantitative preparation of cytoplasmic RNA from small numbers of cells. 
Anal Biochem 1988, 173:93-95 
21. Sambrook J, Fritsch EF, Maniatis Τ (Eds): Molecular Cloning: A Laboratory Manual, ed 2. Cold 
Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1989 
22. Scarpati EM, Wen D, Broze GJ, Miletich JP, Flandermeyer RR, Siegel NR, Sadler JE: Human 
tissue factor: cDNA sequence and chromosome localization of the gene. Biochemistry 1987, 26:5234-
5238 
23. Einspanier R, Sharma HS, Scheit KH: Cloning and sequence analysis of a cDNA encoding poly-
ubiquitin in human ovarian granulosa cells. Biochem Biophys Res Comm 1987, 147:581-587 
24. Feinberg AP, Vogelstein В: A technique for radiolabeling DNA restriction endonuclease fragments 
to high specific activity. Anal Biochem 1983, 132:6-13 
25. Vogt Ρ, Hennig W: Molecular structure of the lampbrush loops nooses of the Y chromosome of 
Drosophila hydei. I. The Y chromosome-specific repetitive DNA sequence family ayl is dispersed in 
the loop DNA. Chromosoma 1986, 94:449-458 
26. Mackman N, Morrissey JH, Fowler B, Edgington TS: Complete sequence of the human tissue 
factor gene, a highly regulated cellular receptor that initiates the coagulation protease cascade. 
Biochemistry 1989, 28:1755-1762 
27. Crossman DC, Carr DP, Tuddenham EGD, Pearson JD, McVey JH: The regulation of tissue 
factor mRNA in human endothelial cells in response to endotoxin or phorbol ester. J Biol Chem 1990, 
265:9782-9787 
28. Tse WT, Forget BG: Reverse transcription and direct amplification of cellular RNA transcripts by 
Taq polymerase. Gene 1990, 80:293-296 
61 

Chapter 3 
Vascular Permeability Factor Expression Influences 
Tumour Angiogenesis in Human Melanoma Lines 
Xenografted to Nude Mice 
Andy J.G. Pötgens, Nicolette H. Lubsen, Margarethe C. van Altena, John G.G. 
Schoenmakers, Dirk J. Ruiter, Robert M.W. de Waal 
This Chapter was also published in: 
the American Journal of Pathology 1995, 146:197-209. 
Chapter 3 
We studied the expression of the angiogenic factor vascular permeability factor 
(VPF, also called vascular endothelial growth factor/VEGF) in human melanoma 
cells in vitro and in vivo. Melanoma lines that develop tumours with a low metastatic 
potential in nude mice were found to have low expression levels of VPF in vitro, and 
the VPF expression levels in melanoma lines that yield highly metastatic xenografts 
were high. However, in vivo the correlation between VPF mRNA levels and the 
frequency of metastasis was lost: in all xenografts equally high levels of VPF mRNA 
were found, independent of the parental cell line. Hence, in vivo VPF gene expression 
was upregulated in the low expressing lines. The external factor responsible for this 
induction may be hypoxia, since we found that low oxygen tension caused a 
(reversible) increase in the VPF mRNA levels in otherwise low expressing melanoma 
lines in vitro. A melanoma line with an inducible VPF expression was engineered into 
a line with a constitutive VPF expression. In the xenografts from this line a change in 
the vascular architecture was seen, indicating that the pattern or the level of VPF 
expression is important for tumour angiogenesis in melanoma xenografts. 
64 
VPF expression in melanoma 
Introduction 
Vascular permeability factor (VPF), also known as vascular endothelial growth factor 
(VEGF), is a glycosylated, secreted protein factor that increases blood vessel 
permeability, stimulates endothelial cell division in vitro, and induces angiogenesis in vivo 
(1,2). Two different receptors for VPF have been characterized: fms-like tyrosine kinase 
(fit) and fetal liver kinase 1/kinase insert domain-containing receptor (flk-1/KDR). These 
appear to be expressed almost specifically by endothelial cells and haemopoietic cells (3-
6). VPF is an important angiogenic factor, along with other factors such as acidic and 
basic fibroblast growth factor (aFGF, bFGF) and transforming growth factor ß (TGF-ß) 
(7,8). Apart from its expression by some normal, well-vascularized tissues, embryonic 
tissues and during wound repair (9-12), VPF has been found in many tumours and tumour 
cells (13). In glioblastoma VPF expression was found to be highest near necrotic areas, 
and clusters of newly formed capillaries were found around the sites of VPF production 
(14,15), suggesting that VPF can be recruited to augment angiogenesis if the tumour 
vasculature and therefore the oxygen supply is insufficient. The role of VPF in tumour 
angiogenesis was confirmed by blocking its activity in tumours by a monoclonal antibody, 
and by application of a dominant-negative VPF receptor mutant (16,17). These treatments 
led to a decrease in angiogenesis and to slower tumour growth. 
Several protein variants of VPF exist due to alternative splicing of the VPF mRNA. The 
molecular variants differ in their efficiency of secretion. The smaller forms (VPFm and 
VPF165) are efficiently secreted by the producing cells, and can easily reach their target 
cells. The larger forms (VPFI89 and VPF^) are retained at the extracellular matrix, but 
biologically active parts of these proteins can be released by plasmin (18-20). 
Theoretically, different cell types may benefit from particular VPF variants. Tissue-
specific expression of certain VPF messenger variants has indeed been demonstrated 
(19,21). 
As a consequence of its proposed role in tumour angiogenesis, VPF may also facilitate 
metastasis, as this process is dependent on the vascular bed (22). To study the relation 
between VPF expression and metastasis, a panel of human melanoma cell lines was used. 
Xenografts of these melanoma lines in nude mice give rise to tumours with distinctly 
different biological behaviour. Some of these lines develop into rapidly metastasizing 
tumours, whereas other lines metastasize at a low frequency or very slowly (23, JR 
Westphal et al; manuscript in preparation). The metastatic phenotype of these lines was 
found to correlate with the expression of a series of genes or antigens, such as urokinase-
plasminogen activator (uPA) and its type 1 inhibitor (PAI-1), various integrins, the 
epidermal growth factor receptor (EGF-R), thymosin BIO and calcyclin (24-28). We 
report here that low and highly metastatic melanoma lines have distinctly different 
expression patterns of VPF. Highly metastatic melanoma lines have constitutively high 
levels of VPF expression, whereas the less metastatic lines have a low level of VPF 
expression in culture, which is elevated in mouse xenografts. In vitro data suggest that 
hypoxia may be an important trigger in this upregulation of VPF gene expression. 
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Transfection experiments show that an alteration of VPF expression in melanoma 
xenografts profoundly affects vascular architecture. Hence, at least in this melanoma 
model, the VPF expression pattern is an important determinant of angiogenesis, and 
possibly of angiogenesis-dependent biological behaviour. 
Materials and Methods 
Cell culture 
Human melanoma cell lines were cultured as previously described (23). Transfected 
melanoma lines were cultured in medium supplemented with 200 ^g/ml Hygromycin В 
(Boehringer Mannheim, Germany). Human brain capillary pericytes were isolated and 
cultured as described elsewhere (29). U937 cells and Balb-ЗТЗ cells were from ATCC 
(Rockville, MD), and cultured in Dulbecco's Modified Eagle's Medium (DMEM, Flow 
Laboratories, Irvine, UK) with 10% fetal calf serum (FCS, Gibco BRL, Paisley, UK), 2 
mM L-glutamine and 40 /tg/ml gentamycin (Schering Corporation, Amstelveen, The 
Netherlands). 
Melanoma xenografts 
Human melanoma cells were trypsinized and 2xl06 cells were injected s.c. into BALB/c 
nu/пи mice, as previously described (23). Xenografts were dissected at different time 
points after inoculation, measured, rapidly frozen in liquid nitrogen, and stored at -70°C. 
Isolation of RNA 
RNA was isolated from cultured cells either using LiCl/urea (30), or using guanidinium 
chloride (31). RNA from tumours and normal murine tissues was isolated after disruption 
in guanidinium isothiocyanate by CsCl centrifugation (32). RNA concentration was 
determined spectrophotometrically at 260 nm (32). 
Northern blotting and probes used 
Samples of total RNA were denatured in 50% formamide in formaldehyde/phosphate 
buffer (65 mg/ml formaldehyde, 25 mM NaH2P04/Na2HP04, pH 7.0) for 15 min at 
55°C, run on a 1% agarose gel in formaldehyde/phosphate buffer and blotted to 
nitrocellulose membranes (32). As a probe for VPF mRNA, a fragment was used which 
comprised the protein coding region of VPF,M. To isolate this fragment, RT-PCR was 
performed on RNA from PMA-treated U937 cells (1), using reverse primer (5'-TTCCT-
CCTGCCCGGCTCACCG-3') and forward primer (5'-CCCGGTCGGGCCTCCGAAAC-
CA-3'). Blunt-ended PCR products were cloned into J/nal-digested pUC19 vector DNA 
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and characterized by sequencing. PCR products from the alternatively spliced messengers 
for VPFI2I, VPF163, and VPF189 were identified. A 0.6 kb VPFI6J insert was isolated as a 
Xftal/A/wiI-fragment and labelled. Control hybridizations were performed with a human 
ubiquitin probe (33), a human ß-actin probe (34), or with a Drosophila ribosomal RNA 
probe. Fragments were labelled with [cx-32P]dATP after random hexamer priming (35). 
Northern hybridizations were performed in 50% formamide, 6 χ SSC, 0.1% SDS, 0.1 
mg/ml denatured herring sperm DNA and 5 χ Denhardt's (32) at 45°C, followed by 
washing in 0.2 χ SSC, 0.1% SDS at 65°C. Intensities of hybridization bands were 
scanned with an Ultroscan XL Enhanced Laser Densitometer from LKB (Bromma, 
Sweden). 
Analysis of alternatively spliced VPF mRNA 
2-8 /ig of total RNA isolated from cell lines or melanoma xenografts was reverse 
transcribed using 0.5 μg reverse primer (5'-TTCCTCCTGCCCGGCTCACCG-3')( 0.4 
mM deoxyribonucleotides (dNTPs; Pharmacia LKB, Woerden, The Netherlands), 5 units 
AMV-RT (Stratagene, San Diego, CA), 5 units RNasin (Boehringer Mannheim, 
Germany) and reaction buffer provided by the supplier of AMV-RT, in final volumes of 
10 μί, for 1 h at 42°C. After ethanol precipitation and redissolving in 10 μί distilled 
water, half of the cDNA was used in PCR reactions containing 0.3 pg reverse primer (see 
above), 0.3 pg forward primer (5'-GCACCCATGGCAGAAGGAGGA-3'), 0.2 mM 
dNTPs, 0.25 units Supertaq polymerase and reaction buffer (HT Biotechnology, 
Cambridge, UK), in final volumes of 25 μί. 20 cycles of 1 min at 96°C, 1.5 min at 52°C 
and 4 min at 72°C were performed. 5 μί of every reaction mix was transferred to a new 
tube containing the same reagents, for one more cycle (6 min at 72CC). 10 μ\ samples of 
the products were separated on a 1.5% agarose gel, Southern blotted to nitrocellulose and 
probed with the VPFI6J fragment in formamide hybridization mix at 42°C. 
Determination of the species origin of VPF mRNA 
1-12 ^g of total RNA isolated from human cell lines, murine tissues or melanoma 
xenografts was reverse transcribed using 0.5 /ig reverse primer (5'-TTGGTGAGGTTTG-
ATCCGCAT-3'), 0.4 mM dNTPs, 5 units AMV-RT, 10 units RNasin and reaction buffer 
provided by the supplier of AMV-RT, in final volumes of 10 μί, for lh at 37°C. After 
ethanol precipitation and redissolving in 10 μί distilled water, half of the cDNA was used 
in PCR reactions containing 0.3 /ig reverse primer (see above), 0.3 μg forward primer 
(S'-CGAAACCATGAACTTTCTGCT-S*), 0.2 mM dNTPs, 0.25 units Supertaq 
polymerase and reaction buffer, in final volumes of 25 μί. 20 cycles of 1 min at 96°C, 
1.5 min at 48°C and 2.5 min at 72°C were performed. 1 μί samples of the products were 
transferred to new tubes with all the PCR reagents, and subjected to one more cycle (10 
min at 72°C). PCR products were then precipitated and redissolved. One third was 
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digested with 5 units Styl - which only cleaves the human product (2,36), separated on a 
1.5% agarose gel, Southern blotted, and hybridized with the VPF16j probe. 
Analysis of secreted VPF protein 
Melanoma cells were cultured for 24 h in serum-free medium, when indicated with 100 
/xg/ml heparin. Conditioned media were centrifuged and used for VPF analysis. To 
correct for differences in cellular density, cells were scraped and lysed, and the cellular 
protein content was determined by a standard protein assay (Bio-rad, Veenendaal, The 
Netherlands). Based on this protein determination, samples of conditioned media derived 
from equal amounts of cell material were taken, and proteins were acetone precipitated, 
electrophoresed on 17.5% Polyacrylamide gels under reducing conditions, and 
electroblotted to nitrocellulose membranes. Antisera against VPF were raised in rabbits 
using purified VPF produced in a bacterial expression system. Antiserum was diluted 
1:100 or 1:250 for detection of VPF on Western blots and the immune reactions were 
visualized using the chemiluminescent substrate AMPPD (Tropix, Westburg, Leusden, 
The Netherlands) following the manufacturer's protocol. The crude antisera had some 
non-specific reactivity towards some bands of higher molecular mass than VPF on 
Western blots. Where indicated this was diminished by affinity purification of anti-VPF 
antibodies using purified E. co/i'-produced VPF absorbed by nitrocellulose membranes 
(37). 
VPF induction experiments 
The response to serum, fibroblast-conditioned medium or growth factors/cytokines was 
tested after preculturing subconfluent melanoma cell cultures in DMEM without serum for 
24 h. Medium was then replaced for 4 h or 24 h by DMEM with 10% FCS, or by 
DMEM (with and without FCS) conditioned by Balb-ЗТЗ cells for 24 h. Alternatively, 
serum-free medium was replaced for 4 h by DMEM containing 0.1% bovine serum 
albumin and one of the following growth factors or cytokines: 5 ng/ml epidermal growth 
factor (EGF, Collaborative Research, Bedford, MA); 5 ng/ml transforming growth factor 
alpha (TGFa, Bachern, Bubendorf, Switzerland); 2 ng/ml transforming growth factor beta 
1 (TGFßl, R&D Systems, Minneapolis, MN); 10 ng/ml platelet-derived growth factor 
AA (PDGF-AA, a gift from Dr. C.H. Heldin, Uppsala, Sweden); 100 ng/ml basic 
fibroblast growth factor (bFGF, a gift from Scios Inc., Mountain View, CA); 
approximately 100 ng/ml VPF,M (in culture supernatant of COS cells transfected with 
plasmid containing VPF165 cDNA under control of an SV40 early promoter); 50 ng/ml 
tumour necrosis factor alpha (TNFa); 100 units/ml interleukin 4 (IL-4); 400 units/ml 
interferon gamma (IFN?) (TNFa, IL-4 and IFNy were from Boehringer Ingelheim, 
Germany); 100 units/ml interleukin 1 beta (IL-lß); 50 units/ml interleukin 2 (IL-2) (IL-lß 
and IL-2 were from Genzyme, Sanbio, Uden, The Netherlands). Hypoxia experiments 
were performed using subconfluent melanoma cell cultures in 10 mM Hepes-buffered 
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DMEM with 10% FCS. Rubber-capped flasks were flushed for 1 h at room temperature 
with 30 volumes of nitrogen that was made oxygen-free using a BASF R 3-11 catalyst 
(BASF, Ludwigshafen, Germany). Oxygen-free C0 2 was added up to 5%, and the flasks 
were then placed back at 37eC for the indicated times. At the end of each incubation, gas 
samples were tested for 0 2 content by gas chromatography, and the pH of the media were 
determined. In some cases, also the Po2 of the media were determined (CIBA-Corning 
288 Blood Gas System, Houten, The Netherlands). Control experiments were performed 
(in air/5% C02) to investigate the influence of the pH of the medium. To achieve a low 
final pH, cells were grown in Hepes-buffered medium for several days, and to achieve a 
high pH, medium was replaced for 6 h by Hepes-buffered fresh medium, preincubated in 
air for 1 h. 
Production of stably transfected melanoma lines 
The protein coding region of VPFI2I was cloned directionally as a XbaVKpnl fragment 
into the expression vector EBOpLPP (38), by which the sequence was brought under 
control of SV40 transcriptional elements. This plasmid also codes for the hygromycin 
phosphotransferase (HPH) gene. The recombinant plasmid, as well as the empty vector, 
were digested with Apal, thus eliminating some non-essential sequences. The residual 8 
kb fragment was transfected into Mel57 cells by calcium phosphate precipitation followed 
by a 3 min shock with 25% DMSO (31). After 48 h the cells were trypsinized, seeded 
sparsely in culture flasks and selected in medium with 200 μg/ml hygromycin В 
(Boehringer Mannheim, Germany). Single resistant colonies were removed by scraping 
and grown until analysis of VPF expression, and storage of stocks in liquid nitrogen was 
possible. 
Histological analysis of tumours from transfected melanoma lines 
Transfected melanoma lines were inoculated in nude mice as described above. Every 
line was injected in at least two mice on both flanks. Tumour volumes were measured 
weekly, and growth curves were prepared. Tumours of sizes between 150 and 800 mm3 
were excised 30-60 days after inoculation, and cut into three fragments. One part was 
formalin-fixed and used to study overall tumour morphology. The other parts were 
snapfrozen in liquid nitrogen; one was used for RNA isolations, the other to study the 
vascular patterns and the organization of stroma and extracellular matrix. Cryosections 
were stained with monoclonal 9F1 which reacts specifically with mouse endothelium (JR 
Westphal et al, manuscript in preparation), and which is suitable for the examination of 
tumour vasculature. Also tumour sections were stained with a polyclonal rabbit anti-
mouse laminin antiserum (provided by Dr. J. van den Born, Dept. of Nephrology, 
Nijmegen). 
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Results 
Analysis of VPF mRNA in cultured melanoma cells 
The four melanoma cell lines IF6, Mel57, BLM, and MV3 differ in metastatic potential 
upon s.c. injection in nude mice (23). To determine whether this behaviour correlates 
with VPF expression, RNA was isolated from these cell lines and examined by Northern 
analysis. VPF mRNA was readily detectable in RNA from the cell lines BLM and MV3 
(Fig. 1) as a major band of 3.7 kb. RNA from the cell lines IF6 and Mel57 showed only 
very weak hybridization signals with the VPF probe. The highest VPF mRNA levels were 
thus found in the cell lines BLM and MV3, which were shown in earlier studies to give 
rise to highly metastatic tumours in nude mice. The other lines, which had a low level of 
VPF mRNA expression, produced tumours with a much lower metastatic frequency (23). 
The observed difference in expression of VPF mRNA is not likely to be caused by a 
genomic rearrangement or an amplification of the VPF gene. Southern analysis of the 
genomic DNA isolated from these melanoma lines and from normal human buffy coat 
showed no obvious differences in intensities of the bands hybridizing with a VPF probe, 
nor were shifts of bands or extra bands observed in any of the melanoma lines (data not 
shown). 
Alternatively spliced messengers of VPF cannot be distinguished by Northern blotting. 
To determine whether the melanoma lines differ in the ratio of these mRNA variants, an 
RT-PCR was performed, which amplified the alternatively spliced region of the 
in 5 m 
>β s 3 > 
A (kb) fe ¡§ Sa s 
7.5 
4.4 
2.4 
1.4 
Figure 1. Northern blot analysis of VPF mRNA 
in melanoma cell lines. 10 μ% samples of 
LiCl/urea-isolated RNA were loaded in each lane. 
A: VPF hybridization; B: ubiquitin hybridization. 
Only relevant parts of the autoradiographs are 
shown. Positions of RNA size markers are shown 
on the left. 
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messenger. RNA from all the melanoma cell lines yielded the same pattern, in that the 
product from the RNA coding for VPF121 was the most prominent (52-70%), followed by 
the VPF165 product (26-42%). The VPFi89 mRNA was in all cases found to be a minor 
species (4-8%), while no VPF206 mRNA was found in any of the melanoma cell lines 
(Fig. 2, lanes 2-5). No correlation between the biological behaviour of the melanoma 
lines and the predominance of the VPF variants produced could therefore be 
demonstrated. The observed ratio of splice variants does not seem to be specific for 
melanoma cells, or even for tumour cells, as the same ratio of splice variants was found 
in RNA from the human lymphoma cell line U937 and in RNA from normal human 
pericytes (Fig. 2, lanes 6 and 7). 
Levels of secreted VPF protein correlate with the VPF mRNA levels 
The amount of VPF protein secreted from the melanoma cell lines was determined by 
culturing the cells in serum-free medium containing heparin, to release also the longer 
VPF variants from the extracellular matrix (20). The proteins in the conditioned medium 
were Western blotted and stained with a polyclonal antibody against VPF. In the 
conditioned media from cell lines BLM and MV3 detectable amounts of VPF were 
present. Several bands with apparent molecular masses between 17 and 25 kD were 
identified (Fig. 3), which agree with the expected sizes of non-glycosylated and 
glycosylated VPFI21 and VPF165 (19,20). VPFI89 and VPF206 (expected around 30 kD) 
could not be found, supporting the finding that their mRNAs are poorly expressed in 
Cell lines Xenografts 
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Figure 2. Analysis of VPF mRNA splice variants. RT-PCR was performed on RNAs isolated from 
various sources, amplifying the alternatively spliced region as indicated in Materials and Methods. 
Left panel: human cell lines: IF6, Mel57, MV3, BLM: melanoma cells; U937: histiocytic lymphoma 
cells; Pericytes: from human brain capillaries. Right panel: melanoma xenografts - see also legend to 
Fig. 4. The left and the right panel are from different gels. Southern blots were hybridized with a VPF 
probe. Positions of DNA size markers are shown on the left. Expected PCR products: VPF121: 381 bp; 
VPF165: 513 bp; VPF18,: 585 bp; VPFM6: 636 bp. Note that no PCR products are expected from mouse 
VPF mRNA, as the primers do not match the murine sequence completely. 
5 * * 
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{^  « ._ Figure 3. Western blot analysis of VPF in 
ve "3 ¡j ¡> .,-, conditioned media from melanoma cells. 
— 2 PS *s Confluent cultures of melanoma cells were grown 
in serum-free medium with 100 /ig/ml heparin for 
66 24 h. Precipitated proteins from 0.225-0.7 ml 
conditioned media (but derived from the same 
45 amount of cellular mass) were subjected to SDS-
PAGE under reducing conditions. Western 
blotted, and stained with affinity-purified 
_31 antiserum against VPF. Molecular mass markers 
are shown on the right. 
21.5 
14.4 
melanoma cells (Fig. 2; the band in the MV3 lane of Fig. 3 at 38 kD is probably caused 
by a dimer of VPF12, or by a non-specific reaction rather than by a monomeric form of 
one of the larger VPF variants). In conditioned media from cell lines IF6 and Mel57 no 
VPF could be detected, which agrees with the fact that these cells contain low amounts of 
VPF mRNA (Fig. 1). These results indicate that the levels of VPF mRNA in melanoma 
cells are reflected in the levels of VPF protein expression. 
Analysis of melanoma xenografi RNA 
To determine whether VPF mRNA levels change when melanoma cell lines form 
tumours in nude mice, RNA isolated from melanoma xenografts was examined. The four 
melanoma lines that were also used in the above experiments (IF6, Mel57, BLM, and 
MV3) were injected in mice, and the resulting tumours were collected at different time 
points after injection. All xenografts contained comparable levels of VPF mRNA (Fig. 4), 
including those derived from the lines IF6 and Mel57, which had hardly detectable levels 
of VPF mRNA in culture. Scanning of autoradiographs from blots containing both cell 
line RNAs and xenograft RNAs (not shown) revealed that the average VPF mRNA level 
in xenografts was 75% of the average level in the cultured cell lines BLM and MV3 
(range 30-170%). The small differences between the VPF mRNA levels in xenografts 
were independent of the parental cell line. The levels of VPF mRNA did tend to decrease 
with increasing tumour size for those tumours that were derived from the IF6, Mel57, 
and MV3 lines, but in tumours derived from cell line BLM the opposite effect was seen, 
namely an increase in the VPF mRNA level with increasing tumour size (Fig. 4). No 
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Figure 4. Northern blot analysis of VPF mRNA in melanoma xenografts. 10-16 /xg samples of total 
RNA were loaded in each lane. Parental cell line and number of the xenograft are given with the age 
and the estimated tumour volume. IF6-X1: 31 days, 180 mm'; IF6-X2: 31 days, 720 mm3; IF6-X3: 45 
days, 320 mm3; Mel57-Xl: 31 days, 80 mm3; МЫ57-Х2: 31 days, 1200 mm3; Mel57-X3: 45 days, 
1340 mm3; MV3-X1: 31 days, 490 mm3; MV3-X2: 31 days, 3400 mm3; MV3-X3: 45 days, 18750 
mm
3; BLM-X1: 24 days, 6000 mm3; BLM-X2: 24 days, 10000 mm3. A: VPF hybridization; B: 
ubiquitin hybridization. Only relevant parts of the autoradiographs are shown. Positions of RNA size 
markers are indicated on the left. 
change in the splicing pattern was found in xenografts: the ratios of alternative splicing 
products were equal to those in the cultured cell lines (Fig. 2, lanes 8-11). 
The VPF messengers found in melanoma xenografts could derive from melanoma cells, 
but also from host cells within the tumour (stromal cells) or from small amounts of 
surrounding tissue (e.g. skin). VPF mRNA was indeed found in some murine tissues such 
as skeletal muscle and heart, but was not detected in normal mouse skin (Fig. 5). These 
normal mouse tissues are not readily comparable, however, with host tissue within 
melanoma xenografts. To confirm the melanoma origin of the xenograft VPF mRNA 
unequivocally, an RT-PCR assay was carried out which discriminates between human and 
murine VPF sequences. RNA was reverse transcribed and amplified using a set of 
primers based on sequences common to both the human and murine VPF messenger. PCR 
products were then digested with Styl, which cleaves the human, but not the murine 
sequence. As predicted, a 0.35 kb band was found when RNA from murine tissues was 
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used, whereas two products of 0.25 and 0.1 kb (the latter only slightly visible) arose from 
human RNA (Fig. 6). Although xenograft RNAs were amplified to different extents, 
leading to varying amounts of total PCR product, a consistent pattern was seen. In all 
cases, the human-specific band of 0.25 kb was the most prominent product. The mouse-
derived 0.35 kb band was also present in all xenograft RNAs, but its intensity was only 
14-25% of that of the human-derived band. The majority of the xenograft VPF mRNA is 
thus synthesized by the human melanoma cells. For IF6 and Mel57 cells this implies that 
the expression of VPF is distinctly higher in vivo than in vitro, and that in vivo their VPF 
expression is no longer different from that in the cell lines BLM and MV3. 
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Figure 5. Presence of mRNA for VPF in mouse organs. 
10-16 /ig samples of total RNA were loaded in each lane. 
S: skin; M: skeletal muscle; H: heart; L: liver. A: VPF 
hybridization; B: the 28S signal upon hybridization with a 
ribosomal probe. Positions of RNA size markers are shown 
on the left. 
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Figure 6. Determination of Human Mouse Xenografts 
the species origin of VPF 
mRNA. RT-PCR followed < _ Ц Ц Ц g 
by Sfyl-digestion was ç Î B < l ï ï S S i ï S j ï 
performed on RNA from 
various sources to determine 
the origin of the VPF 
messengers, as explained in 
Materials and Methods. 
Lanes 1-3: Human cell line 
RNAs; lanes 4-5: Mouse 
RNAs: skeletal muscle and 
heart; lane 6: no RNA; 
lanes 7-15: melanoma xeno-
graft RNAs - see also legend to Fig. 4. A Southern blot was hybridized with a VPF probe, and 
washed in 2 χ SSC at 50°C. Subsequent washing in 0.2 χ SSC at 50°C did not change the pattern. 
Positions of DNA size markers are indicated on the left. Expected fragments from human VPF 
mRNA: 256 and 90 bp; and from murine VPF mRNA: 343 bp. 
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Inluencing VPF gene expression 
Apparently, VPF mRNA levels are induced in IF6 and Mel57 cells during 
tumourigenesis in nude mice. To investigate possible mechanisms that could contribute to 
this induction, Mel57 cells were exposed in vitro to factors that may also have been 
present in vivo. After serum deprivation, the cells were incubated for 4 h or 24 h in 
serum-containing medium, in medium conditioned by mouse fibroblasts (Balb-ЗТЗ cells) 
with or without serum, or in serum-free media to which a growth factor or cytokine 
(listed in the Materials and Methods section) was added. No increase in the VPF mRNA 
levels was found (not shown). IF6 cells also did not respond to addition of serum or Balb-
ЗТЗ-conditioned medium. Hence, growth factors or cytokines present in serum or 
fibroblast-conditioned medium, or added separately, apparently do not augment VPF 
messenger levels under these conditions. When Mel57 cells were cultured in low oxygen 
tension for 6 h or 24 h, however, a dramatic increase in the VPF messenger content was 
found (Fig. 7). After reoxygenation of the flasks these levels started to decrease: within 3 
hours a reduction of 50% was observed (Fig. 7, lanes 5 and 6). No effect on the VPF 
mRNA levels was seen when the pH of the medium was varied between 7.2 and 8.1 (Fig. 
7, lanes 1 and 2), which excludes the possibility that pH differences due to the hypoxic 
treatment caused the observed induction. In IF6 cells cultured under low oxygen tension 
for 24 h, a dramatic induction of the VPF mRNA level was found as well (not shown). 
(кЬ) 1 7 1 4 ^ 6 Figure 7. Induction of VPF mRNA in 
^ ' Mel57 cells by hypoxia. Cells were 
cultured under nitrogen, as described 
4 . 4 тЛ •<» ш Materials and Methods. At the end 
of the incubations, oxygen levels in 
the gas phase were 0.5-1.0% and Po2 
values in the media were 2.8-3.0 kPa. 
Control cells were incubated in 
2 . 4 _ air/5% C02 in media of different pH. 
Final pH values of the media are 
indicated. 8-22 μg samples of 
guanidinium chloride-isolated RNA 
were loaded in each lane. Lane 1: 
β air/C02, pH 8.1; lane 2: air/C02, pH 
7.2; lane 3: N2-flushed and 5 h in 
air/C02, pH 7.5; lane 4: 6h in 
in 
pH 7.5; lane 6: 20 h in 
N2/C02 and 3 h in air/C02, pH 7.4. 
A: VPF hybridization; B: ß-actin 
hybridization. Ubiquitin was not used as a control, since the expression of mis gene may be altered in 
stress situations. Positions of RNA size markers are shown on the left. 
1.4 
•
шшт mm m m
 w N2/C02, pH 7.8; lane 5: 24 h 
75 
Chapter 3 
The absolute induction of VPF messenger levels reached in Mel57 and IF6 cells after 24 
h of hypoxia cannot be measured, as hybridizing bands are hardly visible in the uninduced 
state. The maximally induced VPF mRNA levels in Mel57 and IF6 cells were 1.3-fold 
and 2-fold the already high basal level in MV3 cells, respectively. The high level of VPF 
mRNA in MV3 cells could further be increased by a factor of 3 when cultured in low 
oxygen levels (not shown). These results show that hypoxia increases VPF mRNA levels 
in melanoma cells such that cell lines with distinctly different levels under normal 
conditions reach comparable levels under conditions of low oxygen tension. Relative 
levels of VPF splice variants were analyzed, and found unaltered upon hypoxic shock in 
Mel57, IF6, and MV3 cells (not shown). 
Production of a VPF-overproducing transfectant melanoma line 
To determine whether the pattern of VPF expression - constitutive versus inducible -
actually makes a difference in the process of angiogenesis, and perhaps metastasis, during 
the development of the melanoma xenografts, we transformed a VPF inducible line into a 
VPF constitutive line by stably transfecting a construct containing the protein coding 
region of VPFI21, the VPF variant most abundantly expressed in melanoma cells (Fig. 2), 
into cell line Mel57. The resulting transfectants should have a constitutive VPF 
expression (as in lines MV3 or BLM) instead of an inducible VPF expression. As a 
control Mel57 cells were also transfected with vector DNA without a VPF sequence. A 
number of stable tranfectant lines was examined for expression of recombinant VPF 
RNA, which is easily recognizable as it is much shorter than endogenous VPF mRNA 
(see Fig. 8). The transfectant line 1-3 had the highest level of recombinant VPF RNA, 
and was used for further study. Medium conditioned by these cells contained clearly 
detectable levels of non-glycosylated and glycosylated VPF121, visible as bands of 17 and 
20 kD on a Western blot stained with polyclonal anti-VPF. The vector-transfected line 
E2, which did not show any signs of (recombinant) VPF RNA or protein expression (Fig. 
8), was used as control in further experiments. 
VPF-transfected line 1-3, control transfected line E2 and the parental cell line Mel57 
were injected into nude mice. The tumours that developed after inoculation of line 1-3 still 
expressed the 1 kb recombinant VPF RNA, but the endogenous 3.7 kb VPF messenger 
was detectable in these tumours as well (Fig. 8). The upregulation of VPF mRNA was 
only a minor contribution to the total amount of VPF RNA produced in these tumours: 
the band intensities of VPF mRNA were only about 50% of the intensities of the 
recombinant VPF RNA bands. Tumours from control transfected line E2, as expected, 
had elevated levels of VPF mRNA but did not show recombinant VPF RNA. Tumours 
from line E2 did express the vector-encoded hygromycin phosphotransferase RNA (not 
shown). 
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Figure 8. Expression of recombinant VPF RNA and protein by transfected melanoma lines. I: RNA 
isolated from control- (E2) and VPF (I-3)-transfected cell lines (left panel, 10-15 μg of RNA loaded in 
each lane) and from their respective xenografts in nude mice (middle panel, 22-30 μ.% of RNA loaded 
in each lane). IA: VPF hybridization (with endogenous VPF messenger bands at 3.7 kb, and 
recombinant VPF RNA bands at 1 kb); IB: ubiquitin hybridization. Only relevant parts of the 
Northern blots are shown. II: Proteins from 0.2 ml of serum-free conditioned media of transfected 
lines E2 and 1-3 were acetone precipitated, electrophoresed on SDS-PAGE, electroblotted and stained 
with crude antiserum against VPF. Specific staining for VPF121 is observed at 17-20 kD. Also some 
non-specific staining of higher molecular mass bands is visible in both lanes. Positions of molecular 
mass markers are indicated on the right. 
Vascular architecture in transfectant xenografts 
Tumours from the parental and the transfected cell lines did not differ significantly in 
growth rate, nor did they differ in their extent of necrosis (as judged from HE-stained 
cross sections). Staining of cross sections with the monoclonal antibody 9F1, which reacts 
specifically with mouse endothelium, showed that the vascular pattern in tumours from 
VPF-transfected line 1-3 was clearly different from the pattern in tumours from the 
control lines. Tumours from control lines Mel57 and E2 had similar vascular patterns. 
Typically, in tumours from control lines blood vessels always appeared separately. Large 
vessels with lumina were visible, as well as smaller microvessels and capillary sprouts in 
which no lumen could be observed upon light microscopy. Between different regions 
within one tumour differences in vessel density did occur: some tumour parts were well 
vascularized and viable, whereas other parts were poorly vascularized and highly 
necrotic. In regions with a low density of vessels, as in the section shown in Fig. 9A, 
vessels were surrounded by a layer of viable tumour cells while at a greater distance 
tumour tissue was necrotic. Tumours from VPF-transfected line 1-3 had quite a different 
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arrangement of blood vessels (Fig. 9B). Vessels formed a dense network around nodules 
of tumour cells. The endothelial staining in cross sections appeared to be largely 
continuous, suggesting that there is a three-dimensional plexus of blood vessels 
surrounding the tumour nodules. Within the tumour nodules very few or no blood vessels 
were present, often leading to viable layers of tumour cells surrounding necrotic centres. 
Staining for the extracellular matrix component laminin showed that in tumours from 
both the control lines and the VPF-overproducing line tumour nodules were surrounded 
and separated from each other by stromal septa (Fig. 9, С and D). However, on the 
average the tumour nodules in the line 1-3 tumours were larger than those in control 
tumours, and the stromal component consisted for a large part of endothelial cells (Fig. 
9B), unlike the situation in control tumours, in which only single blood vessels were seen 
(Fig. 9A). The change in the pattern and level of VPF expression has therefore 
dramatically changed the vascular architecture in the tumours from this transfectant 
melanoma line. 
Discussion 
The initial goal of this investigation was to determine whether the level of VPF 
expression in several human melanoma lines correlated with the metastatic potential of 
these lines in nude mice. We did observe this correlation in cultured melanoma cells: 
lines IF6 and Mel57, which produce rarely or slowly metastasizing tumours, had much 
lower levels of VPF mRNA and secreted less VPF protein than lines BLM and MV3, 
which develop into highly metastatic tumours in mice (23, JR Westphal et al; manuscript 
in preparation). However, these differences in VPF expression were no longer observed 
in vivo: tumours from all four melanoma lines had high levels of VPF mRNA, produced 
mainly by the melanoma cells. Therefore the highly metastatic melanoma lines have a 
constitutive VPF expression which apparently is not dependent on the extracellular 
environment, while the less metastatic lines can have the same level of VPF expression, 
but only if it is induced by external factors. 
The upregulation of VPF expression in IF6 and Mel57 cells in vivo might have been 
caused by protein factors released by e.g. stromal cells. In several cell lines, induction of 
VPF expression by transforming growth factor β and platelet-derived growth factor BB 
has been demonstrated (39-41). We did not find any induction of VPF mRNA by various 
growth factors or cytokines, serum, or conditioned media of fibroblasts in the melanoma 
cells IF6 and Mel57. We cannot exclude, however, the possibility that other growth 
factors, or combinations of such factors can cause an increased VPF expression in these 
cells. 
One of the mechanisms that may lead to enhanced VPF expression in vivo is hypoxia, 
since a dramatic upregulation of VPF messenger levels was evident after incubation of 
Mel57 and IF6 cells under low oxygen pressure. VPF expression was already known to 
be induced by hypoxia in glioma and hepatoma cells (14,42), and also the expression of a 
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Figure 9. Visualization of tumour vessels and laminin in tumours from transfected melanoma lines. 
Cross sections were stained with monoclonal 9F1 for endothelium/blood vessels (A and B), 
magnification 45x, or with rabbit anti-mouse laminin (C and D), magnification 225x. A and C: cross 
sections of line E2-derived tumours, В and D: cross sections of tumours from VPF-transfected line I-
3. Arrowheads point to areas of necrosis. 
number of other genes is induced by hypoxia. The intracellular mechanisms responsible 
for this kind of induction are only beginning to be understood (43,44). There is evidence 
that an intracellular haeme protein is involved in hypoxia-induced expression of both VPF 
and erythropoietin, and this effect of hypoxia on glioma and hepatoma cells is mimicked 
by cobalt chloride (42). VPF mRNA levels in Mel57 cells were also upregulated by 
cobalt chloride (not shown), suggesting a regulatory mechanism that is common to many 
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cell types. In MV3 cells, which have a higher expression of VPF mRNA than Mel57 and 
IF6 cells when cultured under normoxic conditions, VPF mRNA induction by hypoxia 
was relatively small. These cells may have undergone an irreversible switch to a high 
VPF producing phenotype, which would make them less sensitive to VPF-inducing 
mechanisms. 
Hypoxia is thought to be one of the major causes of tumour necrosis. In situ 
hybridization studies have shown that VPF mRNA levels were highest around necrotic 
sites in glioblastoma lesions, suggesting an involvement of hypoxia in the regulation of 
VPF expression (14,15). However, in other tumour types most tumour cells produced 
VPF mRNA in abundance, with only slightly increased levels being found adjacent to 
necrotic areas (45). In our study we found two sets of melanoma lines, one in which VPF 
mRNA levels were upregulated by hypoxia, and a second in which VPF mRNA levels 
were only slightly affected by oxygen tension. Further evidence for the assumption that 
hypoxia is the major trigger for the VPF mRNA upregulation observed by us in vivo can 
only be provided by in situ hybridization or by immunohistochemistry. These experiments 
are in progress in our laboratory. 
A relation between tumour angiogenesis and metastasis has been postulated on 
theoretical grounds, and has also been demonstrated in practice in several tumour types 
including melanoma (8,46-49). Since VPF is a potent angiogenic factor, it might also play 
an important role in the development of the metastatic phenotype of melanoma xenografts. 
Although the xenografts of all melanoma lines examined showed comparable VPF 
expression, this expression in the less metastatic lines IF6 and Mel57, had to be 
upregulated first in vivo. A lower expression level of VPF in early IF6 and Mel57 
xenografts might result in a delayed development of the vascular bed compared with BLM 
and MV3 xenografts, which might eventually hamper the opportunities for dissemination. 
To separate the effect of VPF expression on the vasculature from the effects of other 
factors (differentially) produced by the various melanoma lines, it is necessary to 
manipulate VPF expression in one of the melanoma lines. 
By transfection into cell line Mel57 of a VPF,21 sequence, we were able to produce a 
Mel57-derived cell line that had a constitutively high expression of VPF. In this way it 
was possible to study the biological behaviour of tumours from melanoma lines with an 
inducible or a constitutive VPF expression, in an otherwise unchanged genetic 
background. The arrangement of the tumour vasculature indeed turned out to be quite 
different in tumours resulting from the constitutive VPF-expressing transfectant line. In an 
other study (50), two types of vascular branching in tumours were distinguished. 
"Tumour-penetrating branches of variable diameter" were found in some tumours, and 
"lateral surface branches that formed an arborizing and anastomosing plexus of 
interconnecting vessels" were found in other tumours. The vasculature in tumours from 
the control melanoma lines resembled the first type, whereas in tumours from the VPF-
transfected line the vasculature appeared to be more like the second type. An altered VPF 
expression obviously is sufficient for a switch from one vascular type to the other. 
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Studies from others, in which Chinese hamster ovary cells or HeLa cells were 
transfected with VPF expression constructs, showed that overexpression of VPF can lead 
to a growth advantage in nude mice, combined with higher angiogenic activity (51,52). 
The tumours from the VPF-transfected melanoma line used in our study did not show 
such behaviour: they did not have a faster growth rate, and angiogenesis was qualitatively 
rather than quantitatively different. Obviously, angiogenesis is too complex a process to 
have its outcome predicted by the level of VPF expression only. Similarly, the 
vasculature in xenografts from transfectant line 1-3 might have been expected to be very 
much like that in xenografts from other constitutively VPF-producing melanoma lines 
such as BLM and MV3, but this was not at all the case (JR Westphal et al; manuscript in 
preparation). VPF expression in line 1-3 was probably much higher than in lines BLM 
and MV3, and transfectant lines with a lower recombinant VPF expression than line 1-3 
should therefore be studied. Even then, VPF is probably not the only factor relevant to 
angiogenesis in these tumours; a number of other factors directly or indirectly involved in 
angiogenesis may be differentially expressed between BLM and MV3 on one hand and 
Mel57 and its transfectants on the other hand. Differences in expression of various 
integrins and of proteins involved in the plasminogen activator pathway have indeed been 
shown between some of these melanoma lines (24,25). The vascular phenotype in any 
tumour will be the result of a large number of factors influencing angiogenesis, but our 
study shows that VPF is at least one of the important factors governing angiogenesis in 
these melanoma xenografts. 
Further study has to be undertaken to completely understand the way the aberrant 
vascular phenotype in tumours from line 1-3 evolves. Furthermore, it is an interesting 
question whether the altered VPF expression pattern leads to a different degree of 
vascular permeability for e.g. fibrinogen or for labelled tracers (50). Experiments 
addressing this issue are currently in progress. 
We also hope to answer the initial question whether VPF expression is important for the 
metastatic potential of melanoma xenografts in nude mice. However, as the constitutive 
expression of VPF by the Mel57-derived cell line 1-3 led to a vascular phenotype unlike 
that of other constitutive VPF-producing lines such as BLM and MV3, the metastatic 
frequency of line I-3-derived tumours may not simply be expected to increase to the 
frequencies found for tumours from lines BLM and MV3. Although it is still of interest 
to study the metastatic potential of tumours from line 1-3, xenografts from other 
transfectant melanoma lines with expression levels of recombinant VPF lower than in line 
1-3 perhaps will provide a better basis for comparing the metastatic potential with lines 
BLM and MV3. Therefore other transfectant lines will need to be included in future 
studies on the correlation between VPF levels, vascular pattern, and metastasis. 
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Chapter 4 
Vascular permeability factor (VPF) is an important mediator of vascular 
development in tumours. Some human melanoma cell lines have a low VPF 
expression level in culture but this level is upregulated when growing as a tumour in 
nude mice. Other melanoma lines have a constitutively high VPF expression. To 
compare the biological behaviour of tumours with these two expression patterns, a 
human melanoma cell line with an inducible VPF expression was transfected with 
VPF expression constructs. In this way several lines were obtained that constitutively 
produce either the soluble VPF121 or the matrix-associated VPF1M variant at levels of 
4 to 30 times the VPF level in mature tumours derived from the parental line. The 
recombinant VPF RNA, which lacks most of the 5' non-coding sequences present in 
the endogenous VPF mRNA, was much more efficiently translated than the 
endogenous messenger. Upon injection in nude mice all VPF-transfected lines 
developed tumours with aberrations in vascularization and in distribution of matrix 
components. In tumours from the parental line or from vector-transfected lines blood 
vessels were found as separate units randomly penetrating the tumour cell mass. 
Small groups of tumour cells were found to be surrounded by a thin layer of matrix 
material containing laminin and heparan sulphate proteoglycan. In VPF-
overproducing tumours, on the other hand, blood vessels were almost exclusively 
found in large stromal septa separating large nests of tumour cells. These septa 
stained intensely with a marker for endothelial cells, but also contained other cell 
types and extracellular matrix components that were not found within the tumour 
nests. Furthermore, in the tumours from VPF-transfected lines, blood vessels were 
hyperpermeable for an i.v. injected protein tracer. However, this enhanced 
permeability did not yield a more extensive extravascular fibrin matrix. We could 
not demonstrate a significant difference between the metastatic potential of tumours 
from the VPF-transfected lines and from the control lines. We conclude that the 
pattern or the level of VPF expression has a profound impact on the development of 
the vascular pattern, on vascular permeability, and on matrix distribution in these 
melanoma xenografts. 
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Introduction 
Angiogenesis, the formation of new blood vessels from existing vessels, is a process 
essential for tumour growth. Tumours without a vascular bed do not grow beyond a 
diameter of 1-2 mm3 (1). In addition, tumour metastasis is dependent on angiogenesis, as 
blood vessels provide the most important escape route for disseminating tumour cells (1-
3). In recent studies a correlation between tumour vascularization and metastatic risk has 
indeed been demonstrated (4-8). Outgrowth and malignant behaviour of a tumour, 
therefore, is accompanied by rapid development of the tumour vasculature, and, perhaps 
because of this, tumour blood vessels often have a chaotic architecture and some other 
characteristics distinct from normal blood vessels (reviewed in 9,10). The permeability of 
the tumour vasculature for macromolecules is often higher than in normal blood vessels 
(9,10), although this permeability differs significantly between various tumour types (11). 
Vascular permeability has also been shown to be lower in tumour-penetrating vessels than 
in a vascular plexus at the tumour-host interface (12,13). Tumour blood vessels are often 
prone to intravascular coagulation, leading to deposition of fibrin and the occurrence of 
intravascular thrombi (14). 
The development of the tumour vascular bed is thought to be mediated by a number of 
tumour-derived angiogenic growth factors and cytokines (reviewed by 2,15, and 16,17). 
Among these factors, vascular permeability factor/vascular endothelial growth factor 
(VPF/VEGF) is gaining attention, as it has become clear that it is an essential factor in 
tumour angiogenesis and tumour growth (18-20). The main targets of VPF are endothelial 
cells, which are almost the only cells expressing VPF receptors (21-25). The capacity of 
VPF to induce angiogenesis is probably due to the induction of a variety of functions in 
the endothelial cell, including proteolytic activity, Chemotaxis, and proliferation (21,26-
28). VPF may also be responsible for other characteristics of the tumour vasculature, like 
vascular hyperpermeability (29,30) and intravascular coagulation (via the induction of 
tissue factor expression on endothelial cells, 31). By enhancing tumour vessel 
permeability, VPF may contribute indirectly to angiogenesis, as fibrinogen leaking from 
the vessels can form an extravascular fibrin matrix serving as a substrate for endothelial 
outgrowth (32). 
In a previous report we described that a human melanoma cell line, Mel57, expressed 
low VPF messenger and protein levels in culture, but contained elevated levels of VPF 
mRNA after injection into nude mice and the formation of a tumour (33). Hypoxia was 
shown to be a likely mediator of this VPF upregulation. The tumours from this melanoma 
line had a characteristic vascular pattern, with blood vessels penetrating the tumour 
parenchyma in an apparently random fashion. This melanoma line was engineered into a 
line constitutively expressing VPF by transfection. Xenografted to nude mice this line 
developed into tumours with a vascular pattern distinct from parental line tumours: these 
tumours consisted of several tumour cell nodules devoid of blood vessels, separated by 
robust stromal septa very rich in blood vessels (33). 
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In the present study we have extended these findings by generating a panel of VPF-
transfected melanoma lines expressing different molecular variants of VPF at different 
levels. The recombinant VPF RNA, lacking most of the 5' non-coding sequences of the 
VPF gene, was translated into protein much more efficiently than the endogenous VPF 
messenger. We further demonstrate that transfectant lines with differing levels of 
recombinant VPF expression all develop tumours with the same distinct vascular 
phenotype. Furthermore, the same aberrant vascular pattern was found in tumours from 
lines overproducing either VPF
m
, a readily secreted VPF splice variant, or VPF1M, a 
variant that is largely retained in the extracellular matrix of the producing cells (34). In 
addition, we show that an altered VPF expression pattern changes the distribution of 
matrix proteins within the melanoma xenografts, and enhances the permeability of the 
tumour blood vessels for macromolecules. However, the altered VPF expression could 
not be shown to affect the metastatic potential of the tumours significantly. 
Materials and Methods 
Cell culture 
The human melanoma cell line Mel57 was cultured as previously described (35). 
Transfected Mel57 cells were cultured in medium supplemented with 200 μg/mI 
hygromycin В (Boehringer Mannheim, Germany). 
Production of stable transfectants 
The protein coding regions of VPF121 and VPF l8, were obtained by RT-PCR on RNA 
from cell line U937, and were subsequently cloned into vector pUC19, as described 
elsewhere (33). After sequence analysis, the inserts were recloned between the Xba\ and 
Kpnl sites of the plasmid EBOpLPP (36). Plasmids with VPF121 and VPF,M inserts, as 
well as the empty vector, were linearized with Apai, the 7-8 kb fragments were isolated 
from low melting point agarose gel slices, and were transfected into Mel57 cells by 
calcium phosphate precipitation (37). Transfected clones were selected in medium with 
200 /xg/ml hygromycin B, removed by scraping and expanded until analysis of the clones 
and storage of stocks in liquid nitrogen was possible (see also ref. 33). 
Analysis of VPF expression on the RNA and protein level 
RNA from cell lines was isolated using guanidinium chloride according to (37), and 
RNA from tumour xenografts was isolated by disruption in guanidinium isothiocyanate 
and CsCl centrifugation, as described in (38). Northern analysis and hybridizations with 
VPF and ubiquitin probes were performed as described earlier (33). To monitor VPF 
protein secretion cells were cultured for 24 h in serum-free medium lacking hygromycin, 
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containing 100 μg/ml heparin where indicated. Conditioned media were cleared by 
centrifugation and used for VPF protein analysis. To correct for differences in cellular 
density, cells were scraped and lysed, and the cellular protein content was determined 
with a standard protein assay (Biorad, Veenendaal, The Netherlands). Based on this 
protein determination, samples of conditioned media derived from equal amounts of cell 
material were taken and tested in a procoagulant assay (31,39). Similarly, samples were 
acetone precipitated, run on SDS-PAGE, and analysed by Western blotting and staining 
with a polyclonal antiserum raised against E. co//-produced VPF, as described elsewhere 
(40). 
Xenografts from line Mel57 and transfectants in nude mice 
About 2.5xl06 cells were injected s.c. into BALB/c nu/пи mice as described in (35). 
Every week tumour volumes were estimated. Tumours of between 300 and 1200 mm3 
were harvested and cut into three fragments. One part was formalin-fixed, HE-stained, 
and used to study overall tumour morphology and to assess the percentage of necrosis. 
The other parts were snap-frozen in liquid nitrogen: one was used for RNA isolations, the 
other to study the vascular patterns, the organization of extracellular matrix components, 
and the spatial distribution of VPF within the tumours (see below). To study vascular 
morphology in early stages of tumour development, for some lines also smaller tumours 
were taken (within one week after the occurrence of a palpable tumour), snap-frozen, and 
stained immunohistochemically. Acetone-fixed 4 μτη cryosections were stained with a rat 
monoclonal, MEC 7.46, directed against mouse vascular endothelium (a gift from Dr. A. 
Vecchi, Milano, Italy, 41), a rabbit polyclonal against mouse laminin (a gift from Dr. J. 
van den Born, Dept. of Nephrology, Univ. Hosp. Nijmegen), a goat polyclonal against 
(human) heparan-sulphate proteoglycan (HSPG, a gift from Dr. L. van den Heuvel, Dept. 
of Pediatrics, Univ. Hosp. Nijmegen), or with a rabbit polyclonal antibody against human 
VPF/VEGF (Santa Cruz Biotechnology, Sanvertech, Breda, The Netherlands). For 
visualization of the immune reactions, alkaline phosphatase-conjugated secondary 
antibodies were used, except for the anti-HSPG reaction, which was visualized using a 
peroxidase-conjugated donkey anti-goat antibody. All sections were counterstained with 
haematoxyllin. 
For the analysis of tumour vessel permeability, mice bearing tumours with sizes 
between 100 and 700 mm3 were i.v. injected with 0.1 ml of a 3% solution of fluorescein 
isothiocyanate-labelled bovine serum albumin (FITC-BSA, 11 moles FITC per mole BS A, 
Sigma, Brunschwig, Amsterdam, The Netherlands). Tumours were excised 2, 10, or 45 
min after the injection of tracer, and snap frozen in liquid nitrogen. Cryosections of these 
tumours, 4 μΐη thick, were immediately fixed in 2% formaldehyde solution for 10 min. 
The distribution of the tracer was shown by fluorescence microscopy. The deposition of 
extravasated fibrin was analysed in parallel acetone-fixed tumour sections with a goat 
polyclonal against mouse fibrinogen/fibrin (Nordic Immunological Laboratories, Tilburg, 
The Netherlands), using a peroxidase-conjugated donkey anti-goat secondary antibody. 
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Other parallel sections of these tumours were stained for endothelium or HSPG (see 
above). 
Metastasis ofMel57 and transfectant xenografts 
To study the time-course and the frequency of metastasis, a number of lines was 
injected in 10-20 mice. Mice were sacrificed when the tumours reached a volume of 
between 300 and 2000 mm3. The lungs were formalin-fixed, and cross-sections were HE-
stained and analysed for the occurrence of metastases as described in (35). Scoring was 
performed by 3 independent observers. The number of metastases found in two cross-
sections of both lungs was plotted against the tumour volume. The metastatic frequency 
was defined as the number of mice having one or more lung metastases divided by the 
number of mice having a primary tumour. 
Results 
Selection of melanoma cell transfectants 
Mel57 is a melanoma line with a low level of VPF expression in culture, but in which 
this level is elevated when growing as a tumour in nude mice. A transfectant of this line, 
producing VPF121 constitutively, had quite a different vascular pattern in mouse xenografts 
compared with the parental line tumours (33). To determine if the level of recombinant 
VPF expression, or the molecular variant expressed, is of influence on the arrangement 
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Figure 1. Expression of endogenous and recombinant VPF RNA by melanoma cell transfectants. 
Northern blots containing RNA from cell lines (A) or xenografts in nude mice (B) were hybridized 
with a VPF probe (upper panels) and with a ubiquitin probe (lower panels). Endogenous VPF mRNA 
is visible as multiple bands around 3.7 kb in tumour RNA only, recombinant VPF RNA is apparent in 
VPF-transfected lines and their tumours as a band of about 1.0 kb. Mel57: parental melanoma line; 
El, E2: lines transfected with vector DNA only; III-8: line transfected with VPF189 cDNA; 1-3, 1-4, I-
Positions of length standards are indicated on both sides. 
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and the functionality of the tumour vasculature, we selected several other VPF12r and 
VPF189-transfected melanoma lines. 
The expression levels of the transfectants were determined by Northern blotting. In 
RNA from the VPF-transfected cell lines a band of approximately 1.0 kb was seen upon 
hybridization with a VPF probe, representing the recombinant VPF RNA (see Fig. 1, 
panel A). The highest levels of recombinant VPF RNA were produced by lines 1-3 
(expressing VPF]21, described before in ref. 33) and III-8 (expressing VPF189). Lines 1-4, 
1-9, and 1-11 contained lower but still detectable levels of VPF,21-encoding recombinant 
VPF RNA (see also Table 1). The major endogenous VPF transcript is 3.7 kb in length, 
but this was undetectable in RNA from cell line Mel57 or its derivatives. Southern blots 
of genomic DNA from transfected lines, digested with Hinàlïl, showed multiple bands 
upon hybridization with a VPF probe, in addition to the bands deriving from the 
endogenous VPF gene (not shown), indicating that multiple copies of the transfected 
construct had been integrated. 
To confirm that the recombinant VPF RNA levels found in the lines described above 
correlate with the amounts of active VPF protein secreted, conditioned serum-free media 
of these lines were harvested. The supernatants were Western blotted and stained with a 
polyclonal antiserum against VPF. In conditioned media of the parental line Mel57 and 
the vector-transfected lines El and E2 no VPF protein could be detected. Lines 1-3, 1-4, 
1-9, and I—11, expressing the RNA encoding recombinant VPFI21, secreted detectable 
amounts of 16 kD and 20 kD proteins (Fig. 2), being the expected molecular masses of 
the non-glycosylated and glycosylated forms of VPFI2I (42). Line III-8, expressing the 
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Figure 2. VPF protein expression by Mel57 transfectants. Proteins were precipitated from 0.2-0.4 ml 
(standardized amounts, see "Materials and Methods") serum-free conditioned media of melanoma cell 
transfectants, electrophoresed under reducing conditions, electroblotted and stained with a polyclonal 
antiserum against human VPF. Mel57: parental cell line; El, E2: lines transfected with vector DNA 
only; III-8: line transfected with VPF189 cDNA; 1-3, 1-4, 1-9, Ml: lines transfected with VPF121 DNA. 
Conditioned media in the four left-most lanes contained 100 /ig/ml heparin, conditioned media in the 
other lanes did not contain heparin. The four right-most lanes were run on a separate gel. Positions of 
molecular mass standards are indicated for both gels. 
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RNA for recombinant VPF189, was expected to secrete VPF proteins of a molecular mass 
of 28 and 31 kD which would need heparin to be released from extracellular matrix 
(34,42). Indeed, detectable amounts of VPF were only found in the conditioned medium 
of this line if heparin was added (Fig. 2). The biological activity of the recombinant VPF 
was tested in a procoagulant assay, measuring the capacity to induce tissue factor 
expression on endothelial cells. No significant activity was present in the conditioned 
media of Mel57 and control transfectants, but the lines that produced recombinant VPF 
were all positive in this assay (not shown). The highest tissue factor level was induced by 
conditioned medium from line 1-3. Although no VPFI89 was detectable in the heparin-free 
conditioned medium of line III-8 by Western blotting (Fig. 2), sufficient VPF activity was 
present in this supernatant to cause a significant increase in the tissue factor level. 
The efficiency of translation of recombinant VPF RNA 
The endogenous VPF mRNA has a 1 kb 5' non-coding sequence in which a very GC-
rich region and several alternative translational start sites are present (43). These features 
may inhibit the efficiency of translation of the VPF mRNA. The recombinant VPF RNA 
lacks these sequences: only a stretch of 21 bases of the 5' non-coding sequence of the 
VPF gene is contained in the recombinant RNA. The efficiency of translation of the 
recombinant VPF RNA in Mel57 transfectants was compared with that of the endogenous 
VPF messenger in melanoma line BLM which has a constitutively high VPF expression 
(33). 
In transfectant cell line 1-9 no endogenous VPF mRNA was detectable; its level of 
recombinant VPFm-encoding RNA (1 kb) was about the same (in a molar ratio) as the 
level of endogenous VPF mRNA in melanoma line BLM (3.7 kb, Fig. 3, panel A). The 
VPF mRNA in line BLM was previously shown to encode predominantly VPF121, along 
with some VPF1H (33). The VPF protein secreted by cell line BLM was barely detectable 
on Western blots (bands representing VPF121 and VPFIM can be seen between 16 and 24 
kD), whereas the VPF,21 bands produced by line 1-9 are clearly visible (Fig. 3, panel B). 
Scanning of bands on autoradiographs from several Northern and Western blots revealed 
that VPF is 16 to 40-fold more efficiently produced from recombinant VPF RNA in line 
1-9 than from the endogenous VPF messenger in line BLM. In estimating the expression 
levels of recombinant VPF protein in tumours we have taken this higher efficiency of 
translation into account (see below, and Table 1). 
Expression of recombinant VPF in xenografts 
Transfected melanoma lines positive for recombinant VPF expression, as well as the 
parental line Mel57 and vector-transfected lines El and E2, were injected into nude mice, 
and from the resulting tumours RNA was isolated. Northern blotting of these RNAs 
showed that recombinant VPF RNA was present in tumours from the VPF,21-producing 
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Figure 3. Analysis of the relative 
translation efficiency of recombinant VPF 
k D
 RNA. A: Northern blot with RNA from 
melanoma cell line BLM and from 
VPF121-transfected cell line 1-9, hybri­
dized with a VPF probe (upper panel) 
and a ubiquitin probe (lower panel). 
Length markers are indicated on the left. 
B: Serum-free conditioned media con-
3 1 taining 100 μg/ml heparin from mela­
noma cell line BLM and transfectant cell 
21.5 line 1-9, were electrophoresed on SDS-
PAGE under reducing conditions, 
14.4 electroblotted, and stained with poly­
clonal antiserum against VPF (blocked 
before use with 3 volumes of heat-
denatured FCS to reduce non-specific 
background). Loaded were 285 μΐ of line 
I-9-conditioned medium (as in Fig. 2) 
and 500 μΐ of BLM-conditioned medium (derived from 3 times more cells than the sample from line I-
9). Molecular mass standards are indicated on the right. VPF121 bands are visible at 16 and 20 kD; cell 
line BLM produces VPF variants of 121 and 165 amino acids, which are faintly visible as bands 
between 24 and 16 kD. 
lines 1-3, 1-4, and 1-11, and from the VPF189-producing line III-8 (Fig. 1, panel B). In 
these tumours, as well as in the tumours from vector-transfected lines El and E2, the 
vector-encoded RNA for hygromycin phosphotransferase was also still expressed (not 
shown). Line 1-9 produced only one small tumour after the first series of four injections, 
and was not included in further experiments. 
In all xenografts the levels of endogenous VPF mRNA were increased, as expected 
(33). However, in tumours from the lines expressing the highest levels of recombinant 
VPF RNA (1-3 and III-8) the levels of endogenous VPF mRNA were about half of the 
level in line Mel57 tumours. This suggests that VPF might - possibly through inducing 
angiogenesis and preventing hypoxia - inhibit the expression of its own gene in vivo. The 
relative levels of recombinant VPF RNA and endogenous VPF mRNA in the various 
transfected cell lines in vivo are summarized in Table 1. 
Extrapolation of the higher efficiency of VPF production from the recombinant VPF 
RNA than from the endogenous messenger (see above) to the in vivo situation, suggests 
that the levels of recombinant VPF protein expressed by the VPF-transfected tumours 
greatly exceed the VPF levels expressed by the parental line tumours. The level of 
recombinant VPF RNA in line 1-3 in vivo is only 1.8-fold its endogenous messenger 
level. The amount of recombinant VPF protein produced would be, however, 13 to 33-
fold the amount of VPF produced by Mel57 tumours. Tumours from the lower expressing 
lines 1-4 and 1-11, are still predicted to express 4 to 10-fold the VPF levels in Mel57 
tumours (Table 1). 
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Line 
гее VPFRNA 
in vivo 
end VPF mRNA 
in vivo 
predicted VPF 
expression level 
Mel57 
El 
E2 
1-11 
1-4 
1-3 
III-8 
-
-
-
0.19 
0.27 
0.82 
0.78 
(0.15-0.25) 
(0.17-0.38) 
(0.53-0.97) 
(0.74-0.80) 
1 
0.7 
2.1 
1.1 
0.58 
0.47 
0.44 
(0.5-1.2) 
(0.6-0.8) 
(0.7-3.8) 
(0.9-1.2) 
(0.5-0.7) 
(0.2-0.6) 
(0.3-0.5) 
1 
0.7 
2.1 
4 - 9 
5 - 1 1 
14-33 
13-32 
Table 1. Relative levels of recombinant (ree) VPF RNA and endogenous (end) VPF mRNA in 
(transfected) melanoma lines in vivo, and predicted expression levels of VPF protein in vivo. VPF 
band intensities after Northern hybridizations were quantified by densitometry. Values were corrected 
for the amount loaded by dividing the VPF intensities by the ubiquitin intensities. The average value 
for VPF mRNA calculated for Mel57 tumours was defmed as 1. The ranges of values obtained with 
different tumours from one line are given in parenthesis. Estimates of VPF protein expression levels in 
the rumours were made by considering the contribution from endogenous VPF mRNA and from 
recombinant VPF RNA in the tumours, assuming a 16-40-fold higher translation efficiency of the latter 
RNA. The predicted VPF protein expression level in Mel57 tumours was defmed as 1. 
Growth of transfected melanoma xenografts 
The growth curves of at least 4 tumours from each of the transfectant melanoma lines 
and from the parental line Mel57 were compared, and were found not to differ 
significantly. Only tumours from line III-8 had a somewhat higher growth rate in vivo 
than the other lines, but the cells from this line grew faster in vitro as well (not shown). 
Therefore it is unlikely that the increased rate of tumour growth was caused by the 
enhanced expression of VPF. The percentages of tumour necrosis were determined from 
formalin-fixed and HE-stained sections. Again, no significant differences between the 
lines were discovered (data not shown). All lines produced some tumours with extensive 
necrosis (up to 60-80% of cross-sections), while most lines (I-11, 1-4, III-8, El, and E2) 
also developed tumours with low necrosis percentages (10-40%). The higher levels of 
VPF expression in the VPF-transfected lines thus did not cause faster tumour growth or a 
higher ratio of viable cells, which might have been expected if the increased level of VPF 
had increased the density of tumour blood vessels. 
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All VPF-transfected melanomas have an altered vascular pattern 
Staining of Mel57 xenograft sections with the vascular marker MEC 7.46 showed blood 
vessels of different sizes scattered in an apparently unorganized fashion over large parts 
of the tumours. This vascular phenotype also developed in vector-transfected xenografts 
El and E2 (Figs. 4a, 4b, 5a). Many necrotic sites with little or no vasculature were 
present in these tumours as well (not shown here, but see also (33), in which an identical 
vascular pattern was described). 
Staining of xenograft sections from VPF-transfected lines with MEC 7.46 showed a 
vascular pattern very different from that in the control tumours. These tumours were 
divided into multiple nodules separated by stromal septa. Mostly, the tumour cell nests 
were devoid of endothelial staining, and developed a central necrosis. The stromal septa, 
however, showed intense endothelial staining (Figs. 4c-e, 5b). Endothelial cells extended 
through large parts of the septa, tending to surround most of the tumour cell nodules. 
However, the stromal septa also contained cells not staining with the endothelial marker. 
A double layer of endothelium was often observed within the septa (Figs. 4e and 5b), 
either suggesting hyperproliferation of endothelial cells, or compression of larger vessels 
by the (expanding) tumour mass. Cavities lined by endothelial structures were detectable, 
which probably acted as functional blood vessel lumina (Figs. 4c-e, 5b). This was 
confirmed by tracer studies (see below), since immediately after i.v. injection tracer was 
predominantly found in and around such cavities within the stromal septa. 
Line 1-3 expressed the highest levels of VPFI2I, whereas lines 1-4 and I-11 expressed 
lower, but still constitutive, levels of VPF121 (see Table 1). Yet, the lower levels of VPF 
expression in the latter lines still caused the development of the same vascular phenotype 
as found in line 1-3 tumours. 
In xenografts derived from line Ш-8, which overexpresses the extracellular matrix-
bound variant VPF,89, the vascular patterns (Fig. 4e) were similar to those found in the 
lines overproducing VPFI21 (1-3, 1-4, and 1-11). Stromal septa were often wider than 
observed in line 1-3, 1-4, or 1-11 tumours: especially at the junctions between several 
septa, enclosed by two layers of endothelial cells, a layer of non-endothelial stromal cells 
was often found, presumably consisting of fibroblasts (Fig. 4e, right hand side). 
Endothelial staining in line III-8 xenografts was exclusively found in the stromal septa. 
The morphological similarity demonstrates that also the heparin-binding VPF189 variant 
has an effect on vascular development in vivo, and that there is no significant difference 
between the biological effect of the diffusible and the matrix-bound VPF variants. 
The differences in the vascular phenotype between tumours from control lines and from 
VPF-transfected lines were already established in very small tumours (< 20 mm3, 
isolated within one week after the occurrence of a palpable tumour). A line El tumour 
with dimensions of 1.5 χ 0.8 mm already showed a few tumour-penetrating vessels, 
whereas a line 1-3 tumour with dimensions of 3 χ 2 mm already demonstrated a nodular 
phenotype with strong endothelial staining in the stromal septa (not shown). 
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Figure 4. Endothelial staining of sections of tumour tissue originating from several melanoma 
(transfectant) lines. The monoclonal MEC 7.46 was used to locate the murine endothelium in tumours 
from the following lines: a: Mel57, parental melanoma line; b: E2, vector-transfected line; c: 1-4; d: 
I-11 ; e: III-8. Areas of necrosis are marked "n". Blood vessels are marked by arrows, and apparent 
stromal structures that do not stain with the anti-endothelial antibody (non-endothelial stroma) are 
marked by arrowheads. Magnifications: 80x. 
Distribution of extracellular matrix 
Vascular endothelium is generally lined by a basal lamina consisting of extracellular 
matrix. In addition, melanoma cells may produce and deposit an extracellular matrix as 
well. To study the distribution of extracellular matrix components in the xenografts we 
used antibodies directed against laminin and heparan-sulphate proteoglycan (HSPG). Both 
antibodies demonstrated a finely branched network of extracellular matrix in the tumours 
from vector-transfected line El (see Figs. 5c and 5e), which was also apparent in tumours 
from lines Mel57 and E2 (not shown). A similar pattern was seen upon staining with an 
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anti-collagen IV antibody (not shown). Matrix staining did not colocalize with endothelial 
staining: only part of the matrix proteins was associated with blood vessels (compare Fig. 
5a with Figs. 5c and 5e). A layer of matrix proteins was found to surround small groups 
of tumour cells, suggesting that melanoma cells produced a large part of the matrix 
proteins themselves. In tumours from the VPF-transfected line 1-3, on the other hand, 
extracellular matrix components were mainly found in the stromal septa: laminin staining 
was observed throughout the stroma (Fig. 5d), whereas HSPG staining was mainly seen at 
the interface of the stromal septa with tumour parenchyma (Fig. 50- Also collagen IV 
staining was most intense at the boundary between the septa and the tumour nests (not 
shown). Similar patterns were observed in tumours from other VPF-transfected lines (not 
shown). Within the tumour cell nodules, a dotted matrix staining was observed in tumours 
from line 1-3 and other VPF-transfected tumours (Figs. 5d and 50- Only occasionally and 
locally a fine network of matrix proteins as present in control tumours was observed (see 
e.g. Fig. 7i). These results suggest that extracellular matrix deposition between melanoma 
cells is inhibited in the tumours from VPF-transfected lines, either through 
downregulation of matrix protein synthesis, or through enhanced matrix protein 
breakdown. 
In early tumours from lines El and 1-3 the typical matrix patterns were already visible. 
A fine network of laminin and HSPG was present in a small El tumour, whereas laminin 
staining in a small line 1-3 tumour was seen almost exclusively in stromal septa (not 
shown). 
Distribution of VPF protein in the xenografts 
VPF is thought to exert its activity on endothelial cells, and has been found to 
accumulate on tumour blood vessels (44). To study the distribution of VPF in the 
melanoma xenografts sections were stained with a polyclonal anti-VPF antibody. In 
general low staining intensities were found, especially in control tumours (from lines 
Mel57, El, or E2). Diffuse VPF staining throughout the tumours was found in cross-
sections of line 1-3, 1-4, and III-8 tumours, indicative for the fact that VPF is expressed 
constitutively by these tumours. More intense VPF staining was often seen in the stromal 
compartments of VPF-transfected tumours (Figs. 6d and 6e) as well as of control tumours 
(Fig. 6b). VPF staining colocalized, in part, with endothelial cells, confirming the finding 
that VPF accumulates on tumour blood vessels, but it was also seen on stromal cells that 
did not stain with the endothelial marker (compare Figs. 6b and 6c). Although especially 
VPFU9 has a high affininty for heparin, VPF staining in tumours from the line expressing 
this variant, III-8, or from other lines, did not colocalize with HSPG staining (not 
shown). 
Hypoxia was suggested to be a cause for the observed upregulation of VPF expression 
in Mel57 xenografts (33). This hypothesis predicts that higher levels of VPF should be 
expressed around necrotic areas in such tumours. In some sections of line Mel57, El, and 
E2 tumours, staining for VPF was indeed most intense in cells lining necrotic areas (Fig. 
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Figure 5. Comparison of endothelial and matrix staining in tumours from transfected melanoma lines. 
Serial sections of a line El tumour (a, c, e) and a line 1-3 tumour (b, d, f) were stained with the 
endothelial-specific monoclonal (a, b), an anti-laminin polyclonal (c, d), and an anti-HSPG polyclonal 
(e, f)· Necrotic regions are marked "n", blood vessels are marked by arrows, and a double layer of 
endothelium in a stromal septum in panel b is marked by an arrowhead. Note that in the line El 
tumour only a few vessels are visible and that the matrix distribution is dense and chaotic, whereas in 
the line 1-3 tumour both the endothelial staining and the matrix stainings yield the same H-shaped 
figure formed by the boundaries of several tumour nodules. Magnifications: 80x. 
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Figure 6. Localization of VPF in tumours from untransfected and transfected melanoma lines. Sections 
of tumours were stained with a polyclonal anti-VPF/VEGF antibody (a, b, d, and e) or with the anti­
endothelial antibody (c). Tumours were from the following lines: a: Mel57, parental line; b and c: El, 
serial sections showing the same region of a small tumour (1.5 χ 0.8 mm) stained for VPF and 
endothelium, respectively; d: 1-3, serial section to Figs. 5b, 5d, and 5f; e: III-8. Necrotic areas are 
marked "n". Delicate VPF staining is faintly visible in black and white reproduction. Therefore, the 
regions staining for VPF are also marked by arrowheads. In panel c, endothelial staining is marked 
by arrows. Asterisks indicate non-endothelial stromal structures in panel с that do stain for VPF in 
panel b. Magnifications: a-c and e: 160x; d: 80x. 
6a), suggesting an influence of hypoxia on the induction of VPF expression in the control 
tumours. However, there was not always an intense VPF staining seen adjacent to 
necrosis, while in a very small line El tumour without any necrosis VPF staining was 
already visible in the stroma (Fig. 6b). Therefore, tumour necrosis appears to be neither 
necessary nor sufficient for the induction of VPF expression, and other mechanisms than 
hypoxia must be involved in this induction as well. 
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Examination of vascular permeability in the transfectant xenografis 
Since VPF is an inducer of vascular permeability (29), the permeability of the blood 
vessels for proteins may be enhanced in tumours derived from the VPF-transfected lines. 
This was tested by i.v. injections of fluorescein-conjugated albumin (FITC-BSA), and 
subsequent examination of the tumours. 
In tumours from line Mel57 or from vector-transfected lines, 2 min and 10 min after 
injection very little extravasation of tracer had occurred: fluorescence was almost 
excusively seen within the vascular walls (Fig. 7a). After 45 min, however, small 
amounts of tracer had leaked from the vessels into the tumour mass, visible as short 
protrusions coming out of the vessels (Fig. 7b). In all VPF-transfected tumours, 2 min 
after injection, tracer was found not only in the walls of what appeared to be functional 
blood vessels (Fig. 70, but part of it was also found in the rest of the stromal septa. 
These septa, therefore, seemed to contain channels connecting the blood vessels. These 
channels partly colocalized with endothelial cells, and thus they may be part of the 
vascular system. Very extensive leakage from the vascular system into the tumour mass 
was evident 10 min and 45 min after injection, as tracer was not only seen in the stromal 
compartments rich in endothelial cells, but had also spread through parts of the tumour 
parenchyma (Fig. 7g). Still, the tracer was retained within parts of the tumour cell mass 
rich in matrix proteins (Figs. 7g and 7i, right hand side), which apparently formed a fine 
network of interstitial channels. In the control tumours a similar or even more extensive 
network of matrix proteins was present (Figs. 5c, 5e, 7d), but tracer leakage was much 
less intense (see above). The centres of the tumour nodules, poor in matrix proteins, were 
not reached by the protein tracer (Fig. 7g), in accordance with earlier reports on protein 
leakage from tumour blood vessels (13,44). These data thus show that in VPF-
overproducing tumours protein leaks more extensively from the tumour vessels into the 
tumour cell compartment than in control tumours, and that the distribution of the 
extravasated protein in the tumour parenchyma colocalizes with a network of extracellular 
matrix. 
As a consequence of this higher vascular permeability, the formation of an extravascular 
fibrin matrix may be favoured, facilitating the growth of new blood vessels (32), or 
directing the pattern in which angiogenesis takes place. Staining for fibrinogen/fibrin in 
Figure 7. Leakage of macromolecular tracer from blood vessels and deposition of extravascular fibrin. 
FITC-labelled BSA was i.v. injected in mice bearing line Mel57 tumours (a-e) or line 1-4 tumours (f-
j). Sections shown in panels a and f are from tumours removed 2 min after injection, panels b and g 
show tumours removed 45 min after injection. Tracer was visualized by fluorescence microscopy. 
Leakage of tracer is indicated by arrows. Panels c-e are serial sections corresponding with panel b; 
panels h-j are serial sections corresponding with panel g. с and h: staining with the anti-endothelial 
antibody, showing the distribution of blood vessels; d and i: staining with an anti-HSPG antibody, 
showing the distribution of matrix proteins; e and j : staining with an anti-fibrinogen/fibrin antibody, 
showing the deposition of (extravascular) fibrin. Necrotic areas are marked "n". Magnifications: 80x. 
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cross-sections of these tumours did not show significant differences in the distribution of 
fibrin, however. Fibrin staining was most intense in the vascular walls, but some fibrin 
deposition was also visible as short protrusions from blood vessels in all types of tumours 
(Figs. 7e and 7j). The network of extravascular fibrin was certainly not more extensive in 
VPF-overproducing tumours. Apparently, extravasated fibrin was deposited close to the 
blood vessels, and protein leakage from tumour vessels was not rate-limiting for the 
development of an extravascular fibrin matrix. 
Metastatic properties of the transfectant xenografts 
Since tumour angiogenesis is believed to be essential for tumour metastasis (1-3), the 
altered vascular phenotype caused by a different VPF expression pattern may also change 
the metastatic potential of the tumours. To test the metastatic properties of the transfectant 
melanoma xenografts, lines Mel57, E2, 1-3, 1-4, and III-8 were injected s.c. in 10 or 20 
mice each. When the tumours reached a size of between 300 and 2000 mm3, the mice 
were sacrificed, and the numbers of lung metastases were determined. These numbers 
were plotted against the volume of the primary tumour at the moment the mice were 
sacrificed. In this experiment, the percentage of mice bearing a line Mel57 tumour having 
one or more metastases (73%), and the number of Mel57 metastases found per mouse, 
were quite high compared with mice with line E2 tumours, and also with most VPF-
transfectant tumours (see Fig. 8). Melanoma line Mel57 is of an earlier passage than all 
the transfected lines at the time of injection, since the latter lines have all been cloned and 
selected in hygromycin-containing medium for a prolonged period (see the Materials and 
Methods section). Therefore, vector-transfected line E2 is probably a better control in this 
experiment than parental cell line Mel57. Similar frequencies of metastasis were found for 
lines E2 (35%), 1-3 (50%), 1-4 (30%), and III-8 (25%). In most cases the numbers of 
metastases per mouse, if present at all, were rather low. In a few mice carrying line 1-3 
tumours many metastases were found occurring relatively early in tumour development 
(tumours between 400 and 700 mm3, see Fig. 8), but the total number of mice with a line 
1-3 tumour was very small (6). To allow for thorough statistical analysis, much higher 
numbers of mice would have to be tested, but at present these data do not support the 
possibility that the alteration in vascular pattern changes the metastatic potential of the 
tumours. 
Figure 8. Metastatic behaviour of the tumours from Mel57 and transfected lines. The number of 
metastases counted in two cross-sections of both lungs of an animal was plotted as a function of the 
tumour volume at the time of obduction. The table in the top right hand corner shows the calculated 
metastatic frequencies for the different lines. 
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Discussion 
The aim of this study was to test whether a change from an inducible to a constitutive 
VPF expression pattern in melanoma cells affects the development of the tumour vascular 
bed, and if so, whether the level of VPF expression influences the vascular pattern. This 
question was inspired by the observation that human melanoma lines differed in their 
pattern of VPF expression. Some lines, like BLM, had a constitutively high level of VPF 
expression, whereas other melanoma lines with a somewhat different vasculature, like 
Mel57, had a much lower expression level of VPF in culture, which in vivo was 
upregulated to the same level as that found in line BLM (33). By transfection of line 
Mel57 several lines with a high basal level of VPF expression were obtained. These lines 
provided a model to test the influence of the VPF expression pattern in vivo. 
An intriguing observation using the transfectant lines in vitro, was the higher efficiency 
of translation of the recombinant VPF RNA compared to that of the endogenous VPF 
mRNA. In the 5' non-coding sequence of the endogenous VPF messenger a GC-rich 
region is present as well as several AUG and GUG alternative initiation codons (43). 
Such features have also been found in the 5' non-coding region of the PDGF-B chain 
transcript, where they have a profound inhibitory effect on the translation efficiency 
(45,46). The 5' region of the recombinant VPF RNA contained a vector-encoded SV40-
derived leader and only a 21 base stretch of the 5' non-coding sequence of the VPF gene. 
The higher translation efficiency of this recombinant transcript indicates that also in the 5' 
non-coding region of the VPF mRNA sequences are present that inhibit translation. 
When studying and interpreting the differences in biological behaviour induced by the 
transfection of VPF expression constructs, one should be aware of unexpected genetic 
changes that can occur during the transfection and selection procedure. Chromosomal 
integration of the transfected DNA fragment may alter the expression of a gene essential 
for e.g. metastasis. During selection of transfected cell lines spontaneous mutations may 
also occur which could influence the biological behaviour of the lines. Finally, 
spontaneous mutations may occur in vivo, and expression of the transfected fragment may 
be lost because of the absence of hygromycin selection. Mutations may yield a selective 
advantage in vivo, and cause heterogeneity of the tumour cell population. With respect to 
the vascular patterns, the vascular permeability, and the matrix distribution studied, 
significant differences were never observed between the parental line Mel57 and the 
vector-transfected lines on one hand and the various VPF-transfected lines on the other 
hand. Also morphological heterogeneity within tumours was rarely seen. Therefore, there 
is no reason to assume that the observed differences in tumour morphology and 
physiology are caused by unexpected genetic changes; they are much more likely to be 
caused by the experimentally intended changes in the VPF expression pattern. The 
difference in metastatic potential observed between tumours from the parental line and 
from the vector-transfected line E2, however, may be the consequence of an unintended 
genetic change, and argues caution in interpretating these data. 
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The lines transfected with VPF expression constructs produced tumours with a strikingly 
different vascular pattern than the parental line or vector-transfected lines. The vascular 
pattern seen in tumours from the VPF-transfected lines was, unexpectedly, also very 
different from that in other melanoma lines constitutively expressing VPF, such as BLM 
(33, J.R. Westphal et al., unpublished results). This comparison is not quite appropriate, 
however, as VPF is probably not the only determinant of the vascular phenotype. 
Furthermore, the VPF expression levels of the transfectant lines are presumably an order 
of magnitude higher than the expression level of line BLM. 
The aberrant vascular phenotype induced by the VPF-transfected lines in the present 
studies was not dependent on the level of recombinant VPF expression. It should be 
noted, however, that even in the line with the lowest expression level (1-11), VPF was 
probably still overexpressed by a factor of 4 to 9 compared with normal Mel57 
xenografts. Transfectant lines with even lower expression levels than line 1-11 would have 
been useful, but were difficult to identify by Northern blotting because of their extremely 
low levels of recombinant VPF RNA. 
The vascular pattern in tumours from line Ш-8, which expresses the heparin-binding 
VPFIM variant, was not significantly different from the pattern in the tumours producing 
the diffusible variant VPF121. This indicates that this molecular variant is biologically 
active and that it must, at least in part, be released from the producing cells. Assuming 
that VPF189 is normally retained by heparan sulphate proteoglycan (HSPG) in the 
extracellular matrix (34), it is important to note that little HSPG appeared to be present in 
the tumour nodules from all VPF-transfected lines, thus allowing VPF189 to diffuse away. 
Furthermore, proteases like plasmin may be present in the tumour parenchyma which can 
release a biologically active part of VPF189 (34). 
It is difficult to give an explanation for the development of the aberrant vascular 
phenotype in the tumours from VPF-transfected lines. A suitable explanation for the 
absence of tumour-penetrating vessels in the VPF-overproducing tumours could be the 
absence of a VPF concentration gradient that would develop in control tumours as a result 
of hypoxia-induced VPF expression. However, the correlation between tumour necrosis 
and VPF staining was not as strong as might have been expected if hypoxia were the only 
inductive factor. Also the fact that different vascular patterns had already evolved in very 
small tumours from lines El and 1-3, without any signs of necrosis, makes this hypothesis 
unlikely. 
Varying degrees of extravascular fibrin deposition could influence the patterns of 
neovascularization in the tumours as well (32). Although the permeability of the tumour 
vessels for proteins was, as expected, chronically increased in the tumours producing 
recombinant VPF, it did not lead to a more extensive fibrin network in these tumours. 
Extravasated fibrinogen may be quickly converted into fibrin, and be deposited close to 
the blood vessels from which it originated. Furthermore, along with larger amounts of 
extravasating fibrinogen, also larger amounts of plasminogen may leak from the vessels. 
This may be activated by plasminogen activators, which are probably expressed in 
increased amounts by endothelial cells due to the action of VPF (26), and which may also 
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be expressed by the tumour cells. Plasmiti could then remove most of the deposited 
fibrin. An enhanced activity of proteinases in the tumours from VPF-transfected lines 
could also explain the low amounts of matrix proteins detected within their tumour cell 
nests. It is therefore of great interest to investigate in future studies the presence and 
distribution of specific proteases in these tumours. 
Although changing VPF expression in a melanoma line from inducible to constitutive 
does change the pattern of tumour vascularization qualitatively, the mechanism by which 
VPF influences this pattern is still unclear. The determination of the vascular pattern is 
clearly dependent upon a number of parameters, of which VPF expression is one, that are 
not quite understood. Therefore, further studies on the role of VPF in angiogenesis and 
tumour vessel function are required. 
The idea that the tumour vasculature is important for metastasis, urged us to study the 
consequences of varying vascular types on the metastatic potential of the tumours. As yet 
we could not demonstrate significant differences in the metastatic behaviour between the 
tumours from a vector-transfected line and several VPF-transfected lines. The data are 
difficult to interpret, however. The parental line Mel57 produced tumours with a higher 
frequency of metastasis despite the fact that its vascular morphology was indistinguishable 
from that in tumours from vector-transfected line E2. Mel57 was of a lower passage at 
the time of injection into mice, and had not undergone the transfection and selection 
procedures, and therefore may not be a fair control line in these experiments. On the 
other hand, unexpected events may have genetically altered line E2 (as discussed above). 
This possibility is hard to verify, but it does undermine the reliability of line E2 as a 
control in the metastasis experiment. 
Initially we expected that overexpression of VPF would increase the number of tumour 
blood vessels. However, in spite of the dramatic differences in the vascular patterns 
observed between the control tumours and the VPF-overproducing tumours, the density of 
functional blood vessels was not obviously altered. Hence, this system may not be a 
suitable model to test if the number of tumour blood vessels is rate-limiting to the process 
of metastasis. An intense staining with markers for laminin and proteoglycans in the 
stromal septa of VPF-overproducing tumours, suggests that these matrix proteins act as a 
basal membrane, forming a barrier between tumour cells and the highly vascular stroma. 
This is another complicating factor in this model system. 
It would be useful for future experiments if melanoma lines were found which do not 
upregulate VPF expression in vivo. Melanoma lines forming very slowly growing tumours 
in nude mice do exist, but their VPF expression in vivo was not studied, just because of 
this practical disadvantage. However, such tumours might have low VPF expression 
levels, which would make their cell lines attractive candidates for transfections with VPF 
expression constructs. Such an approach might improve the vascularization of the 
resulting tumours, yielding a model very suitable for studying the influence of tumour 
vascularization on the process of metastasis. 
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Chapter 5 
Vascular permeability factor, or vascular endothelial growth factor (VPF/VEGF), is 
an important factor in the regulation of vascular growth and vascular permeability. 
VPF is a secreted, dimeric protein and has eight cysteine residues conserved with 
platelet-derived growth factor (PDGF). To study the role of some of these cysteine 
residues in maintaining the structure and function of VPF, we replaced the codons 
for the 2™1, 3rd, 4th, and 5th cysteine by serine codons, and expressed the mutant 
proteins in a mammalian expression system. Cysteine residues 2 and 4 in VPF were 
found to be directly involved in anti-parallel interchain disulfide bonds, as in PDGF. 
VPF mutants lacking one of these cysteines were severely impaired in their S-linked 
dimerization, whereas upon coexpression of both mutants the ability to form dimers 
was restored. The VPF mutants lacking cysteine residue 2 or 4 also competed poorly 
for receptor binding of labelled VPF and had low biological activity, but these defects 
were also complemented by coexpressing the two mutants, indicating that for 
efficient receptor binding and activation VPF needs to be a covalent dimer, unlike 
PDGF-BB. Furthermore, cysteine residue 5 was found to be essential for VPF 
dimerization and activity, whereas the mutant lacking cysteine residue 3 was only 
mildly affected in its ability to dimerize and had partial biological activity. 
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Introduction 
Vascular permeability factor (VPF) was first discovered as a protein factor that 
increases vascular permeability (1), but upon cloning of its gene it appeared to be 
identical to vascular endothelial growth factor (VEGF), an inducer of endothelial cell 
proliferation and angiogenesis (2,3). More recently, other activities of VPF/VEGF have 
been described, such as its ability to induce the expression of tissue factor, plasminogen 
activators, plasminogen activator inhibitor-1, and interstitial collagenase by endothelial 
cells (4-6), and its ability to attract and activate monocytes (4,7). VPF has an N-linked 
glycosylation site (2,3) but is often found as a mixture of glycosylated and non-
glycosylated proteins (8,9). Glycosylation does not appear to be essential for biological 
activity of VPF, but does affect the efficiency of cellular secretion (8). 
Two different receptors for VPF have been characterized and cloned, which appear to 
be expressed only by endothelial cells and haemopoietic cells (10,11). Apart from its 
expression during physiological processes (12-16), VPF is thought to be an essential 
factor in tumour progression (17-19). Therefore it is useful to investigate the structure of 
VPF, as this may help in the design of VPF inhibitors. 
Due to alternative splicing of the VPF messenger, various molecular variants of VPF 
exist with different isoelectric points, affinities for heparin, and cysteine contents. The 
smallest variant VPFm contains 9 cysteine residues, while larger variants contain 16 
cysteine residues (9). VPF has been classified as a member of a growth factor family to 
which also the platelet-derived growth factors (PDGF) belong. VPF has an amino acid 
homology of 15-18% with the PDGF-A and -B chain, but most notable is the perfect 
conservation of eight cysteine residues between these proteins (2). In the PDGF-A and -B 
chain, two of the eight cysteine residues are directly involved in dimerization: the 2nd 
cysteine of one subunit forms an intermolecular disulfide bridge with the 4th cysteine of 
the other, and vice versa (20,21). Mutations of either cysteine 2 or cysteine 4 to a serine 
residue abolished S-linked dimerization of PDGF, but a heterodimer could be formed by 
coexpression of both mutants (20). The Cys to Ser mutants of the PDGF-B chain still 
bound to their receptor and had agonist activity. Recently, evidence was presented that 
these mutants still form dimers which are kept together by non-covalent interactions (22). 
The monomeric Cys2 to Ser and Cys4 to Ser PDGF-A chain mutants, on the other hand, 
did not bind to their receptor, but heterodimers formed by these mutants had recovered 
receptor binding and biological activity (20). The other six cysteine residues in the 
PDGF-B chain are involved in intra-subunit disulfide bridges: in the crystal structure 
Cysl is linked to Cys6, Cys3 to Cys7 and Cys5 to Cys8 (21). These six cysteine residues 
are conserved in nerve growth factor (NGF) and transforming growth factor-ß2 (TGF-B2) 
as well, which also share the same arrangement of intramolecular cystine bridges, called 
"cystine knot", with PDGF-BB (23-25). 
Replacement of cysteine residues to serine residues in \-sis, a homologue of the PDGF-
B chain, revealed that cysteines 1, 3, 6, and 7 are essential for biological activity, 
whereas mutants lacking cysteines 2, 4, 5, and 8 still have transforming activity (26,27). 
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All eight Cys to Ser mutants were impaired in their ability to form S-linked dimers, 
however, suggesting that also the intramolecular disulfide bridges may be essential for 
dimerization, by maintaining a proper subunit structure. 
In VPF, as stated above, eight of the cysteine residues are conserved with PDGF. 
Therefore, it is tempting to assume that VPF has the same arrangement of intramolecular 
and intermolecular disufide bridges as PDGF. As yet no study has been reported in which 
this hypothesis is tested. Furthermore, it is unknown if VPF dimerization is essential for 
receptor binding and activation. In this paper we describe the expression of VPF mutants 
with the 2nd, 3rd, 4"1 or 5* cysteine residue replaced by a serine residue. Cysteines 2 and 4 
appear to be involved in intermolecular disulfide bridges analogous to the situation in 
PDGF. In contrast with earlier findings with \-sis, cysteine 5 was also essential for VPF 
dimerization and activity, whereas dimer formation and biological activity were only 
slightly affected by the mutation in cysteine 3. Our data further indicate that, in contrast 
to PDGF-BB, covalent dimerization of VPF is essential for effective receptor binding and 
biological activity. 
Materials and Methods 
Production and expression of VPF cysteine to serine mutants 
A cDNA clone containing the protein coding region of VPF165 was obtained by RT-PCR 
on RNA from phorbol 12-myristate 13-acetate (PMA)-stimulated cell line U937 (2). The 
PCR product was cloned into vector pBluescript II KS + (Stratagene, San Diego, CA, 
USA) from which single stranded antisense template was prepared. The protocol for site-
directed mutagenesis was adapted from (28). 20- or 21-mer primers were designed which 
corresponded to the 2й1, 3rd, 4й1, or 5* cysteine (amino acids 51, 57, 60, and 61, 
respectively) and surrounding amino acids, but carrying a G to С change at the second 
cysteine codon position (see also Fig. 1). The phosphorylated primers were annealed with 
the template and a second DNA strand was synthesized using DNA polymerase Klenow 
fragment (Gibco BRL, Paisley, UK). VPF mutant clones were obtained by transformation 
to E. coli strain BMH71-18 mut S (29) and subsequently to strain XL-1 Blue (Stratagene, 
San Diego, CA, USA), and were identified by sequencing. The wild type and the four 
mutant VPF sequences were recloned as SañIKpnl fragments to vector pSPTBM20 
(Boehringer Mannheim, Germany), and then as SaulNotl fragments to the expression 
vector pBPV (Pharmacia LKB, Woerden, The Netherlands) by ligation into the Xhol (5') 
and Noti (3') sites. The plasmids were transfected into mouse C127I cells (ATCC, 
Rockville, MD, USA) using DOTAP (Boehringer Mannheim, Germany) as transfection 
reagent. Transfected cells were first cultured for 6 weeks in Dulbecco's Modified Eagle's 
Medium (DMEM, Flow laboratories, Irvine, UK) supplemented with 10% fetal calf 
serum (FCS, Gibco BRL, Paisley, UK), L-glutamine, penicillin and streptomycin, to 
allow for enrichment of cells transformed by the BPV sequence (30). After this period, 
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Figure 1. Schematic illustration of cysteine residues in VPF165 and the serine substitutions in VPF 
mutants. The top bar represents mature wild type VPF11S5 from the N-terminus (1) to the C-terminus (165). The eight large "C"s represent the cysteine residues shared with PDGF. In VPF mutants C2S, 
C3S, C4S, and C5S one of these cysteine residues is substituted for a serine residue (S, arrowhead). 
VPF or VPF mutants were harvested by placing cells in DMEM without serum for 24 
hour periods twice a week. The recombinant proteins continued to be expressed for at 
least 6 weeks. To double-check that the transfected lines contained the appropriate 
constructs, DNA was isolated from the transfected cells, amplified by PCR, and 
hybridized to the original mutant primers. 
Production of polyclonal antiserum against VPF 
For large scale expression of VPF in a bacterial system the last two arginine codons in 
the VPF16J cDNA were changed into a BamHl site by PCR, and a 0.5 kb 
NcoI(blunt)/Bam//I fragment was recloned to the Bûwi//I(blunt)/Bg/II-digested vector 
pQE16 (Q1AGEN, Westburg, Leusden, The Netherlands). The resulting plasmid, pQE-
NcoVPFH, was transformed into E. coli strain M15pREP4 (QIAGEN). The recombinant 
protein expressed by these cells consisted of the VPF amino acids 3-163, plus 4 additional 
amino acids at the N-terminus and a Gly-Ser-(His)6 sequence at the C-terminus. IPTG-
induced bacteria were lysed in 6 M guanidinium chloride, and the recombinant protein 
was purified on a Ni-NTA column (QIAGEN) by elution with 8M urea and a descending 
pH gradient. The purified protein was acetone precipitated, dissolved in phosphate-
buffered saline (PBS) with 0.1% SDS, and injected into a rabbit 3 times to obtain 
antiserum against VPF. To minimize non-specific staining of high molecular mass serum-
115 
Chapter 5 
derived bands on Western blots, the antiserum was blocked before use with 3 volumes of 
heat-denatured FCS. 
Determination of protein concentrations 
Before analysis by electrophoresis, VPF mutants were precipitated from samples of 
serum free conditioned media by addition of 2 volumes of acetone. To determine the 
concentrations of VPF mutants in the conditioned media the precipitates were 
electrophoresed on SDS-PAGE under reducing conditions, together with a range of 
known amounts of commercially obtained recombinant human VPF/VEGF (Peprotech, 
Sanvertech, Breda, The Netherlands). Gels were electroblotted to nitrocellulose 
membranes, which were incubated in FCS-blocked and 250-fold diluted antiserum against 
VPF and stained with the chemiluminescent substrate AMPPD (Tropix, Westburg, 
Leusden, The Netherlands) according to the manufacturer's protocol. Intensities of bands 
were quantitated by laser scanning. 
Analysis of VPF mutant dimerization 
To determine the ability of VPF mutants to form S-linked dimers, precipitates from 
conditioned medium were electrophoresed on SDS-PAGE without prior reduction. As the 
antiserum stained fully reduced VPF stronger than non-reduced VPF, gels were incubated 
before electroblotting in electrophoresis running buffer with 5% ß-mercaptoethanol for 10 
min at 100CC. Immunodetection of VPF was performed as described above. To study the 
ability of mutants to form non-covalently linked dimers, proteins were trapped in the 
dimeric state by adding the cross-linking agent disuccinimidyl suberate (DSS; Pierce, Oud 
Beijerland, The Netherlands) to conditioned media to a final concentration of 2.5 mM. 
After 90 min at 37°C the reactions were stopped by addition of glycine to 100 mM and a 
further incubation of 10 min at 37°C. Precipitations, SDS-PAGE under reducing 
conditions, blotting, and immune detection were performed as described above. 
Biological assays 
For biological assays crude centrifuged conditioned media from C127I cells were used, 
in which VPF concentrations had been determined by Western blotting (see above). 
Samples containing VPF or VPF mutants were diluted to the appropriate volumes with 
conditioned medium from С1271 cells transfected with pBPV vector DNA only (control 
supernatant, or pBPV supernatant) to keep protein backgrounds as constant as possible. 
Procoagulant assays, measuring tissue factor expression, were performed with human 
umbilical vein endothelial cells (HUVEC), essentially as described elsewhere (4,31). To 
0.75 ml of assay medium 0.25 ml samples of conditioned medium containing VPF or 
VPF mutants were added, and after 5 h tissue factor amounts were determined. Mitotic 
assays were performed on microvascular endothelial cells (MVEC) from human foreskin 
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(provided by Dr. V. van Hinsbergh, Leiden, The Netherlands). These cells were cultured 
as described in (32). For assays they were plated in 24-well tissue culture plates coated 
with gelatin. 1.5ХІ04 cells were seeded per well in 0.9 ml M199 (Flow laboratories, 
Irvine UK) supplemented with 5% newborn calf serum (Gibco BRL, Paisley, UK), 5% 
human serum, 20 mM HEPES, pH 7.3 (ICN, Zoetermeer, The Netherlands), L-
glutamine, penicillin and streptomycin. After 24 h 100 μ\ samples of VPF (mutants) were 
added, and another 48 h later 0.5 ^Ci [3H]thymidine (ICN, Zoetermeer, The Netherlands) 
was added to each well. Cells were incubated for 6 h in 7.5% C0 2 at 37
eC, washed 3 
times with PBS, fixed in methanol, and lysed in 0.2 N NaOH. [3H]Thymidine 
incorporation was measured by scintillation counting. Miles-type vascular permeability 
assays were performed essentially as in (1,33). In short, anaesthesized and shaved albino 
guinea pigs were i.v. injected with Evans Blue, i.d. injected with 100 μΐ samples of VPF 
(mutants), and sacrificed 15 min later. The extravasated dye was extracted from skin 
sections in formamide at 45 °C and quantitated spectrophotometrically at 620 nm. 
Competition for I25I-VPF receptor binding 
2 μι of purified VPF/VEGF (Peprotech, Sanvertech, Breda, The Netherlands), 
dissolved in 10 μΐ PBS, was labelled with 0.5 mCi [I2iI]NaI (Amersham, Amersham, UK) 
using the Iodo-Beads protocol (Pierce, Oud Beijerland, The Netherlands), and was 
recovered from a Sephadex G50 column equilibrated in PBS with 0.1% BSA. Specific 
activity was 3.9xl07 cpm^g protein. Human umbilical vein endothelial cells (HUVEC) 
were isolated and cultured as described elsewhere (34,31). For receptor binding 
experiments these cells were cultured to near confluence in 24-well plates, washed twice 
with binding buffer (DMEM with 25 mM HEPES, pH 7.0, 0.1% BSA, and 0.15% 
gelatin), and placed in 0.25 ml binding buffer (C127I cell-conditioned medium instead of 
fresh DMEM) containing І.ЗхІО3 cpm 12iI-VPF and varying concentrations of unlabelled 
VPF or VPF mutants. For positive and negative controls commercially obtained 
VPF/VEGF and recombinant bFGF (a gift from Scios Ine, Mountain View, CA) were 
added. Incubations were for 90 min at 20°C and were followed by three washes in PBS 
with 0.1% BSA, lysis in 0.25 ml 1% Triton X-100, 20 mM Tris/HCl, pH 7.5, and y-
counting. 
Results 
Expression of VPF mutants 
A prerequisite for the expression of recombinant VPF in a mammalian expression 
system is that the host cells do not produce VPF themselves. After screening a number of 
expression systems we found that mouse С1271 cells meet this criterion. These cells, even 
when transformed by BPV sequences in the vector, did not contain detectable amounts of 
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VPF mRNA, and did not produce detectable VPF-like activity (not shown) or VPF 
protein (Fig. 2). 
С1271 cells were transfected with pBPV vector constructs, which ensure stable episomal 
maintenance, containing VPF I 6 5 wild-type DNA or mutations thereof with one of the 
cysteine codons 2, 3, 4, or 5 substituted for a serine codon (see Fig. 1). Transformed 
cells secreted VPF protein into the medium for a prolonged period. Concentrations in 
serum-free conditioned media were between 0.1 and 0.6 μg/ml, as determined by Western 
blotting under reducing conditions followed by staining with a polyclonal antiserum 
against VPF (Fig. 2). Wild type VPF and all VPF mutants were apparent as a band of 25 
kD, which is the expected size of glycosylated VPF 1 6 5 (9). The VPF used as concentration 
standard was E. со/г'-produced and non-glycosylated, and therefore migrated faster on 
these gels (Fig. 2). 
To test if conditioned media from pBPV-transformed С1271 cells influenced the 
biological activity of VPF in various assays, the activity of different concentrations of 
commercially obtained VPF/VEGF diluted in serum-free medium with 0.1% BSA, was 
compared with the activity after dilution in supernatant from vector-transfected C127I 
cells. The dose-response curves did not differ significantly, hence C127I cell-conditioned 
kD 
66 
45 
31 
21.5 
14.4 
> Ï 
CÛ Q-
o. > 
со 
CM 
υ 
CO 
cr> 
о 
CO 
^ 
υ 
CO 
LO 
О 
СП 
с 
LO 
*-
СП 
с 
о 
η 
СП 
с 
о 
СО 
СП 
с 
о 
С\| 
г— 
s 
Figure 2. Expression of VPF mutants. Proteins were precipitated from 0.2 ml conditioned media of 
transfected С1271 cells and electrophoresed under reducing conditions. An electroblot of this gel was 
stained with a polyclonal antiserum against human VPF. pBPV: conditioned medium of pBPV 
(vector)-transfected cells. Concentrations of VPF wild type and Cys to Ser mutants of VPF were 
determined by comparing band intensities with a dilution range of commercially obtained VPF/VEGF 
(four right-most lanes), which was expressed in E. coli, and therefore non-glycosylated and of a 
smaller apparent molecular mass (apparently containing a product of an even smaller size as well). 
Positions of molecular mass markers are indicated on the left. Note that remaining traces of albumin 
from fetal calf serum in conditioned media, and albumin added to commercially obtained VPF/VEGF 
as a carrier protein, is weakly stained as a band of 66 kD. 
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medium did not influence the biological activity of VPF (data not shown). There were 
also no significant differences observed between the activities of commercially obtained 
VPF/VEGF and С1271 cell-derived VPF (not shown). Thus for the present experiments 
there was no necessity to purify VPF or its mutants: in the experiments reported below 
unpurified conditioned media were used. 
Dimerization of VPF mutants 
The capacity of the cysteine to serine mutants of VPF to form S-linked dimers was 
tested by SDS-PAGE under non-reducing conditions and subsequent staining of blots with 
anti-VPF polyclonal antiserum. Wild type VPF165 was found as a band of 46 kD, which is 
the expected molecular mass of the dimeric VPF protein (Fig. 3). All four mutants were 
more or less impaired in their ability to form S-linked dimers. Mutants in cysteine 2 or 5 
(C2S and C5S) were almost completely monomeric, whereas mutants in cysteine 3 or 4 
(C3S and C4S) consisted in part of dimers (50% and 20% dimers, respectively). 
Cysteines 2, 3, 4, and 5 are obviously all important, directly or indirectly, for VPF 
dimerization. 
If dimerization requires interchain disulfide bridges between two different cysteines, 
then complementation of the dimerization defect should take place upon coexpression of 
the two mutants with the respective cysteines mutated. Therefore all possible pairs of 
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Figure 3. S-linked dimerization of VPF mutants. Proteins precipitated from 0.25 ml conditioned media 
of transfected С1271 cells were electrophoresed under non-reducing conditions, electroblotted and 
stained with a polyclonal antiserum against VPF. Left panel: conditioned medium of pBPV (vector)-
transfected cells; VPF wild type; and single Cys to Ser mutants of VPF. Right panel: double 
transfections with two mutants; and (C2S)+(C4S): a mix of conditioned media containing mutants 
C2S and C4S, allowed to interact for 30 min at 20°C before precipitation. Positions of molecular mass 
markers are indicated on the left. Monomeric VPF is found at approximately 25 kD, whereas dimeric 
VPF is apparent as a band of 46 kD. Note that a weak albumin stain is visible at the top of the gel. 
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mutants were cotransfected, and the resulting VPF was tested for dimer formation. As 
can be seen in Fig. 3 (right panel) only cotransfection of mutants C2S and C4S led to a 
higher degree of dimerization than found for each of the mutants expressed singly: about 
50% of this VPF was dimeric, which was significantly more than the 0-20% dimerization 
found with the individual mutants. This indicates that the 2nd cysteine residue in one 
subunit forms an interchain disulfide bond with the 4* cysteine residue in the other 
subunit, as is the case in PDGF. Nevertheless, VPF mutant C4S is capable of some dimer 
formation by itself, which cannot be explained by the PDGF dimerization model. 
Apparently an alternative way of dimerizing is possible for this mutant. Complementation 
between mutants C2S and C4S was not complete, which may be explained by the fact that 
the plasmids encoding the mutants C2S and C4S were not present in equal amounts in the 
transfected cells; in fact the ratio of C2S/C4S sequences 12 weeks after transfection was 
about 5:2 (data not shown). Mixing of the C2S and the C4S mutants in vitro did not lead 
to extra dimer formation (Fig. 3, right-most lane), suggesting that the disulfide bridge 
between cysteines 2 and 4 has to be formed intracellularly. 
The decreased dimerization level of mutants C3S and C5S could not be complemented 
by cotransfecting them with other mutants. These cysteine residues may be involved in 
intramolecular folding, as in PDGF. Mutating these cysteines could lead to changes in 
subunit folding that are unfavourable for dimerization (C3S) or even abolish dimerization 
(C5S). However, from the present data it cannot be excluded that cysteine residues 3 
and/or 5 are involved in interchain disulfide bridges. 
Mutations in the interchain cysteines could still allow non-covalent dimerization. To trap 
non-covalently associated VPF mutants in the dimeric state they were incubated with the 
chemical cross-linking agent disuccinimidyl suberate (DSS). This treatment almost 
completely cross-linked wild type VPF, but also a considerable fraction of mutants C2S, 
C3S, and C4S was cross-linked by DSS (Fig. 4). The amounts of dimers found after 
cross-linking of these mutants (65%, 65%, and 40%, respectively) were higher than the 
amounts of S-linked dimers, especially for mutant C2S (Fig. 3), suggesting that in 
addition to S-linked dimerization, some non-covalent interaction does indeed take place. 
Mutant C5S was only 20% dimeric after DSS treatment, which is a similar percentage as 
found for wild type VPF completely reduced by DTT (18%), thus probably representing 
non-specific background. The subunits of mutant C5S apparently have a disturbed dimer 
interface. Heparin had no influence on non-covalent dimerization, since the same amounts 
of cross-linked dimer were found for all mutants after DSS treatment in the presence of 
100 /ig/ml heparin (not shown). 
Biological activity of VPF mutants 
VPF activity can be measured in a number of different biological assays. We used an 
endothelial cell mitotic assay, a Miles vascular permeability assay, and a procoagulant 
assay to determine the relative activities of the VPF mutants. In the procoagulant assay, 
measuring tissue factor expression by endothelial cells, wild type VPF had its maximum 
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Figure 4. Non-covalent dimerization of 
VPF mutants. Proteins in conditioned 
media were chemically cross-linked by 
DSS, precipitated, electrophoresed under 
reducing conditions, electroblotted and 
stained with a polyclonal antiserum against 
VPF. pBPV: Conditioned medium of 
pBPV (vector)-transfected cells; VPF165wt 
+ DTT: wild type VPF after reduction 
(10 min in 25 mM DTT at 50°C); 
VPF16Jwt: wild type VPF; four right-most 
lanes: Cys to Ser mutants of VPF. 
Positions of molecular mass markers are 
indicated on the left. VPF monomers 
migrate at 25 kD, cross-linked dimers at 
46 kD. 
inducing effect at about 25 ng/ml (not shown). VPF mutants were also tested at this 
concentration, at which mutants C2S, C4S and C5S did not have significant activity, 
while the partially dimeric mutant C3S was clearly active (Fig. 5). Cotransfections of 
VPF mutants generally yielded inactive VPF as well, although after cotransfections with 
mutant C3S partial activity could be observed, as expected from the activity of mutant 
C3S alone (not shown). The heterodimer formed after cotransfection of mutants C2S and 
C4S, however, did have full biological activity, which was not seen if VPF mutants C2S 
and C4S were mixed in vitro (Fig. 5, two right-most bars). In the mitotic assay and in the 
vascular permeability assay similar results were obtained: at concentrations that were just 
maximal for wild type VPF (5 ng/ml and 20 ng/injection, respectively) significant activity 
was only seen with VPF mutant C3S and with the heterodimer of mutants C2S and C4S 
(not shown, but see also Figs. 6 and 7). 
These results suggest that S-linked dimer formation of VPF is a prerequisite for 
biological activity, and that one interchain disulfide bridge from a Cys2 to a Cys4 suffices 
for full biological activity. One would expect, however, the VPF mutant C4S to be 
partially active as well, as about 20% of this protein is dimeric. Therefore the VPF 
mutants were tested for biological activity over a concentration range including higher 
concentrations. In the mitotic assay, as shown in Fig. 6, mutants C2S and C4S 
complemented each other when coexpressed, yielding an activity that was comparable 
with that of VPF wild type, while for mutant C3S about 4-fold higher concentrations had 
to be added to reach the same effect. VPF mutants C2S and C4S individually showed 
only little activity at high concentrations, thus the partial S-linked dimerization of mutant 
C4S does not contribute to its activity in this assay. Mutant C5S gave no evidence of 
activity in this assay at all. In the Miles vascular permeability assay (Fig. 7) VPF 
produced upon coexpression of mutants C2S and C4S also had an activity equivalent to 
that of the wild type protein. Again, mutant C3S required somewhat higher concentrations 
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Figure 5. Procoagulant assay. Expression of tissue factor activity by endothelial cells was measured 
after addition of 25 ng/ml VPF (mutants), the concentration which was maximal for wild type VPF in 
this assay. pBPV: conditioned medium of pBPV (vector)-transfected cells; (C2S)+(C4S): VPF 
mutants C2S and C4S mixed before addition to endothelial cells; C2S+C4S: mutants C2S and C4S 
coexpressed. For details see "Materials and Methods". The procoagulant activity measured after 
addition of serum-free medium was arbitrarily defined 1. The values presented are the means and 
standard deviations (SDs) of duplicate measurements. 
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Figure б. Thymidine incorporation assay. 
The effect of wild type VPF ( · ) ; 
coexpressed VPF mutants C2S and C4S 
(O); mutant C2S (Δ); mutant C3S (D); 
mutant C4S (v); and mutant C5S (x) on 
DNA synthesis in endothelial cells. See 
"Materials and Methods" for further 
details. Values are the means of triplicate 
measurements. Error bars were omitted 
for clarity; SDs were between 5-35%. 
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(about 3-fold) to reach the same activity as wild type VPF. Of mutant C4S a 5-10-fold 
higher dose was needed to obtain an effect equal to that of the wild type protein, whereas 
mutants C2S and C5S only started to show some activity at the highest concentrations 
used. Interestingly, in the permeability assay mutant C4S is reproducibly more active than 
mutant C2S, in contrast to the mitotic assay, in which mutants C2S and C4S both have 
comparable (low) activities. For practical reasons, we could not test VPF mutants at high 
concentrations in the procoagulant assay. 
To test whether any of the VPF mutants had antagonist activity, wild type VPF was 
mixed with increasing concentrations of the biologically poorly active mutants, and the 
mixture was tested in biological assays. Thus 3 ng/ml of wild type VPF was tested along 
with 5-40 ng/ml of mutants C2S, C4S, and C5S in the mitotic assay, and 20 ng of wild 
type VPF was tested together with 50-160 ng of mutants C2S and C5S in the permeability 
assay. In no case did any mutant inhibit the activity of the wild type protein. On the 
contrary, at the highest concentrations of some mutants the biological response was 
slightly enhanced (results not shown). 
Competition for receptor binding by VPF mutants 
The inability of the poorly active VPF mutants to inhibit the biological activity of wild 
type VPF, suggests that these mutants do not bind to VPF receptors. This was verified by 
[VPF] (ng/100//l) 
Figure 7. Miles-type vascular permea­
bility assay. The effect of wild type VPF 
( · ) ; coexpressed VPF mutants C2S and 
C4S (O); mutant C2S (Δ); mutant C3S 
(D); mutant C4S (v); and mutant C5S 
(x) on vascular leakage in guinea pig 
skin. For further details see "Materials 
and Methods". This graph is a composite 
of data obtained using two animals. In 
each of the animals negative and positive 
control samples (pBPV supernatant and 
20 ng wild type VPF) yielded a five-fold 
difference in Evans Blue leakage (3.35-
16.7 μg for animal 1 and 1.58-7.5 μg for 
animal 2). All measured values were then 
converted into arbitrary units of leakage, 
whereby the effect of 20 ng wild type 
VPF was designated as 1. 
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measuring the capacity of the VPF mutants to compete with l25I-labelled VPF for receptor 
binding. Binding of labelled VPF to endothelial cells was most effectively inhibited by 
wild type VPF (Fig. 8), requiring about 5 ng for 50% inhibition. Mutants C2S and C4S 
also inhibited receptor binding of labelled VPF, but much less efficiently than the 
heterodimer formed by these two mutants, which competed for receptor binding only a 
little less efficiently than wild type VPF, as did mutant C3S. No inhibition of VPF 
receptor binding was evident for VPF mutant C5S, and for an other heparin-binding 
growth factor: basic fibroblast growth factor (bFGF) at the concentrations used. In the 
presence of 100 μg/ml heparin the competition patterns were similar to those without 
heparin, although total binding of labelled VPF to endothelial cells was about 10-20% 
lower in the presence of heparin (not shown). 
Discussion 
If the structure of VPF is indeed homologous to that of PDGF, cysteines 2 and 4 should 
be involved in interchain disulfide bridges. The data presented here confirm the PDGF 
model for VPF: mutants lacking cysteine 2 or 4 were impaired in their ability to 
dimerize, but crucially, mutants C2S and C4S complemented each other's defect when 
coexpressed. VPF dimerization thus is dependent on the formation of disulfide bridges 
between the 2nd cysteine of one subunit and the 4lh cysteine of the other, and vice versa, 
leading to a doubly linked dimer which will have an antiparallel arrangement of the two 
subunits. For PDGF this crosswise orientation of intermolecular disulfide bridges was 
originally deduced from mutational experiments similar to those presented here, and the 
model was later confirmed by crystallography (20,21). 
Unexpectedly, mutant C4S consisted of about 20% dimers, which cannot be explained 
by the dimerization model for PDGF. The cell line that expressed this mutant did not 
contain other plasmids than the one with the C4S mutant sequence, therefore this low 
amount of dimers is not caused by a contamination but is a feature of the mutant itself. A 
PDGF-A chain mutant with its 4Ih cysteine changed to a serine did not show any signs of 
S-linked dimerization (20); in v-sis, on the other hand, both for the Cys2 to Ser mutant as 
for the Cys4 to Ser mutant there was evidence of some dimer formation (27). The C4S 
mutant of VPF must utilize an alternative way to dimerize, possibly by coupling the 2nd 
cysteine residues of two subunits, or by using one of the other cysteine residues in 
VPF163. As yet we have no data to explain this dimerization satisfactorily. The fact that 
this mutant does not show the residual 20% activity in the mitotic assay expected from its 
dimerization level suggests that the "illegitimate" dimerization of mutant C4S leads to a 
dimer structure that is different from normal. It also does not compete for receptor 
binding more efficiently than mutant C2S, while the partially dimeric VPF mutant C3S 
does compete efficiently. In the vascular permeability assay, on the other hand, the 
dimeric portion of mutant C4S appears to contribute to its activity. It is an interesting 
hypothesis that induction of mitosis and induction of vascular permeability may involve 
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Figure 8. Competition for receptor 
binding by VPF mutants. 125I-VPF was 
added to endothelial cells at 1.3x10s 
cpm/well along with varying concen­
trations of unlabelled VPF (mutants) or 
bFGF, and binding of labelled protein to 
the cells was measured. See "Materials 
and Methods" for further details, · : 
wild type VPF; O: coexpressed VPF 
mutants C2S and C4S; Δ: mutant C2S; 
D: mutant C3S; v: mutant C4S; x: 
mutant C5S; •: bFGF. In pBPV 
supernatant 1335 cpm '"I-VPF (+/- 74, 
SD) was bound, and this value was 
designated as 100%. For clarity error 
bars were omitted; SDs were in general 
less than 10%. 
different signal transduction pathways, one of which requires normally arranged dimeric 
VPF, whereas for the other an illegitimately formed S-linked dimer is sufficient. For 
other growth factors, like acidic fibroblast growth factor (aFGF) and Schwannoma-
derived growth factor, alternative signal transduction pathways have recently been 
demonstrated to mediate the induction of DNA synthesis and other biological effects 
(35,36). Alternatively, the 50-fold difference in the concentration ranges at which the 
mitotic assay and the vascular permeability were carried out, may have had an influence 
on the non-covalent dimeric state of mutant C4S, which may also explain its differential 
behaviour in both assays. 
It has been shown that PDGF-B mutants lacking cysteines 2 and 4 are still dimeric, 
albeit non-covalently bound, and fully biologically active (20,22). For VPF mutants 
lacking either cysteine 2 or cysteine 4 this does not hold true: the mutants are barely 
active in inducing endothelial cell proliferation even at high concentrations, and compete 
very poorly for receptor binding. Heterodimers formed upon coexpression of these two 
mutants have full biological activity, indicating that the subunits of mutants C2S and C4S 
are folded correctly. The poor ability to compete for receptor binding and the poor 
biological activity of mutants C2S and C4S individually is therefore caused by the mere 
fact that they cannot form covalent dimers linked between Cys2 and Cys4. The one 
interchain disulfide bridge that is formed in the C2S/C4S heterodimer obviously is 
sufficient to restore biological activity completely. Cross-linking data show that the 
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subunits of at least mutant C2S can associate non-covalently, but these interactions do not 
appear to contribute significantly to biological activity: apparently the non-covalent 
association is of a transient nature and insufficiently stable for receptor activation. 
Substitution of cysteine residue 3 or 5 in VPF by a serine also led to an impaired 
dimerization; mutation C5S did so to a greater extent than mutation C3S. These defects 
could not be complemented by cotransfection with other mutants. Although the possibility 
cannot be excluded that these cysteines are involved in inter-subunit interactions, we 
suggest that cysteine residues 3 and 5 are involved in intramolecular folding, as they are 
in PDGF. Since Cys3 is only separated by 2 amino acids from Cys4, and Cys5 is located 
directly adjacent to Cys4, it is easy to imagine that loss of an intramolecular disulfide 
bridge in which either Cys3 or Cys5 is involved can change the position of Cys4, thus 
hampering the formation of the Cys2-Cys4 disulfide bridge. Mutant C5S does not even 
appear to form non-covalently linked dimers, suggestive for improper folding of the C5S 
subunits. 
The hypothesis that VPF dimerization is required for receptor binding and activation is 
further supported by the finding that mutant C3S, which is 50% dimeric, competes for 
receptor binding and has a biological activity only slightly less than wild type VPF. Also 
consistent with this idea is the fact that mutant CSS, which does not produce detectable 
amounts of S-linked dimer, gives no evidence for receptor binding and has very low, if 
any, biological activity. Especially for mutant C5S it is also possible, of course, that the 
mutation of Cys5 results in an altered subunit structure which is not recognized by the 
receptor, even if this mutant were a dimer. 
In VPF, Cys3 was not essential for biological activity, whereas activity of the VPF 
mutant lacking Cys5 was diminished to nearly zero. This is in contrast with the situation 
in the v-sis protein, in which Cys5 was dispensable and Cys3 was essential for 
transforming activity (26,27). Clearly, there must be folding differences between \-sis 
(PDGF) and VPF. 
As VPF is thought to be important in tumour angiogenesis (18,19), discovery or design 
of VPF inhibitors might be of clinical importance. To test if any of the VPF mutants 
could act as a receptor antagonist, we determined if the VPF mutants with little biological 
activity: i.e. C2S, C4S, and C5S, were capable of inhibiting biological activity of wild 
type VPF. They did not, which is in accordance with the finding that they are inefficient 
in competing for receptor binding with labelled VPF. VPF antagonists should efficiently 
bind to VPF receptors without activating these receptors. Our data show that it is 
necessary to have VPF dimers to meet the first criterion. A strategy for designing 
dominant-negative VPF analogues, which dimerize with and inactivate wild-type VPF 
subunits, may provide a future approach towards VPF inhibition. In a similar fashion, a 
dominant-negative PDGF analogue (PDGF-0) has been designed recently (37). 
The differential efficiency of VPF mutant C4S in inducing endothelial cell mitosis and 
vascular permeability, although used at different concentrations, shows that VPF variants 
may exist which have a partial spectrum of activities. This possibility is not only a 
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challenge to further study the signalling pathways involved in the different biological 
effects of VPF, it might also have clinical applications. 
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Summary and General Discussion 
Every living tissue in higher organisms is dependent on the supply of nutrients and 
oxygen for its survival. For this purpose nearly all mammalian tissues are equipped with 
and connected by a network of blood vessels. Normally, blood vessels do not grow. 
However, in regenerating tissues like the female reproductive organs or wounds, and in 
growing tissues, like embryonic and fetal tissues or tumours, the development of the 
vascular system has to keep pace with the development of the tissue it feeds. The growth 
of new blood vessels from existing ones is called angiogenesis, and is mediated by a 
number of factors referred to as angiogenic factors. Of these angiogenic factors, vascular 
permeability factor (VPF), also called vascular endothelial growth factor (VEGF), is 
considered to be one of the most important. 
Most angiogenic factors factors stimulate the division of endothelial cells, the cells 
forming the inner lining of blood vessels. Apart from the direct stimulation of blood 
vessel growth, many angiogenic factors also induce other effects. VPF, for instance, 
enhances the permeability of blood vessels for proteins, and induces the expression of a 
factor that initiates blood coagulation, tissue factor (TF). Such effects not only contribute 
indirectly to the process of angiogenesis, they also lead to other interesting phenomena. 
For instance, a feature often observed in tumour blood vessels, is the occurrence of 
intravascular clotting, and obstruction of tumour blood flow by microthrombi. In some 
cases, like after treatment with the cytokine TNF, this can even lead to necrosis and 
remission of a tumour. The induction of intravascular coagulation in tumours may, in 
part, be mediated by tumour-secreted VPF. It is, therefore, of great interest to study VPF 
expression in tumours, not only because of its angiogenic property, which is beneficial for 
the growth of a tumour, but also because of its capacity to induce intravascular 
coagulation, which might be useful in anti-tumour therapy. 
The initiation of intravascular clotting by VPF, or by other tumour-secreted factors, is 
caused by the induction of TF expression by endothelial cells, as stated above. The 
elevated TF expression is due to an increase in TF mRNA levels. Thus, TF induction in 
endothelial cells can be monitored on the level of the TF messenger. Measuring TF 
mRNA levels has the advantage that the mRNA can specifically be converted into, and 
amplified as a DNA fragment, by a technique called RT-PCR. This technique is very 
sensitive and thus applicable even when very small amounts of material are available. 
This approach is worked out in Chapter 2. A problem with quantitative RT-PCR is that 
corrections need to be made for tube-to-tube differences in the efficiency of amplification. 
We therefore designed a control RNA which was added to all reactions in an equal 
amount. The control RNA and the TF mRNA were co-amplified in the RT-PCR 
reactions, but the control RNA was chosen such that the length of its product differed 
from the length of the TF mRNA product. In Chapter 2 it is demonstrated that the initial 
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amount of TF mRNA can be estimated quite accurately from the ratio of the two products 
if the initial amount of control RNA is known. Furthermore, in an application of this 
technique, it was confirmed that the induction of endothelial cell TF activity by an 
unidentified melanoma cell-derived factor is accompanied by an elevation of the TF 
mRNA level. 
Quantitative RT-PCR assays are used for the determination of messenger levels for 
other factors as well. Such assays may become especially useful in diagnosis if transcript 
levels are to be measured in very small tissue or tumour samples obtained by biopsy. 
Assays to determine mRNA levels for the angiogenic factors VPF and bFGF in samples 
of tumour material are currently being developed, using an approach similar to that for 
the determination of TF mRNA levels. 
To study the role of VPF in tumour angiogenesis, and the correlation between VPF 
expression and tumour metastasis, a panel of human melanoma cell lines was used. The 
cells from these lines develop tumours with different biological behaviour after injection 
into nude mice. Some form tumours that metastasize more rapidly and frequently than the 
tumours from other lines. Since metastasizing tumour cells are dependent on blood vessels 
for their dispersion, the degree of tumour vascularization may be a rate-limiting factor in 
metastasis. VPF, being an angiogenic factor, might therefore determine not only the 
density of blood vessels in these tumours, but might also be indirectly responsible for 
differences in metastatic behaviour. 
Studies presented in Chapter 3 demonstrated that the tumours derived from various 
melanoma lines had about equal levels of VPF expression. Differences in VPF expression 
were found between melanoma cell lines in culture: the lines which developed into the 
most aggressive tumours in mice, showed much higher levels of VPF expression than less 
malignant lines. The latter lines thus had VPF expression levels that were initially low, 
but which were elevated when the lines formed a tumour. This upregulation of VPF 
expression might be caused by low oxygen tension, as oxygen withdrawal induced 
enhanced VPF mRNA levels in vitro. Tumours often show necrotic areas, which 
presumably develop after a local insufficiency of blood supply, and hence of nutrients and 
oxygen. Upregulation of VPF expression could in that case be a direct way of improving 
the tumour vasculature around such an area. 
To test if the expression pattern of VPF actually influences the vascular development, 
one such melanoma line with an inducible VPF expression was genetically altered to a 
constitutively expressing line by transfecting it with a VPF expression construct, and the 
biological effect in vivo was studied. 
The vascular patterns in the tumours resulting from these lines were indeed dramatically 
different. As is shown in Chapters 3 and 4, the tumours from the parental melanoma line 
had many separate blood vessels penetrating the tumours in an apparently random fashion. 
The vessels in the VPF-overproducing tumours, on the other hand, were localized mainly 
in stromal septa separating tumour cell nests. These experiments have unambiguously 
shown that the pattern or the level of VPF expression does have an influence on the 
vascular development in these tumours, although it is still unclear in what way VPF 
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changes the vascular pattern. The blood vessels in the VPF-overproducing tumours were 
also hyperpermeable to proteins, which was not surprising as VPF was already known to 
enhance vascular permeability. The enhanced permeability of tumour blood vessels might 
have important implications for tumour vessel development if this would lead to a more 
extensive extravascular protein matrix, e.g. consisting of fibrin. Such a matrix was, 
however, not demonstrated. 
The metastatic potential of the tumours might also be influenced by the alteration in 
vascular pattern. However, a significant difference between the metastatic frequencies of 
the tumours from the parental melanoma line and the VPF-transfected lines could not be 
demonstrated. The density of blood vessels in the tumours was perhaps not rate-limiting 
for the process of metastasis. Furthermore, the vascular phenotype in the VPF-
overproducing tumours did not allow an accurate determination of the density of 
functional blood vessels, and this density may not have differed significantly from that in 
the parental tumour type. The separation between tumour cells and the blood vessels 
appeared to be better in the VPF-transfected tumours, however, since in these tumours 
the vessels were harboured within a stromal compartment, and surrounded by a broad 
layer of matrix proteins. The latter observation suggests that metastasis may be inhibited 
in the transfectant tumours rather than enhanced, but the data on the metastatic capacity 
of the tumours do not support this idea either. 
In future experiments melanoma lines should be looked for which do not upregulate 
their VPF expression in vivo and besides have a poor vasculature. Transfecting such lines 
with VPF expression constructs may actually increase the density of blood vessels and 
enhance the growth of the tumours. It would yield a model with which the influence of 
tumour blood vessel density on the frequency of metastasis can be studied. Melanoma cell 
lines producing very slowly growing tumours, which were not included in former 
experiments just because of this practical disadvantage, are potential candidates for these 
future transfection experiments. 
In Chapter 5 a study on the structure-function relationship of the VPF protein is 
described. As a model, the structure of PDGF was used. PDGF is a growth factor with 
which VPF shares 8 cysteine residues. It is a dimeric protein just like VPF, but much 
better characterized than VPF. In PDGF, six of the cysteine residues form intramolecular 
disulfide bridges, stabilizing the structure of the single PDGF chains. Two other cysteine 
residues form interchain disulfide bridges, which stabilize PDGF dimers: cysteine 2 of 
one chain is coupled to cysteine 4 of the other chain, and vice versa. It has been shown 
that point mutations changing either cysteine 2 or 4 of PDGF into a serine residue prevent 
the formation of covalently linked PDGF dimers. Coexpression of the two mutants 
restored the ability to dimerize. Similar cysteine to serine mutations were generated in the 
VPF coding sequence (see Chapter 5). The effect of these mutations on VPF dimerization 
were essentially as expected: single mutants lacking cysteine 2 or 4 were impaired in their 
ability to form covalently linked dimers, while upon coexpression the two mutants 
complemented each other. VPF thus is dependent on the same intermolecular disulfide 
bonds as PDGF for covalent dimerization. 
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The monomeric VPF mutants bound inefficiently to VPF receptors on endothelial cells, 
and had very low, if any, biological activity. The heterodimeric protein formed after 
coexpression of the cysteine 2 and 4 mutants, however, showed normal receptor binding 
and biological activity. The results thus indicated that dimerization of the VPF protein is a 
prerequisite for efficient receptor binding and activation. In contrast with our findings 
with VPF, one of the PDGF variants, the PDGF-B chain, was not dependent on covalent 
dimerization for biological activity. PDGF-B chains were able to form stable non-
covalently linked dimers in the absence of cysteine residues 2 and 4. 
Future studies might focus on the identification of receptor-binding domains of VPF, or 
on the design of VPF mutants that inhibit the action of the wild type protein. It should be 
kept in mind that dimerization is essential for effective receptor binding. For instance, 
peptides based on parts of the VPF amino acid sequence to be tested for receptor binding 
might bind only if they are cross-linked. Also, VPF mutant chains lacking the receptor-
binding domain(s) might inhibit wild type VPF activity in a dominant-negative fashion if 
mutant and wild type chains are covalently linked. 
In conclusion, the studies presented in this thesis have contributed to the understanding 
of the importance of VPF in the development of a tumour vascular bed. They have also 
provided some insight into the mechanisms of VPF dimerization and the importance of 
dimerization for biological activity. The outcome of these studies will hopefully be useful 
starting-points for future investigators on this subject. 
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Samenvatting en Algemene Discussie 
Weefsels in hogere organismen hebben een voedsel- en zuurstofvoorziening nodig om te 
overleven. Daarom zijn bijna alle weefsels in zoogdieren voorzien van, en verbonden 
door, een netwerk van bloedvaten. Meestal is het niet nodig dat bloedvaten groeien. Soms 
moet het vaatstelsel echter meegroeien met het weefsel dat het van voeding voorziet, zoals 
in herstellende weefsels als de vrouwelijke voortplantingsorganen of wonden. Ook in 
groeiende weefsels, zoals in embryo's en foetussen, of in tumoren, moet het vaatstelsel 
zich snel ontwikkelen om de groei van het omliggende weefsel bij te houden. Het ontstaan 
van nieuwe bloedvaten vanuit bestaande vaten wordt angiogenese genoemd. Angiogenese 
wordt in gang gezet door een aantal stoffen die men angiogene factoren noemt. Vascular 
permeability factor (VPF), ook wel vascular endothelial growth factor (VEGF) genoemd, 
wordt beschouwd als een van de belangrijkste angiogene factoren. 
De meeste angiogene factoren stimuleren de deling van endotheelcellen, de cellen die de 
binnenwand van bloedvaten vormen. Daarnaast kunnen angiogene factoren ook andere 
effecten teweeg brengen. VPF verhoogt bijvoorbeeld de doorlaatbaarheid van bloedvaten 
voor eiwitten. VPF induceert ook de expressie van een factor die bloedstolling op gang 
brengt, "tissue factor" (TF). Zulke "bijwerkingen" blijken vaak indirect bij te dragen aan 
de angiogenese, maar leiden ook tot op zich interessante fenomenen. Men neemt 
bijvoorbeeld vaak waar dat stolling optreedt binnen de bloedvaatjes die door een tumor 
lopen en dat de stelsels de stroming van het bloed door de tumor belemmeren. Wanneer 
een tumor wordt behandeld met het cytokine TNF kan de stolling in de tumorvaten 
toenemen, en kan er zelfs afsterving (necrose) van tumorweefsel en een afname van de 
tumorgrootte (remissie) optreden. De inductie van bloedstolling in de tumorvaten zou ook 
door VPF uit tumorcellen kunnen worden veroorzaakt. Het is dus van groot belang om de 
expressie en de rol van VPF in tumoren te bestuderen. Immers, VPF heeft een angiogene 
activiteit, die in het voordeel van de tumor werkt, maar kan tevens de bloedstolling op 
gang te brengen, wat bij anti-tumor therapie van pas zou kunnen komen. 
VPF of andere factoren stimuleren de bloedstolling binnen bloedvaatjes door de TF 
expressie te verhogen in endotheelcellen, zoals al eerder is vermeld. Deze verhoging van 
TF expressie blijkt het gevolg te zijn van een toename van de hoeveelheid boodschapper 
RNA (mRNA) dat voor het TF eiwit codeert. Wil men de inductie van TF in 
endotheelcellen bestuderen, dan kan men dus ook de hoeveelheid TF mRNA meten. Deze 
aanpak biedt een belangrijk voordeel als er slechts weinig materiaal voorhanden is. Met 
de zogenaamde RT-PCR techniek kan het TF mRNA namelijk worden omgezet in een 
DNA molecuul, dat weer kan worden vermenigvuldigd. Wanneer echter met RT-PCR 
kwantitatieve metingen moeten worden gedaan, dan leveren verschillen in reactie-
efficiëntie een probleem op. Dit kan worden opgelost door gelijke hoeveelheden van een 
controle RNA molecuul bij alle reacties te voegen, waarbij het controle RNA een 
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reactieproduct van een andere lengte oplevert. In Hoofdstuk 2 wordt deze aanpak 
uitgewerkt. Hier bleek dat het mogelijk is om de uitgangshoeveelheid TF mRNA vrij 
nauwkeurig te bepalen uit de verhouding van de twee RT-PCR producten, mits de 
uitgangshoeveelheid controle RNA bekend is. Bij de inductie van TF activiteit door een 
onbekende, door melanoomcellen geproduceerde factor, werd deze techniek toegepast om 
ook de boodschapper niveaus te meten. Daarbij bleek inderdaad dat de verhoging van TF 
activiteit gepaard ging met een verhoging van de hoeveelheid TF mRNA. 
Kwantitatieve RT-PCR assays kunnen ook worden gebruikt voor de bepaling van mRNA 
niveaus van andere factoren. Voor de diagnostiek moeten vaak expressieniveaus worden 
gemeten in zeer kleine weefsel- of tumormonsters. Hier kunnen RT-PCR assays goed van 
pas komen. Er worden op dit moment assays opgezet om de mRNA hoeveelheden van de 
angiogene factoren VPF en bFGF te meten in tumormonsters, waarbij een soortgelijke 
aanpak wordt gebruikt als bij de TF mRNA bepaling in Hoofdstuk 2. 
Het grootste deel van het in dit proefschrift beschreven onderzoek was er op gericht om 
de rol van VPF in de tumorangiogenese te bestuderen, en om een eventuele rol van VPF 
in de uitzaaiing (metastasering) van tumoren vast te stellen. Daarbij werd een serie 
humane melanoomlijnen gebruikt. Sommige lijnen vormen in naakte muizen tumoren die 
sneller en vaker uitzaaien naar de longen dan tumoren van andere lijnen. Omdat voor het 
uitzaaien van tumorcellen bloedvaten nodig zijn, is het mogelijk dat de dichtheid van 
bloedvaatjes in een tumor een beperkende factor is voor de metastasering. VPF zou als 
angiogene factor de dichtheid van tumorvaatjes kunnen beïnvloeden en tevens voor 
verschillen in metastaserend gedrag kunnen zorgen. 
Het werk dat in Hoofdstuk 3 beschreven staat, laat zien dat VPF in ongeveer gelijke 
hoeveelheden geproduceerd werd in de tumoren die uit de verschillende melanoomlijnen 
ontstonden. Wel werden verschillen in VPF expressie waargenomen tussen de 
melanoomlijnen onder weefselkweekcondities. De lijnen die in muizen de meest 
aggressieve tumoren vormen produceren in celkweek meer VPF dan de minder 
kwaadaardige lijnen. De laatstgenoemde lijnen hadden dus aanvankelijk een lage VPF 
expressie, die echter veel hoger werd als de cellen tot een tumor uitgroeiden. Ook bleek 
dat een lage zuurstofspanning de inductie van VPF expressie kan veroorzaken, omdat bij 
gekweekte melanoomcellen een verhoging van de VPF mRNA niveaus optrad als ze 
zonder zuurstof gekweekt werden. Tumoren hebben vaak necrotische gedeeltes die 
waarschijnlijk ontstaan nadat er plaatselijk een tekort aan bloedvaten ontstaat, en daarmee 
een tekort aan voedingsstoffen en zuurstof. Door het opdrijven van de VPF expressie zou 
dan de vaatstructuur rond zo'n tumorgedeelte kunnen worden verbeterd. 
Om te kunnen testen of het expressiepatroon van VPF daadwerkelijk van invloed is op 
de vaatontwikkeling, werd een van de melanoomlijnen genetisch veranderd door haar met 
een VPF expressieconstruct te transfecteren. De oorspronkelijke lijn had een induceerbare 
VPF expressie, maar de stabiele transfectanten brachten VPF constitutief tot expressie. Zo 
werd het mogelijk om het biologisch effect van gewijzigde VPF expressie in vivo te 
bestuderen. 
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Samenvatting 
De tumoren die uit de getransfecteerde lijnen ontstonden hadden inderdaad een 
opvallend afwijkend vaatpatroon. Zoals in de Hoofdstukken 3 en 4 te zien is, werden in 
de tumoren uit de moederlijn veelal losliggende vaatjes aangetroffen, die op een 
schijnbaar willekeurige wijze door de tumor heen groeiden. In de tumoren die VPF 
overproduceerden lagen bloedvaatjes dicht opeen gepakt in "stromale" tussenschotten die 
grote groepen tumorcellen van elkaar scheidden. Deze experimenten lieten duidelijk zien 
dat VPF expressie van belang is voor de vaatontwikkeling in deze tumoren. Het is echter 
nog onduidelijk via welk mechanisme VPF het vaatpatroon beïnvloedt. Daarnaast waren 
de bloedvaten in de tumoren uit de getransfecteerde lijnen hyperpermeabel voor eiwitten. 
Dit laatste is niet zo verwonderlijk, omdat van VPF al bekend was dat het de 
doorlaatbaarheid van vaten verhoogt. Een verhoogde vaatpermeabiliteit kan leiden tot een 
uitgebreid netwerk van eiwitten zoals fibrine, dat op zijn beurt de ontwikkeling van 
nieuwe vaatjes weer kan stimuleren. Een uitgebreide fibrinematrix werd echter niet 
waargenomen. 
De verandering in het vaatpatroon zou ook het metastaserend vermogen van de tumoren 
kunnen beïnvloeden. Er kon echter geen significant verschil aangetoond worden tussen de 
metastasefrequenties van tumoren uit de moederlijn en die uit de getransfecteerde lijnen. 
Misschien was de vaatdichtheid in de tumoren wel niet beperkend voor het 
uitzaaiingsproces. Verder was het moeilijk te bepalen of de dichtheid van vaatjes 
inderdaad verschilde tussen de tumoren van de oorspronkelijke lijn en de getransfecteerde 
lijnen. In de tumoren van de VPF overproducerende lijnen leek de scheiding tussen de 
tumorcellen en de bloedvaten groter, omdat de vaatjes ingebed zaten in aparte 
compartimenten, omringd door een dikke laag matrixeiwitten. Dit laatste suggereert dat 
de metastasering in de transfectante tumoren eerder zal worden geremd dan gestimuleerd. 
Tot nog toe blijkt dat echter niet uit de resultaten van de metastaseproeven. 
In de toekomst zou een melanoomlijn moeten worden gezocht waarbij de VPF expressie 
in vivo laag blijft, en die bovendien slecht gevasculariseerde tumoren oplevert. Na 
transfectie van zo'n lijn met een VPF expresieconstruct is de kans aanwezig dat de 
dichtheid van tumorvaatjes daadwerkelijk groter wordt en dat de tumoren sneller groeien. 
Zo zou een model ontstaan dat zich goed leent voor een onderzoek naar de invloed van de 
vaatdichtheid in tumoren op de frequentie van uitzaaiing. Er bestaan melanoomlijnen die 
zeer traag groeiende tumoren opleveren, en die juist vanwege dit practische probleem 
buiten het onderzoek naar VPF expressie zijn gehouden. Toch zijn zulke lijnen misschien 
het meest geschikt om het bovengenoemde experiment mee uit te voeren. 
In Hoofdstuk 5 wordt een onderzoek beschreven naar de structuur-functie relatie van het 
VPF eiwit. Er is bij het opzetten van deze experimenten uitgegaan van de reeds bekende 
eiwitstructuur van PDGF. PDGF is een groeifactor die 8 cysteines gemeenschappelijk 
heeft met VPF, en die net als VPF een dimeer is. In PDGF zijn 6 cysteines betrokken bij 
intramoleculaire zwavelbruggen die de vouwing van de PDGF ketens stabiliseren. 
Daarnaast vormen twee andere cysteines zwavelbruggen met cysteines in een andere 
keten. Het tweede cysteine van de ene keten zit gekoppeld aan het vierde cysteine van de 
andere keten, en andersom. Op deze manier wordt in PDGF de dimeer gestabiliseerd. 
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Samenvatting 
Eerdere experimenten lieten zien dat er geen covalent gebonden dimeren konden ontstaan 
wanneer cysteine 2 of 4 van PDGF vervangen werd door een serine. Werden evenwel 
beide mutanten tegelijk tot expressie gebracht, dan complementeerden de mutanten elkaar, 
en werd het vermogen tot dimerisatie hersteld. Soortgelijke mutaties werden ook in de 
coderende volgorde voor VPF aangebracht (zie Hoofdstuk 5). Het effect van deze 
mutaties op de VPF dimerisatie kwam grotendeels overeen met de verwachtingen. De 
mutanten waarbij cysteine 2 of 4 door een serine was vervangen, waren hun vermogen 
om covalente dimeren te vormen nagenoeg kwijt, terwijl deze deficiëntie werd opgeheven 
bij gelijktijdige expressie van beide mutanten. VPF en PDGF bleken dus dezelfde 
zwavelbruggen te gebruiken voor covalente dimerisatie. 
Ook bleek dat de monomere VPF mutanten inefficiënt bonden aan VPF receptoren op 
endotheelcellen, en dat ze een lage, dan wel geen biologische activiteit bezaten. De 
heterodimeren die ontstonden bij coëxpressie van de cysteine 2 en 4 mutanten bonden 
echter normaal aan de receptoren en waren biologisch actief. Zo werd aangetoond dat 
dimerisatie van VPF een voorwaarde is voor efficiënte binding aan de receptoren en voor 
activering van de receptoren. Dit is heel anders dan bij de PDGF-B keten, een van de 
varianten van PDGF, die geen covalente dimerisatie nodig heeft voor biologische 
activiteit. PDGF-B ketens blijken namelijk stabiele niet-covalent gebonden dimeren te 
vormen, ook als de betrokken cysteines afwezig zijn. 
Toekomstig onderzoek aan VPF zou zich kunnen richten op de identificatie van 
receptorbindende domeinen van dit eiwit, en op het ontwikkelen van VPF mutanten die de 
activiteit van het wildtype eiwit remmen. Hierbij moet dan de noodzaak van dimerisatie 
voor de receptorbinding van VPF in het oog gehouden worden. Wanneer bijvoorbeeld 
peptides die gebaseerd zijn op gedeeltes van het VPF eiwit, getest gaan worden op 
receptorbinding, dan zou het nodig kunnen zijn deze peptides twee aan twee te koppelen. 
VPF mutanten zonder receptorbindende domeinen zouden de activiteit van het VPF 
wildtype eiwit kunnen remmen op dominant-negatieve wijze, als de mutante ketens 
covalent worden gekoppeld aan normale ketens. 
Het onderzoek dat in dit proefschrift beschreven staat heeft bijgedragen tot het begrijpen 
van de rol die VPF speelt in de ontwikkeling van het tumorvaatbed. Verder is er enig 
inzicht verschaft in de manier waarop VPF dimeriseert, en in het belang van dimerisatie 
voor de activiteit van VPF. De resultaten van dit onderzoek zijn hopelijk goede 
uitgangspunten voor onderzoekers die zich in de toekomst met deze onderwerpen zullen 
bezighouden. 
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Abbreviations 
aFGF 
bFGF 
BSA 
cDNA 
dATP 
DMSO 
DNA 
DNase 
dNTPs 
DSS 
DTT 
EC 
EDTA 
EGF 
FCS 
flk-1 
flt 
Hepes 
HUVEC 
IFN(a,7) 
Ш-1) 
IP3 
IPTG 
kb 
kD 
KDR 
LPS 
mRNA 
NCS 
NTPs 
PAI-1 
PBS 
PCR 
PD-ECGF 
PDGF 
P1GF 
PMA 
Po2 
RNA 
RNase 
RNasin 
acidic fibroblast growth factor 
basic fibroblast growth factor 
bovine serum albumin 
complementary DNA 
deoxyadenosine 5'-triphosphate 
dimethylsulfoxide 
deoxyribonucleic acid 
deoxyribonuclease 
deoxyribonucleotides 
disuccinimidyl suberate 
dithiothreitol 
endothelial cells 
ethylenediaminetetraacetic acid 
epidermal growth factor 
fetal calf serum 
fetal liver kinase-1 
fms-like tyrosine kinase 
N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid 
human umbilical vein endothelial cells 
interferon (α,γ) 
interleukin (-1) 
inositol triphosphate 
isopropyl /?-D-thiogalactopyranoside 
kilobase(pair)s 
kiloDalton 
kinase insert domain-containing receptor 
lipopolysaccharide 
messenger RNA 
newborn calf serum 
ribonucleotides 
plasminogen activator inhibitor-1 
phosphate-buffered saline 
polymerase chain reaction 
platelet-derived endothelial cell growth factor 
platelet-derived growth factor 
placenta growth factor 
phorbol 12-myristate 13-acetate 
partial oxygen pressure 
ribonucleic acid 
ribonuclease 
ribonuclease inhibitor 
RT 
RT-PCR 
SD 
SDS 
SSC 
TBE 
TF 
TGF(a,/3) 
TNF(a) 
tPA 
Tris 
uPA 
VEGF 
VPF 
vWF 
reverse transcriptase 
reverse transcription-preceded PCR 
standard deviation 
sodium dodecyl sulphate 
standard saline citrate buffer 
tris-borate-EDTA buffer 
tissue factor 
transforming growth factor (α,β) 
tumour necrosis factor (a) 
tissue plasminogen activator 
2-amino-2-(hydroxymethyl)-l,3-propanediol 
urokinase plasminogen activator 
vascular endothelial growth factor 
vascular permeability factor 
von Willebrand factor 
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STELLINGEN 
behorende bij het proefschrift 
Vascular permeability Tactor, 
a key regulator of endothelial cell function 
and tumour angiogenesis 
Andy Pötgens, 4 mei 1995 
-1-
Voor de dichtheid van tumorvaatjes, en voor de metastasefrequentie van de tumoren die in naakte 
muizen ontstaan uit de humane melanoomlijn Mel57, is het expressieniveau van VPF geen 
beperkende factor (dit proefschrift, hoofdstukken 3 en 4). 
-2-
De mate van homogeniteit van de VPF expressie binnen een tumor zou wel eens een betere maat 
voor maligniteit kunnen zijn dan het niveau van VPF expressie (dit proefschrift, hoofdstuk 3). 
-3-
De groeifactor VPF kan slechts in dimere toestand stabiel aan zijn receptoren binden 
(dit proefschrift, hoofdstuk 5). 
•4-
Ondanks het feit dat VPF12, de meest voorkomende variant van VPF is in zeer veel celtypen, werd 
bij het onderzoek naar cellulaire bindingsplaatsen voor VPF tot nog toe steevast VPF165 gebruikt. 
Deze onderwaardering van VPF121 die, in tegenstelling tot VPFI65, een lage affiniteit voor héparine 
heeft, kan leiden tot te algemene conclusies omtrent de rol van héparine in de interactie van VPF 
met zijn receptoren. 
-5-
De identificatie van hoog-affiene VPF-bindingsplaatsen op melanoomcellen, zonder dat daarbij is 
getest of VPF enig biologisch effect heeft op deze cellen (H Gitay-Goren et al, Biochem Biophys 
Res Comm 1993, 190:702-709), is vooralsnog geen reden om een autocrien mechanisme te 
vermoeden achter door melanoomcellen geproduceerd VPF. 
-6-
De mogelijkheid om de groeifactor voor rode bloedcellen, erythropoietine (EPO), in spierweefsel 
tot expressie te brengen na intramusculaire inspuiting van adenovirussen met het voor dit eiwit 
coderende DNA (SK Tripathy et al, Proc Natl Acad Sci USA 1994, 91:11557-11561), doet vrezen 
dat "gendoping" in de toekomst praktijk zal worden in de topsport. 
-7-
Als wetenschappers bij het interpreteren van hun eigen onderzoeksresultaten dezelfde scepsis aan 
de dag zouden leggen als bij het refereren van andermans manuscripten, zou het aantal publicaties 
aanzienlijk lager liggen dan de 535.000 die per jaar alleen al op het gebied van de biologie 
worden geregistreerd (gegevens BIOSIS Previews 1990). 
-8-
Het gesleep met gigantische hoeveelheden voedsel vanuit ontwikkelingslanden ten behoeve van de 
Nederlandse veeteelt, veroorzaakt hier en in de productielanden milieuproblemen, en zal er 
uiteindelijk voor zorgen dat heel Nederland boven de zeespiegel komt te liggen. 
-9-
Analyse van de recente voorspellingen door Rijkswaterstaat van de te verwachten waterstanden in 
de grote rivieren leert dat van het water vaak geen hoogte is te krijgen. 
-10-
Een Limburger die vanwege de werkgelegenheid afzakt naar de Randstad is een zuivere 
economische vluchteling. 
-11-
De beste wetenschapper blijft altijd een beginneling. 


